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 List of Abbreviations
ATP: Adenosine Triphosphosphate
cDNA: complementary DNA
CpGI: Cytosine-Guanine Island
DDR: DNA Damage Response
DNA: Deoxyribonucleic Acid
GTF: General Transcription Factor
ICR: Imprint Control Region
KDM: Lysine-specific Demethylase
LMR: Low Methylated Region
MBD: Methyl-CpG-binding domain
meCpG: methylated Cytosine-Guanine linear dinucleotide
NuRD: Nucleosome Remodeling and Histone Deacetylation
O-GlcNAc: O-linked beta-N-acetylglucosamine
PcG: Polycomb Group
PGC: Primordial Germ Cell
PIC: Preinitiation Complex
PPI: Protein-Protein Interaction 
PR-Dub: Polycomb Repressive Deubiquitinase
PRC: Polycomb Repressive Complex
PRE: Polycomb Response Element
PTM: Post-Translational Modification
RNA pol II: RNA polymerase II
RNA: Ribonucleic Acid
TF: Transcription Factor
TrxG: Trithorax Group
TSS: Transcription Start Site
WGBS: Whole Genome Bisulphite Sequencing

   “‘But for what purpose was the earth formed?’ asked Candide.
     ‘To drive us mad.’ replied Martin.” 
                 Voltaire, Candide (1759) 
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Introduction
    Basic concepts in molecular biology in relation to epigenetics
   Deoxyribonucleic acid (DNA) is the hereditary material in all domains of life except for 
the cases of some obligate parasites (figure 1)1. DNA is made up of nucleotides that consist 
of a phosphate group, a sugar (deoxyribose), and either of the 4 bases; adenine, guanine, 
cytosine or thymine. The double helix structure consists of the phosphate backbone facing 
outward while the bases form hydrogen bonds (A basepairing with T, and G with C) in-
between the 2 antiparallel strands. DNA is able to inherit all the information it carries by 
replication where it serves as the template.
Figure 1: Representative sketch of the tree of life. The 3 domains of life are depicted as Bacteria, 
Archaea and Eucarya, originating from the last common ancestor (LCA). It is still a matter of 
debate whether and where the obligate parasites with an RNA genome belong in this picture2, 
especially considering the predominant view in the field that the LCA had DNA as its genetic 
material.3 Figure adapted from Woese et al, 1990;4 however the branch lengths do not represent 
any phylogenetic information. All model organisms mentioned in this thesis belong to the Eucarya 
domain: Saccharomyces cerevisiaea in Fungi; Arabidopsis thaliana in Plants; Caernohabditis 
elegans, Drosophila melanogaster, Mus musculus and Homo sapiens in Animals (metazoans).
    The central dogma of molecular biology posits that information stored on DNA is passed 
on to ribonucleic acid (RNA) molecules in a process called transcription5. RNA molecules 
are further ‘decoded’ into functional agents called proteins via a process called translation. 
Although the flow of information was originally postulated to be unidirectional, nature 
has presented exceptions to the rule6,7. A gene is the structural unit encoding for an 
RNA molecule8. Messenger RNAs are translated into proteins, while ribosomal RNAs and 
transfer RNAs are not; but they are required for the process of translation. More recently 
discovered types of RNA, such as long non-coding RNAs and microRNAs, expand the group 
of untranslated and functional RNAs, playing important roles in modulating transcription 
or translation processes9–11. The transcriptome of a cell refers to all the genes that are 
transcribed (active, expressed) and the proteome refers to all the proteins that are translated 
and folded correctly into a functionally capable structure. 
     A cell is the most basic unit of life and, all organisms, however complex they may be in the 
end, arise from a single cell1. More specifically, focusing on the mammalian development, 
the fertilized egg (zygote) transitions into the blastocyst with an inner cell mass (ICM). The 
cells within the ICM then give rise to the three germ layers that form all the subsequent 
organs and tissues of the organism. These germ layers are the endoderm (forming e.g. 
lungs, liver, gut), the mesoderm (muscular system, heart, blood) and the ectoderm (nervous 
LCA
Bacteria Archae Eucarya
Animals Ciliates
Green Plants
Fungi
Flagellates
Microsporidia
14
Chapter 1
system, skin)12. A cell with the potential to give rise to a whole organism is called totipotent. 
A cell with the potential to give rise to any cell type of an organism is called pluripotent. 
From pluripotent cells, progenitors of different tissues are derived which have the potential 
to both self-renew (i.e. proliferate) and further specialize (i.e. differentiate) into the different 
cell types of specific tissues (figure 2). In the end, there are around 250 different types 
of cells in a human12. Starting from a single cell, this level of differentiation is impressive, 
especially considering the fact that all the different cells have the same DNA. However, it 
is well-established that besides some common genes (the housekeeping genes) that are 
required for the basic cellular structures and functions, the transcriptomes and hence the 
proteomes of different cells types vary remarkably12. 
Figure 2: A simplified sketch of cellular differentiation. The zygote transitions into the blastocyst.
Cells within the inner cell mass are pluripotent. Progenitors capable of self-renewal and 
differentiation further differentiate into tissue-specific cells.
 
    A defining property of the eukaryotic family of organisms is that DNA is not free-floating 
in the cell, but confined to the nucleus. Due to the sheer size of DNA (e.g. 2 meters when all 
human chromosomes are aligned end to end), it’s compacted thoroughly by being wrapped 
around 4 types of histone proteins that, in pairs, make up an octamer. DNA wrapped around 
this octamer of histone proteins is called the nucleosome (box 1 and figure 3). The strands of 
DNA that enter and exit the nucleosome structure are stabilized by another histone protein, 
Histone H1, also called the linker histone. Nucleosomes, nucleosome-associated proteins 
and long noncoding RNAs are collectively called chromatin1. 
    Early visualization studies yielded the ‘beads-on-a-string’ image of DNA wrapped around 
nucleosomes which represents the 10 nanometer (nm) chromatin fiber. Images with a 30 nm 
diameter show stacks of polynucleosomes in a higher order chromatin structure, although 
the exact organization of nucleosomes at this stage and beyond need to be resolved13–15. 
It is also known that chromosomes are not in a state of uniform compaction in interphase 
(the longest phase of the cell cycle). Highly dense regions of chromatin are stained more 
strongly by basic dyes and called heterochromatin while the less dense, less intensely 
Zygote Blastocyst
Progenitor cells
Dierentiated cells
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stained regions are called euchromatin. These classifications predate the discovery of the 
structure of DNA and nucleosomes. Amazingly, the functional implications articulated at the 
time hold true to this day, i.e. the euchromatic regions are more transcriptionally active than 
the heterochromatic regions16. 
   Initially considered a structural requirement for the compaction of DNA, the functional 
involvement of nucleosomes in all DNA-templated processes became clear soon enough. 
First of all, chromatin structure is refractory to all processes that require access to DNA 
such as DNA replication, DNA repair and transcription, hence chromatin manipulation 
prior to any of these processes is essential15. Secondly, in addition to acting as a structural 
barrier between DNA and DNA-binding proteins, the components of nucleosomes and 
various modifications they hold affect DNA accessibility and recruitment of factors that alter 
accessibility17,18.  
Figure 3: DNA is found in the context of chromatin in eukaryotic cells. The double helix is 
held together by the hydrogen bonds between adenine-thymine, and guanine-cytosine.  DNA 
is wrapped around histone octamers (beads-on-a-string vision in 10 nm) and nucleosomes are 
further compacted (30 nm) in the nucleus. Mitotic chromosomes represent the most compact 
form of chromatin. Humans have 46 chromosomes.
    The proteins that can manipulate chromatin are divided into 2 groups: Chromatin remodelers 
and chromatin modifiers. The first group of proteins can slide or evict nucleosomes using 
ATP, hence changing the nucleosome density and directly affecting DNA accessibility19,20. 
The second group of proteins catalyzes covalent modifications on DNA or the histones, 
capable of affecting the electrostatic interaction between DNA and histones as well as 
presenting binding platforms for other proteins21. The histone tails (N- and C-terminal) that 
protrude from the nucleosome provide an ideal platform for chromatin modifier activity. 
The modifiers that add a functional group to chromatin are called writers, those that remove 
the mark are erasers; and the proteins that bind to the marks are called readers. There are 
a vast number of chromatin modifications present in a eukaryotic cell, some of the most 
eukaryotic cell
mitotic chromosome
30 nm chromatin 
10 nm chromatinnucleosome
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common ones being DNA methylation, histone acetylation, phosphorylation, methylation 
and ubiquitination22(figure 4).  Collectively, these modifications can be referred to as the 
histone post-translational modifications (PTMs); or to be more comprehensive and include 
the modifications on DNA as well, the term ‘epigenetic/chromatin marks’ could be used. 
Epigenetics refers to all the information passed onto the next generation of cells or organisms 
that is independent of the DNA sequence (i.e. genetic information)23. The variations in the 
definition of epigenetics and the hereditary aspect of the epigenetic marks are discussed in 
detail in chapter 7.
Box 1: Histone variants and some well-known histone marks
The 4 histones mentioned above that make up the nucleosome are Histone H3, H4, H2A 
and H2B. Histone H1 serves as the linker histone between nucleosomes. In addition 
to these canonical histones, there are histone variants that display slight differences 
in sequence and structure24. The variant histones seem to have different functional 
implications as well. For example, Histone CenH3 (also known as CENP-A) is exclusively 
found in the centromeric regions of chromosomes and play a major role in kinetochore 
formation and sister chromatid separation. Histone H2A.Z is another variant enriched at 
transcription start sites. Depending on the Histone H3 it is coupled with (H3.1 or H3.3), it 
increases or decreases the stability of the nucleosome respectively24. 
Histone marks are typically denoted with the histone name, the amino acid and its 
position and an acronym for the modification. For example, H3K4me3 represents Histone 
H3 modified with 3 methyl groups on lysine that is the fourth amino acid in the protein 
sequence. Some well-known histone marks are Histone H3K4me3 found at transcription 
start sites, H3K27me3 found in repressed regions and H3K36me3 found at actively 
transcribed gene bodies. Gamma-H2A.X (which stands for phosphorylated H2A.X in an 
exceptional denotation) is enriched at DNA damage sites.
Figure 4: Histone tails carry multiple post-translational modifications. Here, a small selection of 
modifications is shown: Methylation, phosphorylation, acetylation and ubiquitination. Note that 
N-terminal tails of Histone H3 and H4, and C-terminal tails of Histone H2A and H2B are depicted. 
    Eukaryotic transcription machinery 
  The transcription machinery is assembled on promoter regions of genes. Promoters, 
around 50-100 basepairs in size spanning the transcription start site (TSS), have sequences 
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within that are recognized by general and specific transcription factors (TFs)25. TFs are 
specialized proteins with a sequence-specific DNA-binding domain and an activation 
domain for interacting with other regulators26. The sequences recognized by general 
transcription factors (GTFs) are called core promoter elements (e.g. TATA box, Initiator, 
Downstream Promoter Element (DPE)). The assembly of GTFs, namely, TFIID, TFIIB, TFIIA 
followed by TFIIE, TFIIF and TFIIH, result in the melting of the double strand, providing the 
transcriptional machinery with a single strand of DNA25. GTFs and co-factors, such as the 
Mediator, recruit RNA polymerase II (RNA Pol II), which is the polymerase that transcribes 
all messenger RNAs as well as most noncoding RNAs in eukaryotes27(figure 5). The assembly 
of all these complexes on core promoter elements is called the Preinitiation Complex 
(PIC) formation. In simpler eukaryotes such as Saccharomyces cerevisiae, PIC formation 
is followed by transcriptional initiation and elongation28. However, in metazoans, another 
level of regulation takes place in the form of RNA pol II pausing at promoter proximal sites: 
After PIC formation, transcription may start, but usually is aborted after a few bases (30-
60 nucleotides) are transcribed (abortive initiation). It is only with the help of positive 
elongation factors (and the dissociation of negative elongation factors) that productive 
elongation of transcription is possible28–30. Evidently, it is not only in the proximity of TSS 
that RNA Pol II pausing occurs, but the best studied instance of pausing so far is indeed the 
proximal pausing prior to productive elongation.
    Core promoter elements, the GTFs and the related co-factors mentioned above are 
sufficient for a basal level of transcription to take place in vitro25. Regulated (activated) 
transcription requires the binding of specific transcription factors to their cognate sites 
(motifs) in the proximal promoter region31. Co-factors such as the Mediator seems to 
communicate the signals between the complexes bound to the proximal and core promoter 
elements and regulate the initiation of transcription27.
Figure 5: Basic transcription machinery at a promoter and its corresponding enhancer. 
Multisubunit general transcription factors assemble on the core promoter. Chromatin remodeling 
and histone acetylation take place at promoter and enhancer regions. Chromatin looping brings 
the enhancer into the proximity of the promoter. The Mediator complex is involved in the 
regulation of transcription initiation. Figure adapted from Koster et al., 201536.
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Chapter 1
    Distal elements, such as enhancers and locus control regions (LCRs) are other gene regulatory 
elements that affect transcription25. Enhancers, like proximal promoters, harbor TF-binding 
motifs and also have an ‘open’ chromatin structure (low nucleosome density and high 
histone acetylation levels)32. Enhancers and LCRs are brought to the proximity of promoters 
that they regulate via chromatin looping events and activate/increase transcription of those 
genes33,34(figure 5). A negative regulatory element that is called the insulator, disrupts the 
enhancer-promoter interaction and inhibits/decreases transcription35.  
    Transcription termination is mediated by the recognition of the A-rich sequences at the 3’ 
end of transcripts by termination factors. These factors cause the dissociation of RNA pol II 
from the transcribed strand of DNA37.    
  The chromatin environment plays an important part in transcriptional regulation by 
allowing or hindering the formation of transcriptional machinery on promoters as well as 
affecting the progression of RNA pol II on gene bodies. Nucleosome depletion, i.e. chromatin 
remodeling, is required at the TSS19. Certain histone PTMs, such as acetylation of certain 
residues on Histone H3 and H4 in addition to H3K4 methylation, are strongly correlated with 
actively transcribed gene promoters18. On the other hand, modifications on DNA, such as 
methylation and hydroxymethylation, seem to affect transcription context-dependently38. 
Chromatin remodelers and modifiers, proteins that lack specificity, are recruited by general 
or specific TFs and various chromatin marks. The rest of this introduction will elaborate on 
specific aspects of the chromatin environment and the proteins involved in the processes of 
controlling those aspects. 
 
     DNA methylation
   One of the best studied epigenetic marks is DNA methylation. Notably, it is also the 
epigenetic mark of which the inheritence is well-known with functional consequences39. 
DNA methylation is widely present in many organisms from bacteria to plants, showing 
mosaic or global patterns40. In vertebrates, global methylation of Cytosine in a CpG context 
is observed along with some low abundant nonCpG (CpA, CpT) methylation41. Because 
only CpG methylation (meCpG) is symmetrical on the double-stranded DNA, it is thought 
to be the only type of methylation that is faithfully propagated during DNA replication42. 
All instances of DNA methylation refer to CpG methylation in the rest of this thesis unless 
otherwise stated. 
   Repetitive regions of chromosomes such as centromeres and telomeres are heavily 
methylated in addition to transposable elements within the genome. There is extensive 
evidence suggesting DNA methylation-mediated repression at these particular sequences40. 
In placental mammals, promoters of genes in the inactive X chromosome and some 
promoters of imprinted genes along with non-promoter regulatory sequences (i.e. imprinting 
control regions (ICR)) are also methylated39. Moreover, mammalian genomes, in total 
slightly depleted of CpG (~40%), have long stretches of DNA with high and unmethylated 
CpG content called CpG islands (CGIs). CGIs overlap with ~60% of gene promoters and CpG 
methylation at these sites is tightly regulated during development43,44. All these instances 
show DNA methylation effecting repression and support its role as the model epigenetic 
mark: heritable across cell divisons and having a functional consequence23. Whether (and 
how) it is heritable across generations is a major question the epigenetics field is trying to 
answer45,46. 
    For mammals, transgenerational inheritance of DNA methylation has only been shown 
in the context of imprinting: Imprinting is the phenomenon of allele-specific gene silencing 
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dependent on the parent of origin47. In spite of the genome-wide demethylation the 
primordial germ cells (PGCs) undergo, during maturation, alleles that should be silenced 
and imprinting control regions are correctly methylated in a sex-specific manner48. These 
loci are protected against the further wave of demethylation that takes place during pre-
implantation49. 
   More recent studies, with insight provided by high resolution whole genome bisulphite 
sequencing (WGBS, see box 2), have challenged the DNA methylation-repression association. 
Many genes harbor DNA methylation on the gene-body (genic methylation) which seems 
not to interfere with transcriptional activity40. Further WGBS data sets across different 
human tissue and cell types revealed dynamic regulation of DNA methylation in around 22% 
of autosomal CpGs50. These regions, (referred to as differentially/dynamically methylated 
regions (DMRs)) coincide with enhancers and TF-binding sequences. Other studies in 
parallel reported that at regions with low CpG density (low methylated regions (LMR)), it 
is mainly TF-binding dynamics that determine DNA methylation patterns51,52. These studies 
are important for 1. narrowing down the sites to investigate the methylation status in as yet 
uncharted genomes from different/diseased tissues for comparison purposes 2. narrowing 
down the sites to investigate the mechanistic details of DNA methylation and gene regulation. 
Importantly, the observation in which the presence or absence of TFs seems to regulate DNA 
methylation state is not an instance of DNA methylation ‘instructing’ transcription53. On the 
contrary, it shows the effect of the transcriptional regulatory elements on the methylation 
state. This is in opposition to the promoter methylation examples discussed in the previous 
paragraphs in which DNA methylation instructs repression.
   In summary, the DNA methylation field is ever expanding with surprising findings. The 
functional consequences of DNA methylation need to be dissected in the right context: 
e.g. differentially methylated regions in development or disease and the nature of the DNA 
element that is methylated (promoter, gene-body, intergenic, etc.) should be taken into 
account when a functional link is investigated.
There are three DNA methyltransferases in mammals: the maintenance methyltransferase 
DNMT1 active at replication forks to propagate the methyl-CpG sites to the daughter 
strand, and de novo methyltransferases DNMT3A and 3B, capable of putting down 
methylation to ‘new’ target CpGs. This functional demarcation, while valid for the most 
part, has been shown to be flexible to a certain extent54. A related protein, DNMTL, is 
expressed only in germ cells. It lacks the methyltransferase activity, but is nonetheless 
essential for the maintenance of imprinting42.
Methyl-CpG is oxidized to hydroxymethyl-CpG by the TET enzymes (and further oxidized 
to carboxyl- and formyl-Cytosine). This pathway is thought to constitute the active 
DNA demethylation process. Whether the intermediate products on the genome serve 
another, specific regulatory purpose is not yet known55,56.  
Whole genome bisulphite sequencing (WGBS) has allowed the mapping of methylated 
CpGs with basepair resolution57. Bisulphite-treated cytosines convert to uracil while 
meC is resistant to this conversion. Subsequent high-throughput sequencing reveals 
the U:G mismatches, i.e. unmethylated CpGs. Of note, bisulphite sequencing does not 
distinguish between meC and hydroxymeC. Other methods for sequencing both meC and 
hydroxymeC have been developed.55,58 
     Box 2: Mammalian DNA methyltransferases, DNA demethylation and WGBS
20
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   Proteins that recognize methylated DNA
    Canonically, there are three groups of proteins that interact with methyl-CpG in mammals: 
Methyl-CpG Binding Domain (MBD) family of proteins (discussed in detail below), Kaiso 
and Kaiso-like proteins (Kaiso, ZBTB4, ZBTB38) and the Set and Ring finger associated (SRA) 
domain proteins (UHRF1 and UHRF2)59. Recent unbiased interaction screens have revealed 
more proteins with an affinity for Methyl-CpG60–62. 
   
     MBD Family of proteins
   The Methyl-CpG binding domain was first discovered in the MeCP2 protein due to its 
strong interaction with methylated DNA sequences in band shift assays63. Other proteins 
with a highly homologous MBD are MBD1, MBD2, MBD3 and MBD4.  MBD5 and 6 proteins 
were discovered later than the canonical MBDs in a cDNA screen from brain tissue in 200064. 
Sequence homology studies revealed more proteins with an MBD: BAZ2A, BAZ2B, SETDB1 
and SETDB2 (see figure 1 in chapter 3 (MBD family of proteins)). The canonical MBDs have 
been better studied, probably for the reason of having been discovered earlier. Importantly, 
none of the MBDs of the ‘non-canonical’ members of the family, in addition to MBD3 of the 
canonical ones, have retained an affinity for methylated CpG in mammals59. Nonetheless, 
they all interact with chromatin.  
    Mutations in the MeCP2 gene, located on the X chromosome, have been linked to the 
Rett syndrome where neurodevelopmental defects are observed in females (males are also 
affected in some cases, however the frequency is far lower)65. MeCP2 is also associated with 
other neurological disorders from autism spectrum disorder to schizophrenia. Very abundant 
in the brain, it’s thought to compete with the linker Histone H1 in neurons, implying that 
MeCP2 may function as a chromosomal architecture protein as well. Interestingly, both 
knock-down and overexpression of MeCP2 result in neurological phenotypes, suggesting the 
level of this protein requires a tight regulation. While MeCP2 has been proposed to interact 
with some chromatin complexes (e.g. Sin3A, N-CoR) to exert repression, the exact molecular 
mechanisms and the specific targets of this protein remain under intense investigation. 
     MBD1 is unique within the MBD family because it contains three CXXC domains (variable 
among different isoforms) in addition to its MBD59. CXXC is a zinc finger domain known 
for strongly interacting with unmethylated CpGs. Functionally, MBD1 has been linked with 
heterochromatin maintenance via interactions with HP1 and H3K9 methyltransferase 
SUV39H166. It was also shown to target some genes involved in neuronal differentiation67–69. 
In addition, it has been implicated in propagating histone marks during DNA replication due 
to its reported interaction with a member of the chromatin assembly complex, CAF-1, and 
Histone H3K9 methyltransferase SETDB1 in the S phase of the cell cycle70.
    MBD2 and MBD3 are members of the chromatin complex NuRD that was originally identified 
as a transcriptionally repressive complex (more on NuRD complex later). These proteins 
are found mutually-exclusively within the NuRD complex71. Their function is expected to 
be non-redundant as MBD2 can interact with methylated CpGs whereas MBD3 cannot. In 
mammals, MBD3 is highly expressed at the embryonic stage while the expression of MBD2 
increases upon differentiation.72 This may partly explain why knock-out phenotypes are so 
different: Embryonic lethality in the case of MBD3; whereas in the case of MBD2, some 
defects in maternal behaviour are observed in female knock-out mice59. 
   MBD4 is involved in base excision repair via its glycosylase domain73. It acts on G:T 
mismatches caused by the deamination of methyl-Cytosine, providing an additional link to 
the process of DNA demethylation. In addition to DNA repair and demethylation processes, 
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MBD4 has been associated with apoptosis73. 
   For the non-canonical MBD-bearing proteins, SETDB1 and SETDB2 both have a SET domain 
that methylates Histone H3K9. This mark, mostly linked to repression, is enriched on 
centromeres as well as some euchromatic regions74. Additionally, SETDB1 is implicated in 
the imprinting process and in maintaining the silence of various retrotransposable elements 
as all these sequences also harbor H3K9me375,76. SETDB2 has been reported to regulate left-
right asymmetry in addition to mediating anterior-posterior axis elongation during zebrafish 
embryogenesis77.  
   BAZ2A and BAZ2B proteins, on the other hand, have a PHD-type zinc finger and a bromo 
domain that interacts with acetylated histones. BAZ2A is the better characterized protein 
as it is part of the Nucleolar Remodeling Complex (NoRC) that regulates the expression of 
ribosomal DNA78. More data on the function and interactors of BAZ2B are yet to be published.
   
    MBD5 and MBD6
   MBD5 and MBD6, as mentioned above, were first discovered in a cDNA screen in 2000. 
A thorough biochemical characterization of these proteins was published in 201079. In this 
paper, the proteins were shown not to have a preference for methylated CpG in band shift 
assays. In addition, the chromocentric localization of the proteins were mostly unaffected 
in DNMT knock-out mouse embryonic fibroblasts (MEFs): In wild-type cells, chromocenters 
are hypermethylated, but in DNMT knock-out MEFs the methyl mark is lost80, indicating that 
MBD5 and 6 localization to chromocenters is indepedent of the methylation status.
    MBD5 has two isoforms. The long isoform (isoform 1) has a PWWP domain, a known 
chromatin interaction domain81. Expression profiling in various mouse tissues showed 
that MBD5 isoform 1 and MBD6 are highly expressed in brain and testes. The second 
isoform of MBD5 is highly expressed in oocytes. The observed high expression of MBD5 
in the brain is expected as it is one of the genes that is either deleted or duplicated in the 
2q23.1 microdeletion/duplication syndrome82–87. This locus is within the Autism Spectrum 
Disorder-associated loci. In addition to the drastic change that would be the deletion or 
duplication of a locus, several mutations in the Mbd5 gene are also reported in patients with 
various neurological disorders88. In one such study, genetic interaction screens performed in 
Drosophila melanogaster showed a synergistic relationship between the MBD5 homologue, 
sba, and the EHMT1 homologue, EHMT, which is a histone H3K9 methyltransferase89. The 
mechanistic details of this genetic interaction, however, are not known. In 2012, a paper 
describing Mbd5 knock-out mice was published: The mice displayed perturbed glucose 
metabolism in addition to neurological retardation90. For MBD6, functional data is still 
lacking.
 
     Polycomb Repression
   Among the known chromatin regulatory complexes (excluding remodelers), Polycomb 
group complexes are possibly the best-studied repressors. Initially characterized during Dro-
sophila melanogaster development, a series of mutants were investigated that resulted in 
the repression or derepression of the homeotic genes. The mutated genes that caused dere-
pression were classified as the Polycomb group genes (PcG)91. Further studies revealed that 
many other genes are also targeted by PcG proteins92–94.
    The PcG proteins form two major complexes: Polycomb Repressor Complex 1 (PRC1) 
and PRC294. Conserved from Drosophila to mammals, both complexes mediate repression 
of targets, driving differentiation and development. Both have chromatin-modifying 
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subunits, with the histone marks they catalyze instrumental in mediating repression: 
Ring1b (Sce in Drosophila) in PRC1 lays down monoubiquitin on Histone H2AK119Ub in 
mammals (H2AK118Ub in fly)95,96 and Ezh2 (E(z) in Drosophila) in PRC2 catalyzes Histone 
H3K27 methylation97,98. PRC1 was also shown to repress transcription independently of 
Histone H2A ubiquitination99,100. In addition, there are several variant PRC1 complexes with 
remarkably different subunit compositions101. For a summary of the PcG complexes and 
their subunits in Drosophila and in human, see table 1. For variant complex subunits and 
additional interactors of the PcG complexes in human, see table 2. 
Table 1: PRC1, PRC2 and PR-Dub complex (core) subunits in Drosophila melanogaster and humans 
with critical domains denoted.  Adapted from Schwartz and Pirrotta, 201394.
    Since none of the PcG proteins carries a DNA-binding domain, how recruitment to target 
genes is mediated is an intense area of investigation94,102,103. In Drosophila, the targeting of 
the complexes is mediated by specific sequences called the Polycomb Response Elements 
(PREs)104. In mammals, the targeting mechanisms seem to be more complex, involving 
specific recruiter proteins and long non-coding RNAs. The histone marks catalyzed by 
both complexes are mostly found together on chromatin, forming ‘Polycomb domains’102. 
Even the PRC1 variant complexes that do not catalyze H2AK118/9Ub localize to Polycomb 
domains to mediate repression in an H2AUb-independent manner99. A key finding providing 
insight as to how this cooperation was regulated emerged in 2003: The CBX proteins found 
in PRC1 complexes were shown to interact with the chromatin mark laid down by the PRC2 
Drosophila	  
melanogaster	  
Characteristic	  
domains	  
Homo	  sapiens	  
Polycomb	  repressive	  complex	  1	  (PRC1)	  
E3	  ubiquitin-­‐protein	  ligase	  
dRING	  (Sce)	  
RING	   RING2	  (RING1B)	  
and	  RING1	  
(RING1A)	  
Posterior	  sex	  combs	  (Psc)	  and	  
Suppressor	  of	  Zeste	  (Su(z)2)	  
RING	   PCGF4	  (BMI1)	  and	  
PCGF2	  (MEL18)	  
Polyhomeotic-­‐proximal	  (Ph-­‐p)	  
and	  Polyhomeotic-­‐distal	  (Ph-­‐
d)	  
Sterile	  α-­‐motif	  (SAM)	  and	  
Zinc	  finger	  
PHC1	  (EDR1),	  PHC2	  
(EDR2),	  PHC3	  
(EDR3)	  
Polycomb	  (Pc)	   Chromodomain	   CBX2,CBX4,	  CBX6,	  
CBX7,	  CBX8	  
Sex	  combs	  on	  midleg	  (Scm)	   Malignant	  brain	  tumor	  
(MBT),	  SAM	  and	  zinc	  finger	  
SCMH1	  and	  SCML2	  
Polycomb	  repressive	  complex	  2	  (PRC2)	  
Enhancer	  of	  Zeste	  (E(z))	   SANT,	  CXC	  and	  SET	   EZH2	  and	  EZH1	  
Extra	  sex	  combs	  (Esc)	  and	  
Extra	  sex	  combs-­‐like	  
WD40	   EED	  
Suppressor	  of	  zeste	  12	  
(Su(z)12)	  
Zinc	  finger	  and	  VEFS	  box	   SUZ12	  
Chromatin	  assembly	  factor	  1	  
subunit	  
WD40	   RBBP4	  and	  7	  
Jing	   Zinc	  finger	   AEBP2	  
PR-­‐Dub	  complex	  
Calypso	   UCH	   BAP1	  
Asx	   atypical	  PHD	  type	  zinc	  
finger	  and	  LXXLL	  motif	  1	  
and	  2	  
ASXL1/2/3	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complex, H3K27me3105,106. This finding developed into the hierarchical model in which 
the initial recruitment of PRC2 to target sites catalyzes the methylation of H3K27, which 
acts as a recruiter for both more PRC2 complexes107,108 and PRC1 complexes, which then 
catalyze H2AK119Ub109. The challenge to this model comes from sites on the genome in 
which PRC1 is found without the presence of H3K27me2/3110–113. In addition, in mESCs that 
have diminished PRC2 activity (and hence no H3K27me3 mark), PRC1 targeting and H2AUb 
levels are not completely disrupted. Therefore the hierarchical model of PRC1 and PRC2 
recruitment seems to be valid for a subset of targets where both marks are present.
   In addition, in the past year, consecutive publication of 3 papers (one of which is chapter 
4 of this thesis) showed a re-shuffling in the hierarchical model of polycomb recruitment: 
The biochemical characterization H2AK119Ub interactors in vitro, as well as induced PRC1 
targeting studies in vivo showed a role of H2AK119Ub in recruiting the PRC2 complex114,115. 
These studies form the basis of a model where PRC1 recruitment feeds forward to PRC2 
recruitment which feeds forward to more PRC1 and PRC2 recruitment, and hence, Polycomb 
domain formation. 
Table 2: Additional complex subunits/interactors for the three Polycomb complexes in humans. 
Note that a selection of reported interactors is listed. PRC1 variant complex definitions are based 
on Gao et al., 2012101. (*) indicates loss of meCpG-binding.
	  
Subunit	  /	  Interactor	   Characteristic	  domain	   Complex	  	  
RING1	  and	  YY1-­‐binding	  protein	  (RYBP)	   Zinc	  finger	   PRC1	  variant	  
(multiple)	  
YY1-­‐associated	  Factor	  (YAF2)	   Zinc	  finger	   PRC1	  variant	  
(multiple)	  
BCL6	  Corepressor	  (BcoR)	   ANK	  Repeat	  	  1-­‐3	   PRC1	  variant	  (1.1)	  
BCL6	  Corepressor-­‐like	  protein	  1	  (	  BcoRL1)	   ANK	  Repeat	  	  1-­‐3	   PRC1	  variant	  (1.1)	  
Lysine	  specific	  demethylase	  2B	  (KDM2B)	   CXXC-­‐type	  zinc	  finger	  and	  
Jumonji	  
PRC1	  variant	  (1.1)	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  (USP7)	  	   USP	   PRC1	  variant	  (1.1)	  
Lethal(3)malignant	  brain	  tumor-­‐like	  protein	  2	  
(L3MBTL2)	  
Zinc	  finger	   PRC1	  variant	  (1.6)	  
Max	  protein	  (MAX)	   Basic	  helix	  loop	  helix	   PRC1	  variant	  (1.6)	  
Max	  gene-­‐associated	  protein	  (MGA)	   Basic	  helix	  loop	  helix	   PRC1	  variant	  (1.6)	  
WD	  repeat-­‐containing	  protein	  5	  (WDR5)	   WD	  1-­‐7	   PRC1	  variant	  (1.6)	  
E2F6	   DEF	  box	  and	  Leucine	  zipper	   PRC1	  variant	  (1.6)	  
Polycomb	  group	  RING	  finger	  protein	  1	  (PCGF	  1)	   RING	   PRC1	  variant	  (1.1)	  
Polycomb	  group	  RING	  finger	  protein	  3	  (PCGF3)	   RING	   PRC1	  variant	  (1.3)	  
Polycomb	  group	  RING	  finger	  protein	  5	  (PCGF5)	   RING	   PRC1	  variant	  (1.5)	  
Polycomb	  group	  RING	  finger	  protein	  6	  (PCGF6)	   RING	   PRC1	  variant	  (1.6)	  
Autism	  susceptibility	  gene	  2	  protein	  (AUTS2)	   	   PRC1	  variant	  (1.3	  and	  
1.5)	  
Protein	  Jumonji	  (JARID2)	   Jumonji	   PRC2	  
PHD	  finger	  protein	  1	  (PHF1)	   PHD	  type	  zinc	  finger	  1-­‐2	   PRC2	  
PHD	  finger	  protein	  19	  (PHF19/PCL3)	   PHD	  type	  zinc	  finger	  1-­‐2	   PRC2	  
Metal-­‐response	  element-­‐binding	  TF2	  
(MTF2/PCL2)	  
PHD	  type	  zinc	  finger	  1-­‐2	   PRC2	  
Lysine	  specific	  demethylase	  1B	  (KDM1B)	   CW-­‐type	  Zinc	  finger,	  SWIRM,	  
FAD	  
PR-­‐Dub	  
Forkhead	  box	  protein	  1	  (FOXK1)	   FHA	   PR-­‐Dub	  
Forkhead	  box	  protein	  2	  (FOXK2)	   FHA	   PR-­‐Dub	  
MBD5	   MBD*	   PR-­‐Dub	  
MBD6	   MBD*	   PR-­‐Dub	  
Host	  cell	  factor	  1	  (HCFC1)	   Kelch	  1-­‐5	   PR-­‐Dub	  
O-­‐GlcNAc	  transferase	  subunit	  p110	  (OGT)	   TPR	  1-­‐13	   PR-­‐Dub	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  Although the repressive function of all PcG complexes is well-established, there are 
recent reports emerging with exceptional observations where PcGs seem to mediate gene 
activation116–119. Whether these exceptional cases are due to the composition of the PcG 
complexes in question or the chromatin environment that they act on (or both) remains to 
be seen.
 
The family of proteins in which mutations resulted in the repression of genes as opposed 
to derepression (PcG) were named the Trithorax Group (TrxG). PcGs and TrxGs work in an 
antagonistic manner. Just like PcG, TrxG proteins also catalyze certain chromatin marks: 
methylation of Histone H3K4 and H3K36, marks associated with active transcription. 
There are 3 TrxG complexes in Drosophila melanogaster (Set1, Trx, Trr) and 6 in mammals 
(Set1A, Set1B, MLL1-4). Interestingly, although there is no yeast homologue for PcG 
complexes, there is one TrxG complex (Set1/COMPASS). The corresponding marks, i.e. 
H3K4me1/2/3 and H3K36me1/2/3 are also present in Saccharomyces cerevisiae120.
     Minibox 1: Trithorax Group proteins
    A Novel PcG complex: Polycomb Repressive Deubiquitinase 
   In 2010, a novel repressive complex that was associated with PREs was characterized in 
Drosophila melanogaster121. The two proteins that make up the complex, CALYPSO and ASX, 
catalyze the deubiquitination of Histone H2AK118Ub. CALYPSO is the catalytic subunit, and 
ASX enhances the activity of CALYPSO.  The mammalian homologues, BAP1 (CALYPSO) and 
ASXL1 (ASX) were also shown to catalyze the deubiquitination of H2AK119Ub on in vitro 
reconstituted nucleosomes. This novel complex was categorized as a PcG complex because 
the knock-out of Calypso and Asx resulted in the derepression of target genes and defects 
in development. In addition, both Calypso and Asx were found to associate with PRE as 
mentioned above, hence the complex was named Polycomb Repressive Deubiquitinase (PR-
Dub).
    The observation that removal of monoubiquitin on Histone H2AK118 resulted in derepression 
was surprising, considering the fact that Histone H2AK118 is monoubiquitinated by PRC1 
and this mark has been long linked with repression.
   Although the PR-Dub complex was identified and mostly characterized in Drosophila, the 
mammalian homologue of CALYPSO, BAP1, was already a well-known and well-studied 
protein due to its alleged interaction with BRCA1122. That is the reason why BAP1 stands 
for BRCA1 Associated Protein 1. Brca1 is a tumor suppressor gene mutated in breast 
and ovarian cancers and mutation carriers face high risk of developing these tumors123. 
Subsequent studies showed that BAP1 deubiquitinates the BRCA1 interactor, BARD1, 
rather than interact with BRCA1124. Since BARD1 and BRCA1 form a heterodimer with an E3 
ubiquitin ligase activity125, BAP1 indirectly affects BRCA1 activity via BARD1. However, within 
the BAP1 interactome that was characterized in HeLa cell lines, BARD1 was not detected as 
an interactor as shown in chapter 3 of this thesis.  
   In addition to indirectly modulating BRCA1 activity, BAP1 was linked to several types of 
cancer as mutations in the Bap1 gene were detected in patients with uveal and cuteanous 
melanoma, mesothelioma, renal carcinoma, breast and lung tumors126–129. Strikingly, multiple 
patients from 2 families with germline mutations in Bap1 developed uveal melanoma and 
mesothelioma, an occurrence that would happen 36 times in a trillion if only coincidental. 
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Based on this observation, it was proposed that germline mutations in Bap1 cause a 
‘hereditary cancer syndrome’ that is characterized by patients developing multiple (and 
particular) malignancies130,131. Now a bona fide tumor suppressor, Bap1 was also classified 
as one of the  ‘driver’ genes mutated in malignancy according to a tumorigenesis catalogue 
put together by Vogelstein et al132.
   Knocking out Bap1 results in embryonic lethality133. In 2012, a study reported the effects of 
conditional knock-out of Bap1 in mice133. These mice displayed splenomegaly, monocytosis 
and neutrophilia. This myeloproliferative/myelodysplastic syndrome (MDS) observed in 
mice resembles chronic myelomonocytic leukemia (CMML) in humans. The knock-out mice 
do not display any of the cancer types known to be associated with BAP1 deregulation in 
humans. 
   While the cancer research field established BAP1 as a tumor suppressor, the exact role 
of BAP1 in cell cycle regulation, based on studies performed in various cell lines, remains 
contradictory. Several studies reported that BAP1 knock-down enhances cell proliferation, 
others showed that it slows down the cell cycle134–137. The mammalian homologue is 
interesting in that it has gained a protein interaction domain that is missing in the Drosophila 
CALYPSO: An HCFC1-binding domain (HBM)134–136. HCFC1 is a rather intriguing regulatory 
factor involved in progression of the cell cycle via its interaction with the E2F family of 
transcription factors138,139.  HCFC1 undergoes proteolysis for maturation and the resulting 
subunits, HCFC1-N and HCFC1-C, seem to drive different phases of the cell cycle (G1 and M 
progression, respectively)140. O-linked beta-N-acetylglucosamination (O-GlcNAcylation) of 
the uncleaved, precursor polypeptide of HCFC1 is essential for proteolysis to take place141. 
This PTM is added to HCFC1 by O-GlcNAc transferase (OGT), and interestingly, the activity 
of OGT is regulated by BAP1, which deubiquitinates OGT133. This series of events, i.e. the 
removal of a PTM activating an enzyme to add another PTM to another protein which then 
undergoes proteolysis in order to have active subunits is only a minimal slice of the vast 
regulatory possibilities PTMs and the proteins bearing/adding/removing the PTMs present. 
In addition to deubiquitinating OGT, BAP1 was also reported to catalyze the deubiquitination 
of K48-linked polyubiquitin chains on HCFC1134,135. However, abolishing the catalytic activity 
of BAP1 did not result in significant changes on HCFC1 levels or activity. In a ChIP-Sequencing 
study performed in mouse macrophages, 85% of BAP1 peaks showed co-localization with 
HCFC1 and 70% of OGT peaks were within 400 bp of HCFC1 peaks133. The authors propose 
that BAP1/HCFC1/OGT form a ternary complex and recruit the other known interactors 
of BAP1 to chromatin. BAP1 may have an effect on cell cycle by directly regulating HCFC1 
activity or indirectly affecting the activity of HCFC1 by regulating the activity of OGT, or it 
does both, and/or it indeed forms a recruiter complex with these factors and controls gene 
expression. These possible scenarios remain to be investigated. Interestingly, one study 
reported that in S-phase, Ino80 is stabilized by BAP1 at active replication forks, which may 
represent another way for BAP1 to affect cell cycle progression142. In our interaction screens 
(chapter 3), not Ino80, but both HCFC1 and OGT are identified as BAP1 interactors. 
   In another study, BAP1 was reported to form a ternary complex with HCFC1 and the 
TF YY1136. The resulting complex was shown to activate the expression of a nuclear gene 
encoding a mitochondrial respiratory chain protein, cox7c. 
   In addition to HCFC1 and OGT, the mammalian PR-Dub complex has many more subunits 
compared to the Drosophila PR-Dub complex (see table 2): 
      TFs FoxK1 and FoxK2 interact with the mammalian PR-DUB. FoxK2-dependent 
recruitment of BAP1 to several target genes showed changes in gene expression (both 
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up and downregulation), in addition to a consistent decrease in H2AK119Ub143. More 
recently, it was shown that BAP1 mediates repression of FoxK2 targets; but the absence 
of BAP1 results in derepression only in the presence of BMI-RING1b (which ubiquitinate 
H2AK119)144. 
      The Drosophila ASX has three homologues in mammals: ASXL1, 2 and 3. ASXL1 and 
2 have been shown to interact with BAP1 (chapter 3,133,135,136). Interestingly, mutations in 
ASXL1 were reported in CMML patients (see above for Bap1 knock-out mice) and it is also 
classified as a driver gene in cancer along with BAP1 (also as a tumor suppressor)132,145. 
Both ASXL1 and ASXL2 were shown to regulate the activity of PPAR-gamma nuclear 
receptor in a reciprocal manner during adipocyte generation146. In addition, ASXL2 was 
shown to regulate the activity of the retinoic acid receptor positively and negatively by 
interacting with different chromatin modifiers147. Hence, ASXL1 and 2 seem to regulate 
transcription through interactions with members of the nuclear receptor family, but the 
exact mechanistic details are unknown. Moreover, both ASXL1 and ASXL2 were reported 
to interact with the PRC2 complex and mediate H3K27 methylation by PRC2148,149. ASXL2 is 
reported to be involved cardiac functioning, as mice that survived the knock-out of Asxl2 
(which is partially embryonic lethal) displayed enlarged hearts and cardiac dysfunction in 
addition to reduced levels of H3K27me3150,151.
      KDM1B, a lysine demethylase, is another interactor that is also a chromatin modifier 
like BAP1. It demethylates di-methyl (me2) and mono-methyl (me) residues on Histone 
H3K4152. It is reported to regulate maternal imprinting as knocking out Kdm1B resulted in 
biallelic expression of various, normally imprinted genes in mouse oocytes153. 
      The novel interactors, MBD5 and MBD6, are discussed in detail in the previous section 
and in chapter 3. 
   In summary, the human PR-Dub complex seems to be far more complex than the 
Drosophila counterpart. We do not know whether all the functional implications of the PR-
Dub subunits summarized above take place within the PR-Dub complex context or whether 
these subunits have PR-Dub-independent interactions and functions. 
   BAP1 is also implicated in DNA damage response (see the next section for details). First, 
it was shown to be phosphorylated (at S592) in the S phase upon replicative stress and this 
resulted in the dissociation of BAP1 from chromatin154. Another study reported that BAP1 is 
phosphorylated on 6 sites upon ionizing radiation (IR) and the phosphorylation was required 
for BAP1 to promote the double strand break repair response (via BRCA1 and RAD51)155. 
Finally, another study showed BAP1 recruitment to IR-induced DNA damage sites along with 
ASXL1156. This study also reports that BAP1 facilitates BRCA1 and RAD51 foci formation at 
sites of damage. 
     Histone H2A (De)Ubiquitination
    The first protein that was reported to be ubiquitinated was Histone H2A161. Interestingly, 
the ubiquitination of H2A was originally thought to be involved in transcriptional activa-
tion. Then, H2AUb was observed in heterochromatic regions in several studies. Finally, when 
PRC1 was shown to mediate repression via monoubiquitination of H2A, the functional asso-
ciation with this mark almost exclusively turned to repression162. 
  In the context of Polycomb repression, as mentioned above, Histone H2AK119 
monoubiquitination is well-known and well-studied. Put down by RING1B (and in some 
cases RING1A), it mediates the repression of gene expression during development and 
differentiation. Heterochromatin formation and X chromosome inactivation are processes 
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that involve gene silencing by PRC1. As a mode of repression, H2AK119Ub by PRC1 was 
reported to keep RNA Pol II from elongating at the promoters of a set of genes in ESCs163. 
Similarly, but in another context, H2AK119Ub mediated by another E3 ligase, 2A-HUB, was 
shown to interfere with transcriptional elongation and repress chemokine gene expression 
in macrophages164.
    There are several E3 ligases for H2AK119: RING1B, RING1A, 2A-HUB, CULLIN4B165,166. 
Recently, TRIM37 was identified as another E3 ligase for H2AK119 in breast cancer cell lines, 
it is postulated to act as an oncogene167. BRCA1/BARD1 heterodimer was shown to mediate 
monoubiquitination of H2A at other sites, namely at K127 and K129168. H2AUb mediated by 
BRCA1 was previously shown to be essential for maintaining the genome integrity via the 
silencing of microsatellite regions169. BRCA1 is also a DNA damage response protein123.
    In the context of DNA damage, Histone H2A and the variant histone H2A.X were shown 
to be polyubiquitinated on K13 and K15 (by RNF8/RNF168) and monoubiquitinated on K119 
and K120 (by Ring1b)170. Both events seem to play a role in signaling for DNA damage and 
the recruitment of DNA damage response (DDR) machinery (i.e. foci formation). In fact, 
monoubiquitination on K119 was shown to be required for the phosphorylation of Serine 
   Box 3: Ubiquitin, (De)Ubiquitination and BAP1
Ubiquitin (Ub) is an extremely well conserved, ubiquitious protein. As a PTM, it has a 
remarkable size with 76 amino acids. Ubiquitination of target proteins is a three step 
process involving activation of Ub by an E1 activating enzyme, conjugation of Ub to an 
E2 conjugating enzyme and ligation of Ub to the target protein by an E3 ligase. Ub is 
added to lysine residues on target proteins where an isopeptide bond is formed between 
the last amino acid of Ub (glycine) and the lysine of the target protein157. There are 7 
lysine residues on Ub itself on which polyubiquitin chains can be extended (K6, K11, K27, 
K29, K33, K48 and K63). Polyubiquitination is a trademark of a protein being marked for 
degradation by the Ubiquitin-Proteosome System (UPS). However, different homotypic 
chains of polyUb have been associated with different cellular processes besides protein 
degradation. There are also heterotypic chains where the polyUb formation does not 
extend on a single lysine on Ub.
The isopeptide bond between Ub and target proteins is hydrolyzed by specific proteins 
called deubiquitinases (Dubs). There are 5 classes of Dubs in eukaryotes: The Ub C-Terminal 
Hydrolase (UCH) Domain, The Ub-Specific Protease (USP) Domain, The Ovarian Tumor 
(OTU) Domain, the Josephin Domain, The Jab1/MPN/Mov34 metalloenzyme (JAMM) 
domain158,159. 
BAP1 is within the UCH domain of deubiquitinases. The Drosophila homologue of BAP1, 
CALYPSO, was preferentially shown to act on monoUb121. However, the mammalian BAP1 
was reported to deubiquitinate the K48-linked polyUb chains of HCFC1134,135. Whether 
BAP1 has a preference for monoUb or polyUb remains to be clarified. So far the reported 
targets of deubiquitination by BAP1 are Histone H2A (monoUb)121, OGT (mono or polyUb 
unknown)133 and HCFC1 (polyUb)134,135. Identification of further targets, the nature of their 
ubiquitination and the regulatory consequences are of interest. 
BAP1 itself was reported to be monoubiquitinated by the E2-E3 ligase UBE2O on its 
nuclear localization sequence on multiple lysines160. This results in sequestering BAP1 in 
the cytoplasm. BAP1, in return, deubiquitinates itself and then its nuclear localization is 
restored. 
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139 on histone H2A.X which is a major signal on chromatin for double strand breaks (DSBs)170. 
    In the context of the regulation of cell cycle, Histone H2AK119Ub level is downregulated 
as the chromosomes are compacted for mitosis171. Deubiquitination of H2A by USP16 has 
been shown to be a prerequisite for the phosphorylation of Histone H3S10, which facilitates 
chromosome condensation172. USP3 and USP22 have also been shown to affect the cell cycle 
via their Dub activity on H2AK119Ub171,173.
    Other known Dubs for H2A are: BAP1, USP12, USP21, USP44, 2A-DUB and BRCC36. Some 
known functional associations with these proteins are that: 2A-DUB was reported as a 
positive co-regulator of the androgen receptor in addition to regulating the expression of a 
key hematopoietic TF GFI1164,174. Initially, BRCC36, USP3 and USP44 have all been reported 
to act as negative regulators of foci formation in the DDR mentioned above171; however, in 
a recent knock-down screen of Dubs, depletion of BRCC36 and 2A-DUB resulted in a delay 
in DDR175. 
    So far, the general emerging picture is that H2AUb mediates gene repression: it needs 
to be removed to facilitate higher order chromatin formation and it forms a recruitment 
platform for DDR proteins at sites of DNA damage. The Dubs that have been characterized 
complement this picture in that: they seem to activate gene expression, they mediate the 
progression of the cell cycle when the levels of H2AUb need to be decreased and they 
negatively regulate foci formation at DNA damage sites via removing the poly/monoUb on 
H2A that signal damage. There are exceptional observations as mentioned above, especially 
regarding  BAP1: It was reported to mediate gene repression, its role in cell cycle regulation 
needs clarification and it has been reported to facilitate DNA damage foci formation as 
discussed in the previous section.
    Minibox 2: Double Strand Breaks
One of the most toxic types of DNA damage is Double Strand Breaks (DSBs). Ionizing ra-
diation induces DSBs as utilized in chapter 3 of this thesis. DSBs are fixed by homologous 
recombination (HR) or nonhomologous end joining (NHEJ) pathways. HR can take place 
during S and G2 phases of the cell cycle. Although the 2 pathways differ in downstream 
players, the initial signaling of DNA damage is thought to be conserved and involves the 
ubiquitination of H2A and H2A.X.170
     
    Another chromatin regulatory complex: NuRD
  A major chromatin-associated complex that is conserved among metazoans is the 
Nucleosome Remodeling and Histone Deacetylation (NuRD) complex. The NuRD complex 
is a big, multisubunit protein complex that can manipulate chromatin in different ways: 
CHD3/4 subunit is the ATP-dependent nucleosome remodeler and HDAC1/2 deacetylases 
histones (and other proteins). In various purifications of the complex, LSD1, a lysine 
demethylase, appears as an interactor as well176,177. Other characterized subunits are the 
histone chaperones RBBP4/7, scaffold proteins GATAD2A/B, MTA1/2/3, MBD2/3 and DOC1 
(see table 3). Some of these subunits are found within the complex in a mutually-exclusive 
manner, such as MBD2 and MBD3, and CHD3 and CHD4. Mutual exclusion status for other 
paralogous subunits is not known. 
    The fact that there are many possible distinct subunit compositions for the NuRD complex 
may be functionally-relevant: As mentioned in an earlier section, the expression profile of 
MBD2 and MBD3 seem to be different with MBD3 being expressed abundantly during the 
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pluripotent state and decreasing upon differentiation while the expression profile of MBD2 
follows a reciprocal pattern72. MBD2 and MBD3 are a rather interesting paralogous couple 
of proteins as MBD2 has retained the affinity for methylated DNA but MBD3 has not59. This 
fact has led to speculations about MBD2 recruiting the NuRD complex to sites of methylated 
DNA, whereas the MBD3/NuRD complex cannot be targeted in that fashion. A study with 
a ChIP-Sequencing profile for MBD2 revealed that MBD2/NuRD is indeed enriched at 
methylated CpGs178. However, there are also nonmethylated target sites that MBD2/NuRD 
occupies, suggesting that MBD2 does not always undertake the recruiting function within 
the complex179. 	  
	  
Subunit	   Characteristic	  domain	  
CHD3	  and	  4	   PHD	  type	  zinc	  finger	  1,2;	  helicase;	  chromodomain	  1,2	  
HDAC1	  and	  2	   Deacetylase	  
RBBP4	  and	  7	   WD	  repeat	  
GATAD2A	  and	  2B	   GATA	  type	  zinc	  finger	  
MTA1,	  2	  and	  3	   Zinc	  finger,	  BAH,	  ELM,	  SANT	  
MBD2	   MBD	  
MBD3	   MBD*	  
DOC1	   -­‐	  
	  
	  Table 3: NuRD subunits and characteristic domains. (*) indicates loss of methyl-CpG binding 
capability.
    Indeed, the question of recruitment for the NuRD complex is an area of active investigation 
as it is for the other chromatin associated complexes (discussed previously). In addition to all 
the subunits mentioned above, there are a number of NuRD interactors (Zmynd8, Znf512, 
Znf592, Znf687, CUTL1, Ikaros, etc.)(chapter 5, 180). Among these, many have zinc fingers and 
other known DNA binding domains (such as the homeobox of CUTL1)181; therefore some of 
these interactors are expected to be tissue-specific recruiters of the complex.
    Functionally, The NuRD complex was originally associated with gene repression, especially 
in light of the deacetylation acitivity it possesses. However, genome-wide profiling of 
deacetylases has revealed that histone deacetylation also takes place at actively expressed 
genes182. In line with this observation, some NuRD subunits were found at an active promoter 
that exhibited cyclical expression in response to activation with estrogen183. In addition, 
the NuRD complex has been reported to be required for activation of gene expression in 
other contexts as well (chapter 6,184). Whether these observations are due to the necessity 
of HDAC activity to ‘reset’ chromatin in-between cycles of gene expression or there is a 
compositional and/or functional switch that takes place within the complex to change its 
effect on transcription is not known yet (see chapter 6 for more discussion on the subject).
    The NuRD subunits have been studied in the pluripotency context as well: MBD3 has 
been reported to interact with the core pluripotency network (e.g. OCT4)185–187; however 
we, in our group, have not been able to reproduce this interaction. Nonetheless, whether 
it is through a direct interaction with the pluripotency network or not, MBD3 seems to 
be enhancing the process of iPSC formation from differentiated cells188. It is also required 
for differentiation as MBD3 knock-out is embryonic lethal189,190. In addition, the repressive 
function of the NuRD complex has been suggested to create a threshold for gene activation 
that keeps aberrant gene expression to a minimum in the more open chromatin structure 
of the pluripotent cells191. The open chromatin structure is thought to contribute to the 
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plasticity within pluripotent cells that is required to maintain a high potential to differentiate 
into various lineages. This property comes with the price that spurious and nonspecific 
transcriptional activity would be easier to initiate. The NuRD complex is hypothesized to 
make up for this downfall by increasing the threshold for transcriptional noise. 
  As the complex is involved in regulating differentiation, it is no surprise that multiple 
NuRD subunits, MTAs, DOC1, Rbbp4/7, have been linked to various types of cancer191,192. 
Of note, whether the pathological role of these proteins is within the NuRD complex 
context is not known. However, considering the high regulatory capacity of the complex, 
it would be reasonable to expect that mutations found in NuRD subunits deregulating the 
complex activity has severe consequences. In addition to potential defects in transcriptional 
regulation promoting/maintaining tumorigenesis; NuRD complex has also been linked 
to DNA damage response193–197. Deregulation of NuRD activity resulting in defective DNA 
damage repair could be another functional aspect linking NuRD subunit mutations to 
various types of malignancies. 
    Mass Spectrometry-Based Proteomics
   Classical molecular biology and biochemistry techniques investigate the functional and 
structural properties of biological entities of interest (e.g. a certain transcript or a protein) 
one at a time, singularly focusing on one type of molecule (a population of the molecule 
to be more exact). Various effectors and/or interactors could be taken into account, but 
usually the numbers of entities investigated remain in single digits. With the generation 
of high throughput techniques in the last decade, information on hundreds/thousands of 
biological molecules could be collected in single experiments. Particularly the hybridization 
or sequencing based technological advances in the genomics area have made it possible 
to analyze entire transcriptomes, first in a population of cells, and now in single cell 
settings198. Whole transcriptome datasets, while extremely informative, do not reflect the 
final population of functional agents: The end product of mRNA molecules are proteins and 
the dynamism in regulatory networks controlled by proteins could only be addressed by 
collecting information on the proteome of cells.
  Mass spectrometers are instruments used to measure mass and charge of chemicals for 
identification purposes (figure 6). A revolutionary breakthrough in mass spectrometry 
was the generation of ionization techniques that allowed the measurement of biological 
molecules in mass spectrometers: Matrix assisted Laser Desorption/Ionization (MALDI) and 
ElectroSpray Ionization (ESI)199,200. MALDI involves embedding the biological molecules to 
be measured into a solid organic matrix. In the mass spectrometer, the analyte is excited 
along with matrix molecules (hence desorption) and ionized, followed by the measurement 
of its mass and charge. ESI involves the spraying of biological analytes with a liquid, which 
evaporates in the mass spectrometer, leaving the biological entities as gaseous molecules, 
and the mass and charge of these gaseous ions are measured. Prior to the generation of 
these techniques, biological entities were destroyed in the harsh vacuum environment of 
mass spectrometers before they could be measured201.
     Initially, mostly purified proteins were measured in the mass spectrometer for identification 
purposes, and information on the mass and charge of a few peptides was usually enough 
to identify a protein (mass fingerprinting)203. However, enormous leaps have been made 
regarding sample fractionation, preparation, measurement speed and sensitivity of modern 
mass spectrometers in addition to the generation of elegant algorithms for fast and accurate 
identification of peptides and proteins201. Nowadays, complex cellular mixtures from 
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mammalian cells are easily measured by fractionation (into 6-8 fractions) and within two 
days, 60-70% of the whole proteome is identified204. All of these advances have allowed 
three main areas of investigation in proteomics to be addressed by mass spectrometry-
based techniques in a high throughput manner: Deep expression profiling (i.e. whole 
proteome analysis), interaction proteomics and PTM analysis201.
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Figure 6: Generic components of a mass spectrometer. Precursor ions (e.g. peptide ABCD) are 
detected and isolated in MS1 and fragmented in MS2. Figure adapted from Yuan et al., 2014202.
  Typically, bottom-up proteomics is used to investigate all three questions. Bottom-up 
proteomics refers to digesting the proteome with a protease to generate peptides which 
are usually separated by on-line (directly connected to the mass spectrometer) nano-liquid 
chromatography, have their mass-to-charge ratio measured (MS1), fractionated into further 
ions via collision with an inert gas (MS/MS or MS2); and the information from both MS1 and 
MS2 scans is used to match the peptide ID to a database of peptides (where the proteins 
are theoretically digested with the protease that is used in the experiment to provide the 
mass and charge information)205. For large scale PTM analysis, in addition to this generic 
workflow, an enrichment of the PTM of interest may be necessary206,207. Alternatively, top-
down proteomics could be used to investigate the PTMs on a particular protein or a protein 
complex. Top-down proteomics refers to using whole proteins for the MS1 stage, however, 
the necessity to purify proteins (or protein complexes) and the difficulty to ionize whole 
proteins as opposed to peptides are major drawbacks of this method208. The advantages of 
top-down proteomics is that PTMs on the same protein molecule could be inquired.
    In recent years, another method that attempts to exploit the advantages of both bottom-
up and top-down proteomics has been developed: Middle-down proteomics209. In this 
method, longer peptides are generated by ‘selective’ digestion with proteases. The longer 
peptides provide an elegant compromise between investigating intact proteins and looking 
at short peptic fragments: PTMs co-occuring proximally on the same peptide species can be 
identified. This method has been instrumental in investigating various histone PTMs that 
are impossible to detect with bottom-up methodologies and difficult to study in top-down 
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approaches (such as Histone H3K4 and K9).
 So far, the identification aspect of mass spectrometry-based proteomics has been 
introduced. While it is essential to know the components of the proteome in different cells, 
studying a perturbation in the same cellular system requires quantification of proteins along 
with identification. Elegant quantification methods have enhanced interaction proteomics 
as well. However, as the famous saying goes, “mass spectrometry is not inherently 
quantitative”. Mass spectrometry is not inherently quantitative, because the ion intensities 
measured in MS1 and MS2 scans depend on the peptide composition which affects the 
ionization efficiency of the peptides. But the intensity, however loosely, is correlated with 
abundance, which is why some quantification methods use the ion intensity information 
and try to normalize that according to the size of the proteins204,210,211. However, there is no 
normalization trick that can fully make up for the differences of peptide composition that 
result in uneven ‘mass spectrometric measurability’. Therefore, quantification methods that 
rely on the comparison of the same peptide species in different conditions give the most 
accurate results.
   Quantification methods can be divided into 2 main branches211,212: 1. Methods based on 
labeling proteins or peptides: By integrating stable isotopes into proteins (Stable Isotope 
Labeling By Aminoacids in Cell Culture (see chapter 2 for details)) or peptides (dimethyl 
labeling, iTRAQ, etc.). 2. Label-free methods: Such as spectral counting, based on the 
number of MS1 scans of a peptide; or label free quantification (LFQ) algorithms based on 
measuring and comparing peptide intensities of proteins in 2 different states. 
   Importantly, all these quantification methods provide relative quantifications, comparing 
control vs perturbed states, or specific IPs to control IPs in the context of interaction 
proteomics. It should be noted that some label free methods could be utilized to gather 
absolute abundance information, but high accuracy absolute quantification methods rely on 
the spiking in of known amounts of proteins/peptides and comparing the measurement of 
related species to those of the spiked in entities213,214.   
    In this thesis, a method to perform quantitative interaction proteomics on nuclear extracts 
from a population of cells is presented in chapter 2. In the rest of the chapters, quantitative 
interaction proteomics is performed to screen for interactors of proteins of interest (e.g. 
MBD5, MBD6, BAP1, ASXL2, CDK2AP1, MBD3, etc.) and of a histone PTM of interest (Histone 
H2AK119Ub) utilizing both SILAC (label-based) and label-free quantification methods. 
 
  
133
Introduction
   Scope of this thesis
   Chromatin regulatory complexes are part of epigenetic mechanisms that are required for 
the appropriate propagation of transcriptional control during self-renewal and differentia-
tion of cells of an organism. The next chapters in this thesis focus on various chromatin regu-
latory complexes. A mass spectrometry-based quantitative proteomics approach for identi-
fying nuclear protein-protein interactions is described in chapter 2. This method is utilized in 
chapter 3 for the characterization of  the MBD5 and MBD6 interactomes. Interestingly, the 
Methyl-CpG-binding domain (that has lost the affinity for meCpG) mediates the interaction 
with the PR-Dub complex for both proteins. In addition, we show that MBD6 is recruited to 
DNA damage sites upon microirradiation independently of the reported interaction with PR-
Dub. In chapter 4, we characterize the H2AK118/119Ub interactome in a nucleosomal set-
ting in vitro. Based on the interactors that include PRC2 members, a novel regulatory mech-
anism is proposed in which JARID2/AEBP2/PRC2 complex interacts with H2AK118/119Ub 
and catalyzes H3K27 methylation. In chapter 5, subunit dynamics and stability within the 
NuRD complex is investigated. Protein-protein interactions are quantified using label-free 
and SILAC-based methods. Chapter 6 is a perspective on chromatin regulatory complexes 
that generally act to repress gene transcription. Chapter 7 is a discussion of various aspects 
of these findings and several general questions in the epigenetics field. 
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Abstract
Many cellular proteins assemble into macromolecular protein complexes. Therefore, 
identifying protein-protein interactions (PPIs) is essential to gain insight into the function 
of proteins. Recently established quantitative mass spectrometry-based techniques have 
significantly improved the unbiased search for PPIs. In this chapter, we describe a single-
step GFP affinity purification method combined with SILAC-based quantitative mass 
spectrometry that can be used to identify nuclear PPIs in mammalian cells. 
2GFP AP-MS
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1. Introduction
Proteins drive all processes in a cell through a complex and dynamic network of protein-
protein interactions (PPIs). Identifying these interactions is therefore essential to gain insight 
into the function of proteins. There are several approaches available to identify cellular 
protein-protein interactions. When putative interactors are known, co-immunoprecipitation 
experiments followed by Western blot analysis can be used to validate true interactors 
among the list of candidates. However, it is quite common that potential interactors of a 
protein are not known. In this case, unbiased interaction screening approaches are needed. 
One such approach is the yeast-2-hybrid (Y2H) system which identifies interactors of a 
protein of interest using a library of ‘prey’ proteins.1 The major disadvantage of this method, 
however, is that Y2H tends to result in many false positive interactions. Another limitation is 
that mammalian proteins expressed in yeast may lack some post-translational modifications 
that mediate PPIs. Furthermore, Y2H only detects direct protein-protein interactions 
and thus cannot be used to determine all components of larger protein complexes. An 
alternative to Y2H is the (tandem) affinity purification of the protein of interest followed by 
mass spectrometry (AP-MS).2 This method requires extensive purification of the protein of 
interest (the bait) under high stringency conditions to minimize non-specifically interacting 
proteins. However, even when using very stringent conditions, high-abundant background 
binders are not completely removed. This problem is particularly relevant when making use 
of modern mass spectrometers, which are very sensitive and which can sequence proteins 
when present in a sample in femtomole amounts.3 As a consequence, scientists still need to 
resort to other methods such as those mentioned above to distinguish true interactors from 
background binders. Therefore, although AP-MS is robust in identifying the proteins that are 
co-purified with the bait, the fact that interactions are not quantified compromises the ability 
to discriminate true interactors from background binders. In addition, the high stringency 
conditions can result in the loss of relatively weak but biologically relevant interactions. To 
overcome these problems, quantitative mass spectrometry methods have been established 
in recent years.4 In most of these methods, differential stable isotopic labeling, either on 
protein or peptide level, is used in the specific and the control affinity purification. Prior 
to mass spectrometry analysis, the specific and control pull-downs are combined. Each 
peptide then has a ‘light’ and a ‘heavy’ intensity, and the ratio between these two states 
indicates the relative abundance of a peptide and the corresponding protein in the specific 
and control affinity purification. As a result, the bait and its interactors have a high ratio, 
whereas background proteins have a ratio close to one. Here we describe an application 
of this principle, a SILAC-based GFP affinity purification method from mammalian nuclear 
extracts. The method starts with SILAC labeling of cells that (either stably or transiently) 
express the GFP-tagged protein of interest.5 As a control, wild-type cells lacking the GFP-
tagged bait are labeled in parallel. Nuclear extracts generated from these cells are then used 
for GFP affinity purifications followed by quantitative mass spectrometry to identify and 
quantify protein-protein interactions. 
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2. Materials
For preparing buffers, ultrapure water (18.5 MΩ cm resistance, total organic carbon < 12 
parts per billion) which will be referred to as Milli-Q is used. In addition, to avoid polymer 
accumulation in samples, do not use autoclaved pipette tips and keep all buffers in high 
quality glass bottles. Tabletop centrifuges with cooling capacity for 50-ml tubes and 
microcentrifuge tubes are required throughout the protocol.
2.1 SILAC Labeling 
1. SILAC Dulbecco’s Modified Eagle Medium (DMEM) lacking arginine and lysine
2. L-arginine monohydrochloride light and heavy (13C6
15N4) each dissolved to a final 
concentration of 84 mg/ml in Milli-Q
3. L-lysine monohydrochloride light and heavy (13C6
15N2) each dissolved to a final 
concentration of 146 mg/ml in Milli-Q
4. Dialyzed fetal bovine serum (D-FBS)
5. 200 mM L-glutamine
6. 100 units/ml Penicillin/Streptomycin 
7. 50 ml syringes and 0.22 µm filters
8. Dulbecco’s Phosphate Buffered Saline (PBS): 0.2 g/L KCl, 0.2 g/L KH2PO, 8 g/L NaCl, 2.16 
g/L HNa2O4P.7H2O 
9. Trypsin-EDTA: 200 mg/L EDTA, 170.000 units/L Trypsin
10. 94x16 mm and 145x20 mm cell culture dishes (referred to as 10-cm and 15-cm dishes 
respectively)
Optional (see Section 3.1):
11. SILAC RPMI medium lacking arginine and lysine 
12. 100x Non-essential amino acids
13. 2i inhibitors (Axon Medchem, CHIR99021 and PD0325901)
14. Leukemia inhibitory factor (LIF, 1000000 units/ml)
15. β-mercaptoethanol
16. 100 mM Sodium pyruvate
17. Accutase
2.2 Transient Transfection of SILAC-labeled Cells
Polyethylenimine, linear (PEI, Polysciences), dissolved to a final concentration of 1 mg/ml in 
Milli-Q and neutralized with HCl
2.3 Nuclear Extraction
1. PBS
2. SILAC DMEM
3. Trypsin-EDTA
4. Glass dounce homogenizer with type B pestle (tight); depending on the amount of 
cells, different sizes can be used: 500 µl, 2 ml, 7 ml, or 40 ml 
5. Buffer A: 10 mM KCl, 1.5 mM MgCl2, 10 mM Hepes-KOH pH 7.9
6. Buffer C: 420 mM NaCl, 20 mM Hepes-KOH pH 7.9, 20% (v/v) glycerol, 2 mM MgCl2, 
0.2 mM EDTA
7. Nonidet P40 (NP-40), 10% stock solution
8. Dithiotreitol (DTT), 500 mM stock solution
9. Complete EDTA-free protease inhibitor cocktail tablets (CPI; Roche, 1 tablet/ml = 50x 
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stock solution)
Optional (see Section 3.3):
10. 5 M NaCl
11. 100% Glycerol
2.4 Bradford Assay For Protein Quantification
1. Albumin from bovine serum (BSA) dissolved in Milli-Q to a concentation of 1 mg/ml
2. BioRad Protein Assay Dye Reagent Concentrate (BioRad, 5x) 
2.5 GFP Affinity Purification
1. GFP-binder beads (e.g. GFP-Trap_A from Chromotek)
2. Buffer C*: 300 mM NaCl, 20 mM Hepes-KOH pH 7.9, 20% (v/v) glycerol, 2 mM MgCl2, 
0.2 mM EDTA
3. PBS 
4. NP-40, 10% stock solution
5. DTT, 500 mM stock solution
6. Complete EDTA-free protease inhibitor cocktail tablets
7. Ethidium bromide, 10 mg/ml stock solution
8. Gel-loader tips
Optional (see Section 3.5):
Blocked agarose beads (e.g. from Chromotek) 
2.6 On-Bead Digestion of Proteins
1. Digestion buffer: 2 M urea dissolved in 100 mM Tris-HCl pH 7.5
2. DTT, 500 mM stock solution
3. Iodoacetamide (IAA) or chloroacetamide (CAA) dissolved to a final concentration of 
550 mM in 50 mM ammonium bicarbonate
4. Trypsin dissolved to a final concentration of 0.1 mg/ml in 50 mM acetic acid 
5. Thermoshaker 
2.7 Desalting and Purification of Peptides for Mass Spectrometry
1. Blunt-ended syringe needle (1.2 mm diameter) with a nanotubing end inserted as a 
plunger
2. C18 material (Empore)
3. Methanol (ultra pure)
4. Buffer A: 0.5% (v/v) acetic acid in Milli-Q 
5. Buffer B: 0.5% (v/v) acetic acid, 80% (v/v) acetonitrile (HPLC grade) in Milli-Q
6. 10% (v/v) trifluoroacetic acid (TFA) in Milli-Q 
2.8 Elution of Peptides
1. Buffer A: 0.5% (v/v) acetic acid in Milli-Q
2. Buffer B: 0.5% (v/v) acetic acid, 80% (v/v) acetonitrile in Milli-Q
3. Eppendorf Combitip plus 2.5 ml
4. Speed vacuum concentrator (with 96-well plate compatible rotor) 
5. HPLC autosampler 96 well plate 
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2.9 Mass Spectrometry
1. EASY nLC (Thermo Scientific)
2. High performance mass spectrometer (e.g. LTQ-Orbitrap Velos; Thermo Scientific) 
2.10 Data Analysis
1.   Windows-operated PC (at least 8 GB of RAM and multiple cores are recommended)
2.   MaxQuant software package
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3. Methods
3.1 SILAC Labeling 
The most commonly used metabolic labeling strategy is SILAC (Stable Isotope Labeling by 
Amino acids in Cell culture).5 In this method, cells are grown in the presence of normal 
(light) or heavy stable isotopic versions of certain amino acids (usually arginine and lysine). 
During cell culture, these light and heavy amino acids are incorporated into the proteins, 
enabling relative quantification of proteins between two functional states. The workflow 
described in this chapter consists of a so-called ‘forward’ and ‘reverse’ pull-down. In the 
forward pull-down, the cell line stably expressing a GFP-tagged transgene (referred to as 
GFP cells) is labeled ‘heavy’ and the corresponding wild-type (WT) cell line is labeled ‘light’. 
In the reverse pull-down, the light and heavy labels are swapped. Therefore, four different 
cultures have to be labeled and expanded (see Figure 1a, Notes 1 and 2). 
1. Prepare a bottle of ‘heavy’ and a bottle of ‘light’ medium. Once made, SILAC media can 
be kept for up to six weeks at 4°C. For each condition (light and heavy):
a. Take a bottle of DMEM lacking arginine, lysine, and glutamine (see Note 3).
b. Transfer 20--30 ml of this medium into a 50-ml tube and add 15 mg of light or 
heavy arginine and 36.5 mg of light or heavy lysine (see Note 4).
c. Filter-sterilize these aliquots using a syringe and a 0.22 µm filter back into the 
DMEM bottle.
d. Add 50 ml of D-FBS, 2 mM of L-glutamine, and 550 units of penicillin/
streptomycin.
2. Trypsinize the WT and GFP cells, neutralize trypsin by adding DMEM and divide each 
cell suspension into two 15-ml tubes.
3. Spin down the cells at 400 x g for 5 minutes (min). This step is necessary to remove 
trypsin from the cells. Trypsin provides a source of non-labeled amino acids and 
residual trypsin can therefore compromise SILAC labeling.
4. Aspirate the supernatant and resuspend the cells in light or heavy medium (WT cells 
and GFP cells are both labeled heavy and light). Transfer 25% of the cells of each tube 
into a 10-cm culture dish and add the appropriate amount of medium (heavy or light) 
to each dish.
5. Culture cells for at least eight doublings in SILAC medium. Keep in mind that some cell 
lines tend to grow more slowly in SILAC medium compared to normal DMEM due to 
the use of D-FBS. While labeling, cells can be expanded in order to end up with the 
appropriate amount of labeled cells after eight cell doublings. Although it depends on 
the cell line, a confluent 15-cm dish usually yields around 400 µg of nuclear extract. 
3.2 Transient Transfection of SILAC-labeled Cells
When a stable cell line expressing a GFP-tagged protein of interest is not available, transient 
transfections can be considered (see Note 5). In this case, WT cells are light and heavy 
labeled and expanded. Half of the light and half of the heavy cells are then transfected with 
the plasmid expressing the GFP-tagged bait, while the other two halves are transfected with 
a control plasmid (empty GFP plasmid). In the end, there are four cell populations (light 
control, light GFP, heavy control, heavy GFP; see Figure 1b). The method described below 
requires a total of 20 x 15-cm dishes, but this scale may be adjusted according to the amount 
of nuclear extract that is needed. 
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1. Expand light and heavy labeled cells to the required amount, in this case 10 x 15-cm 
dishes of light labeled cells and 10 x 15-cm dishes of heavy labeled cells. When cells 
reach about 60% confluency (see Note 6), half of the heavy and half of the light labeled 
cells (5 x 15-cm dishes of light and 5 x 15-cm dishes of heavy cells) are transfected with 
the GFP-tagged bait while the other half is transfected with the control GFP plasmid 
as follows:
2. Transfer 15 ml of DMEM without lysine, arginine, and glutamine (i.e. SILAC DMEM 
without anything added to it) into a 50-ml tube for each plasmid (bait and control).
3. Add 150 µg of the plasmid (bait or control) and 450 µl of PEI to each tube (see Note 7). 
Vortex for 10 s and incubate at room temperature (RT) for 30 min.
4. Pipette 1.5 ml of the transfection mix dropwise into each of five 15-cm dishes containing 
light cells and five 15-cm dishes containing heavy cells. Make sure to label the dishes.
5. Culture the cells for an additional 24-48 h at 37°C. In the end, there are four batches 
of cells to harvest: control light and heavy, GFP light and heavy. Prior to harvesting, 
expression of the GFP transgene can be checked by fluorescence microscopy. 
3.3 Nuclear Extraction
The next step in the workflow is the generation of nuclear extracts (see Note 8). The 
following method is based on Dignam et al. and is suitable for cells harvested from multiple 
15-cm dishes.6 However, the method can be adjusted to smaller or larger scale cultures. 
The generation of nuclear extracts is a critical step in the procedure. Differential nuclear 
extraction of different batches of cells results in a variation of individual protein abundance 
and this introduces more noise into the experiment (i.e. background protein ratios strongly 
deviating from 1). Therefore, the different batches of cells should be extracted equally. 
1. Wash the cells once with 15 ml of PBS. 
2. Add 2 ml of trypsin-EDTA to each dish and incubate at 37°C for about 5 min. Long 
incubation with trypsin results in cell lysis. Do not trypsinize more than 10 dishes 
simultaneously.
3. Neutralize trypsin with 10 ml of medium and collect the cells of each batch in a 50-ml 
tube. Keep the cells on ice from now on.
4. Rinse the dishes with PBS to collect the remaining cells.
5. Centrifuge the cells at 400 x g for 5 min at 4°C  and wash them with 20 ml of PBS. 
Centrifuge at 400 x g for 5 min at 4°C again.
6. Resuspend the pellet with 15 ml of ice-cold PBS and transfer the cell suspension to a 
15-ml tube. It is possible to leave the cells in this state for about 30 min.
7. Centrifuge at 400 x g for 5 min at 4°C.
8. Aspirate the supernatant and estimate the volume of the pellet. Resuspend the pellet 
in 5 volumes of ice-cold buffer A.
9. Incubate the cell suspension on ice for 10 min. Cells swell during this incubation due to 
the osmotic uptake of water. The extent of swelling, however, varies between different 
cell lines. HeLa cells, for example, almost double their volume whereas HEK293T cells 
hardly swell.
10. Centrifuge for 5 min at 400 x g at 4°C.
11. Aspirate the supernatant, resuspend cells in 2 volumes of buffer A containing 1x CPI 
and 0.15% NP-40 and transfer the suspension to a dounce homogenizer. Keep the 
dounce homogenizer on ice at all times.
2GFP AP-MS
53
12. Dounce for 30-40 times. Wait for 30-60 seconds after every ten strokes of douncing to 
minimize the temperature increase due to friction.
13. Transfer the suspension into a 15-ml tube and centrifuge for 15 min at 3,200 x g at 4°C.
14. The supernatant is the cytoplasmic extract, which can be aliquoted (See Note 9), snap-
frozen and kept for other purposes. The pellet consists of crude nuclei.
15. Gently add 5 volumes of ice-cold PBS to the pellet and detach the pellet from the tube 
by flicking it a few times. Do not resuspend the pellet since this will result in partial 
lysis of the nuclei.  
16. Centrifuge for 5 min at 3,200 x g at 4°C. Discard the supernatant and remove any 
residual liquid by placing the tubes upside down on a tissue paper for 1 min.
17. Estimate the volume of the nuclei and add 2 volumes of buffer C containing 1x CPI, 
0.1% NP-40 and 0.5 mM DTT. Resuspend the nuclei and transfer the suspension to a 
microcentrifuge tube.
18. Homogenize the nuclei by pipetting up and down 10-15 times.
19. Incubate the suspension at 4°C on a rotating wheel for 60 min. 
20. Centrifuge the microcentrifuge tubes for 40 min in a pre-cooled tabletop centrifuge at 
maximum speed (about 17,900 x g) at 4°C.
 
Aliquot the supernatant (100-200 µl fractions), which is the nuclear extract, snap-freeze 
in liquid nitrogen and store at -80°C. Multiple freeze-thaw cycles should be avoided to 
preserve the quality of the nuclear extract. The pellet represents the insoluble chromatin 
fraction which could also be snap-frozen and kept for other purposes.
3.4 Bradford Assay for Protein Quantification 
1.     Dilute the extracts 1:10 in Milli-Q to a final volume of 20 µl.
2.    Take 4 and 10 µl aliquots from the 1:10 dilution and add 1 ml of 1x Bradford protein 
assay solution to each sample.
3.      Take 0, 1, 2, 5, 7, and 10 µl aliquots of 1 mg/ml BSA and add 1 ml of 1x Bradford protein 
assay solution to each sample.
4.      Measure the samples at 595 nm using a spectrophotometer.
5.               Generate a standard curve using the BSA samples and calculate the protein concentration 
of the extracts using linear regression. Note that the extracts were diluted 1:10 in step 1. 
3.5 GFP Affinity Purification 
The next step in the workflow is the GFP affinity purification (see Notes 10 and 11). Four 
extracts have been generated in section 3.3: light and heavy WT extracts and light and heavy 
GFP extracts (see Note 12). These four extracts are incubated with GFP-binder beads and 
then combined after the incubation and wash steps to generate the forward (WT light + GFP 
heavy) and reverse (WT heavy + GFP light) experiment. 
1. Add 15 µl of GFP-binder beads (from a 50% slurry) into 4 microcentrifuge tubes. Cut 
the tips of 200 µl pipette tips when handling the agarose beads. Centrifuge the beads 
at 1500 x g for 2 min after each wash and never vortex the beads.
2. Wash the beads three times with 1 ml of buffer C* containing 1x CPI, 0.1% NP-40 and 
0.5 mM DTT (see Note 13). Beads are washed by adding buffer, inverting the tubes 5 
times and centrifugation. 
3. Aspirate the supernatant. For each of the four extracts, calculate the volume for 1 
mg of protein. The affinity purification is performed in a final volume of 400 µl that 
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contains the nuclear extract, buffer C* and ethidium bromide at a final concentration 
of 50 µg/ml (see Notes 14 and 15, Figures 2 and 3). First add the necessary amount 
of buffer C* to the beads, followed by the ethidium bromide and finally the nuclear 
extract. If the amount of nuclear extract to be added exceeds 400 µl, the final volume 
can be increased accordingly but it should be kept constant for all the samples.
4. Incubate the samples on a rotating wheel for 90 min at 4°C.
Figure 1: Schematic representation of the method including the SILAC labeling, nuclear extraction, 
and GFP-affinity purification followed by quantitative mass spectrometry. a. The workflow for cells 
stably expressing the GFP-tagged protein of interest and the corresponding wild-type cells. b. The 
workflow for transient expression of a GFP-tagged bait in SILAC-labeled cells.
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5. Centrifuge. Wash the beads twice with 1 ml of buffer C* containing 1x CPI, 0.5% NP-40 
and 0.5 mM DTT (see Note 16).
6. Wash the beads twice with 1 ml of PBS containing 0.5% NP-40.
7. Wash the beads once with 1 ml of PBS. 
8. Add 1 ml of PBS to the 
light WT beads and 
transfer the beads to the 
microcentrifuge tube 
containing the GFP heavy 
beads. This is the forward 
experiment. Combine the 
heavy WT and light GFP 
beads in a similar way. This 
is the reverse experiment. 
9. Centrifuge the samples and 
aspirate the supernatant 
completely using a gel-
loader tip.
Figure 2: Preventing DNA-mediated 
protein interactions. The presence 
of ethidium bromide during the 
GFP affinity purification eliminates 
co-purification of proteins bound 
to DNA in close proximity to the 
bait and its interactors. In addition, 
the cloud of background proteins 
is less tight in the absence of 
ethidium bromide. 
3.6 On-bead Digestion of Proteins
At the end of section 3.5, two samples remain (forward pull-down and reverse pull-down). 
The next step is digesting the proteins off the beads with trypsin. This method is adapted 
from Hubner et al.7,8
Always prepare urea solutions fresh before use and never cool the solutions to avoid urea 
precipitation. Furthermore, do not heat urea-containing samples to avoid adduct formation. 
Thaw and keep trypsin on ice at all times to minimize self-digestion.
1. Add 50 µl of digestion buffer to the samples.
2. Add DTT to a final concentration of 10 mM and shake the samples at 1,400 rpm on a 
thermoshaker for 20 min at RT.
3. Add IAA or CAA to a final concentration of 50 mM and incubate the samples for 
20 min shaking at 1,400 rpm on a thermoshaker. Note that the stock solutions and 
IAA-containing samples need to be kept in the dark. CAA should be used if a post-
translational modification analysis (of ubiquitin in particular) will be performed 
afterwards. IAA can generate adducts on lysine residues that mimic ubiquitination.9
4. Add 2.5 µl of trypsin to the beads. Incubate for 2 h on the shaker at 1,400 rpm at RT.
5. Centrifuge the samples at 2,000 x g for 2 min and transfer the supernatants into new 
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microcentrifuge tubes (avoid taking up any beads). To the remaining beads, add 50 µl 
of digestion buffer and incubate at RT for 5 min while shaking. 
6. Centrifuge the beads, collect the supernatant and add it to the one collected in the 
previous step for each sample. 
7. Add 1 µl of trypsin to the combined supernatant and incubate overnight at RT. 
Figure 3: GFP-CDK2AP1 
affinity purifications in the 
absence or presence of 
ethidium bromide using 
wild-type and GFP-tagged 
C D K 2 A P 1 - e x p r e s s i n g 
HeLa cells. In both 
panels, known interactors 
of CDK2AP1 (NuRD 
complex subunits) are 
indicated and statistically 
significant interactors 
are shown in blue. a. 
The affinity purification 
was performed without 
ethidium bromide. A 
wide spreading of the 
background cloud and 
interactors is observed 
in the scatterplot. This 
spreading affects the 
boxplot statistics used 
for the significance 
calculation of interactors. 
In this pull-down, 
H2AFC, a histone variant, 
shows a high forward 
and low reverse ratio 
clustering with known 
CDK2AP1 interactors. b. 
The affinity purification 
was performed in the 
presence of ethidium 
bromide. In this case, 
the background cloud is 
more compact and tightly 
clustered around the 
origin of the scatterplot. 
As a consequence, 
NuRD complex subunits, which are known interactors of CDK2AP1, are significant 
outliers. Note that in this pull-down, H2AFC is identified as a background protein. 
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3.7 Desalting and Purification of Peptides for Mass Spectrometry
Following digestion of the proteins, the tryptic peptides have to be desalted prior to mass 
spectrometry analysis. This method is adapted from Rappsilber et al.10,11 In brief, C18 
material inserted into a p200 pipette tip (referred to as StageTips) is used to capture and 
purify peptides. After each centrifugation step, check the StageTips to ensure that all the 
liquid has flowed through before proceeding with the next step.
1. For each sample, puncture out a small disc of double-layered C18 material using a 
blunt-ended syringe needle and transfer the C18 material into a p200 pipette tip. Push 
the disc into the tip and fix it at the end but do not apply too much pressure. 
2. Insert the tip into a microcentrifuge tube with a hole in its cap (see Figure 4). The 
pipette tip on the tube should be stable enough but it should not touch the bottom 
of the tube where the flow-through solvents will be collected. 
3. Activate the C18 material by adding 50 µl of methanol on top of it and centrifuge at 
1,500 x g for 3-5 min in a tabletop centrifuge. Check the tip to make sure that all the 
methanol has flowed through.  
4. Add 50 µl of buffer B to the tip and centrifuge at 1,500 x g for 3-5 min. Discard the flow-
through.
5. Load 50 µl of buffer A to the tip and centrifuge at 1,500 x g for 3-5 min. 
6. Repeat step 5.
7. To each of the samples that were digested overnight with trypsin (section 3.6), add 10 
µl of 10% TFA and resuspend. Centrifuge the samples at 2,000 x g for 2 min. Make sure 
not to take up any residual beads that may have been carried over when supernatants 
were collected in the previous section. 
8. Load the samples onto the (labeled) StageTips and centrifuge at 
400 x g for 10-15 min. It is important to centrifuge more slowly 
during this step to ensure efficient binding of peptides to the 
C18 plug.
9. When all the sample has flowed through the StageTip, load 
50 µl of buffer A and centrifuge at 1,500 x g for 3-5 min. The 
StageTips can be stored at 4°C for months at this point.
         Figure 4: Schematic representation of a p200 pipette tip with a C18 
plug inserted (StageTip) mounted on a 2-ml microcentrifuge tube. 
3.8 Elution of Peptides
1. When proceeding directly after desalting and concentration of peptides using 
StageTips, start from step 2 of this section. If the samples have been stored at 4°C on 
StageTips, rehydrate StageTips by loading 30 µl of buffer A and centrifuge at 1,500 x g 
for 3-5 min.
2. Elute the peptides into a 96-well autosampler plate that is compatible with the 
nanoHPLC connected to the mass spectrometer. To elute, add 30 µl of buffer B and 
fit an air-filled Eppendorf combitip to the back of the StageTip. Apply pressure on the 
combitip to slowly force the solvent through the StageTip directly into the autosampler 
plate. 
3. Concentrate the eluted samples until the volume is about 5 µl using the speed vacuum 
concentrator. Add 7 µl of buffer A to the samples and transfer them to the autosampler 
C18 plug
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plate of the nanoHPLC.
3.9 Mass Spectrometry
The following section provides guidelines for measuring GFP affinity purification samples by 
nanoHPLC-MS/MS, e.g. an EASY nLC coupled to an LTQ-Orbitrap Velos mass spectrometer. 
Expertise is required to operate these machines, therefore the following steps should be 
performed under the supervision of an experienced mass spectrometrist.
1. Program for an injection volume of 5 µl of the sample into the nanoHPLC.
2. Peptides are eluted from the nano-column packed with C18 using a 5--30% acetonitrile 
(v/v) gradient followed by a sharp increase to 60% acetonitrile in 10 min with a flow 
rate of 250 nl/min. Total elution time is around 120 min, but this can be increased if 
the sample is very complex.
3. The recommended settings for data acquisition are: for precursor MS spectra, m/z 
range 300--1750 with a resolution of 60,000 and a target value of 1 million ions per 
full scan. For MS/MS spectra, CID is selected as the fragmentation method and the 
15 most intense precursor ions are selected for fragmentation from each full MS 
scan with a minimal ion count target value of 500. Dynamic exclusion is set to 30 
seconds (both repeat duration and exclusion duration), list size 500, early expiration 
enabled (count 2, S/N threshold 2). MS/MS scans are acquired in the centroid 
mode in the dual pressure linear ion trap with a normalized collision energy of 35%. 
3.10 Data Analysis
After data acquisition is complete, raw data are transferred to a Windows-operated PC. We 
use the MaxQuant software package to analyze the raw data which can be freely downloaded 
at www.maxquant.org (11). The software also contains a module for downstream data 
analysis (statistical tests, filtering, clustering, GO term enrichments etc.) called Perseus. New 
versions of the software are continously being generated and made available at the website. 
There is also an active Google group (MaxQuant) for posting questions.
1. Open the MaxQuant.exe program.
2. Load the raw data files (using load files option) that were copied to a local disc in a 
separate data folder containing only the files that are to be analyzed together (in this 
case, only the raw data files of the forward and the reverse experiment). Do not use 
spaces when creating data folders and raw files since this generates an error while 
running MaxQuant.
3. Click on ‘Exp. Design’. Then use Excel to open the ‘experimentalDesignTemplate.txt’ 
that is written into the ‘combined’ folder within the data folder. Specify the forward 
and reverse experiments in the ‘experiment’ column and save the changes.
4. Go to the ‘Group-specific parameters’ tab and check the protease that is used 
(trypsin(P)), the multiplicity (2) and the labeled amino acids (Arg10 and Lys8). If 
necessary, adjust these options according to the experiment.
5. Go to the ‘MS/MS & Sequences’ tab and upload the FASTA file database of the 
appropriate organism. These FASTA files can be downloaded at the MaxQuant website. 
6. Go to the ‘Identification and quantification’ tab and upload the 
‘experimentalDesignTemplate.txt’. 
7. Go to the ‘Misc.’ tab and click the ‘Match between runs’ and ‘Re-quantify’ options. 
8. Start the analysis by clicking on ‘Start’.
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At the end of the analysis, the forward and reverse ratios of proteins are reported in 
‘ProteinGroups.txt’ (within the txt folder that is written into the data folder). Using Perseus 
(or other programs such as R, MatLab etc.), the contaminants, reverse hits and proteins with 
less than 3 reported peptide ratios (Ratio H/L count) can be filtered out. After this step, log-
transform (base 2) the protein ratios and calculate significance B (in Perseus). Significance 
B indicates the probability of a protein being a significant outlier from the background 
cloud based on intensity and ratio. After these steps, plot the log2-transformed normalized 
forward and reverse ratios against each other. The non-specific background binders (with 
1:1 ratios in both experiments) cluster around the origin of the graph while the specific 
interactors have high forward and low reverse ratios (see Figure 1). Contaminant proteins 
(such as keratins and serum proteins) are easily distinguished since they have a low forward 
and a low reverse ratio (as they are not SILAC-labeled).
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4. Notes
1. When a cell line is being labeled for the first time, it is recommended to perform a 
SILAC label incorporation check before proceeding with large scale experiments. 
This can be done by digesting a small amount of heavy-labeled nuclear or whole cell 
extract (10 µg) with trypsin using standard in solution digestion protocols or the filter-
aided sample preparation (FASP) method followed by LC-MS/MS.12 If incorporation 
efficiency is lower than 95%, the maximum observable ratios decrease significantly 
(i.e. 90% incorporation results in a maximum ratio of 9, at 80% the maximum ratio 
is 4, etc.). The minimum recommended incorporation efficiency is 95%. Note that 
the labeling efficiency will never reach 100% due to trace amounts of non-labeled 
amino acids in the culture medium. Another potential problem is arginine-to-proline 
conversion, which can be investigated during the incorporation check. When a heavy 
arginine (Arg10) is converted to proline, this proline is 6 Daltons heavier compared 
to normal proline. For heavy SILAC-labeled peptides containing one or more internal 
prolines, a third isotope cluster appears in the mass spectrum. The intensity of this 
third isotope cluster is not taken into account during quantification and this results 
in an underestimation of the peptide ratio. A small percentage of arginine-to-proline 
conversion can easily be normalized for, but as a rule of thumb, heavy proline peaks 
should not have an intensity of more than 5% of the normal heavy peak. Some cell lines 
are more prone to this problem than others and in some cases, titrating the amount 
of arginine and proline in the SILAC medium can reduce the amount of conversion. 
However, proline to arginine conversion also occurs and this potentially compromises 
arginine labeling efficency. Therefore, the titration should be performed carefully. As 
a last resort, lysine-only labeling can be used to circumvent this problem. In this case, 
LysC instead of trypsin is used to digest the proteins.
2. When working with a stable cell line expressing a GFP-tagged protein of interest, it is 
recommended to SILAC-label this cell line and the WT control cells simultaneously. 
Both lines will be labeled light and heavy. In the end, four batches of cells are harvested: 
light and heavy WT cells and light and heavy GFP cells. While culturing and harvesting, 
it is important to handle all these batches of cells as reproducibly as possible in order 
to minimize variations between the extracts.
3. For suspension cells, SILAC RPMI medium lacking lysine, arginine and glutamine 
is available. For labeling of mouse embryonic stem cells (mESCs), SILAC DMEM 
(with 15% D-FBS, L-glutamine, and penicillin/streptomycin) can be used with the 
necessary additions: 1x non-essential amino acids, 1 mM sodium pyruvate, lysine and 
arginine (light or heavy in amounts described), 1000 units/ml LIF, 4.2 µl of 99% (v/v) 
β-mercaptoethanol and 2i inhibitors (3 µM and 1 µM of CHIR99021 and PD0325901 
respectively). 2i inhibitors consist of small molecule inhibitors of GSK-3 and ERK1/2 
signaling and thus prevent differentiation.13  Note that the mESCs should not be grown 
on feeder cells since these are not SILAC-labeled. Several mESC lines such as IB10 
and R1 can grow in the absence of feeder cells when culture dishes are coated with 
0.15% gelatin. Instead of trypsin-EDTA, accutase is used for detaching the cells which 
is a mixture of proteolytic and collagenolytic enzymes effective in detaching primary 
fibroblasts, neurons, endothetial cells and ESCs.14
4. The amount of labeled amino acids to be added to the medium is optimized for SILAC 
labeling of commonly used cell lines such as HeLa, HEK293T and MCF7. These amounts 
may need to be altered for labeling other cell lines.
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5. We prefer to use cell lines stably transfected with a bacterial artificial chromosome 
(BAC) construct containing the gene of interest.15 These BACs have been recombined 
to express the protein of interest with a GFP tag. Since the BAC is expected to contain 
the proximal regulatory regions for expression, the expression level of the GFP-tagged 
bait is at near endogenous levels. In this workflow, the parental WT cells are used as 
control cell line. An alternative approach is to generate a stable cell line in which the 
expression of the GFP-tagged bait is inducible. In this case, uninduced cells serve as the 
control. If no stable cell line is available, the GFP-tagged bait can be transiently over-
expressed. However, the disadvantage of transient transfection is that the expression 
level of the GFP-tagged bait cannot be controlled. Although the expression level of 
the bait depends on the strength of the promoter in the plasmid, it usually exceeds 
endogenous levels. While this may not necessarily be problematic, a gross over-
expression may induce false positive interactions. In addition, when the majority of the 
bait is not associated with interactors due to over-expression, this may compromise the 
depth of sample sequencing, thereby reducing the identification of substoichiometric 
interactors.
6. The confluency required at the time of transient transfection depends on the 
proliferation rate of the cells. It is recommended to keep the cells in culture after 
transfection for at least 24 hours and at most 48 hours. The confluency at the time of 
transfection should be adjusted accordingly to prevent overgrowth of the cells.
7. Usually 10-20 µg of DNA per 15-cm dish is used for transfection. The amount may be 
reduced in order to lower the amount of GFP-tagged bait in the nuclear extract in case 
of very strong over-expression.
8. When working with nuclear proteins, making nuclear extracts is highly recommended 
since this is an efficient way to get rid of a lot of highly abundant cytoplasmic proteins. 
This step decreases the background in the pull-down and in the mass spectrometer, 
facilitating the sequencing and identification of the GFP-tagged bait and interactors. 
The affinity purification method described here, however, is not restricted to nuclear 
extracts and can also be applied in combination with cytoplasmic or whole cell 
extracts. In these cases, the stringency of the buffer used during extraction and of 
Buffer C* used during the affinity purification should be increased and more input 
material should be used.
9. The cytoplasmic extract should be snap-frozen after adding glycerol to a final volume 
of 10% and NaCl to a final concentration of 150 mM.
10. In this chapter, the GFP tag is used for affinity purification. Although GFP is a large 
protein tag compared to other commonly used tags such as Flag, HA, etc., tagging 
proteins with GFP rarely results in a non-functional fusion protein.15 In our hands, the 
GFP tag works well and does not often interfere with PPIs. This is true even when 
tagging very small proteins.16 Depending on the domain structure of the bait, N- or 
C-terminal tagging may be preferred.
11. The GFP-binder beads used for affinity purification only bear the epitope recognition 
domain of a high-affinity monoclonal GFP antibody. This small, 13 kDa fragment is 
expressed in E.coli and then covalently cross-linked to agarose beads.17 The result 
is a high-affinity enrichment resin lacking the heavy and light immunoglobin chains 
present in conventional antibodies. When using conventional antibodies for affinity 
purification, the heavy and light chains are digested together with the affinity-purified 
proteins and dominate the MS spectra due to their abundance. In that case, a specific 
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elution protocol (peptide elution or acidic elution) or in-gel digestion is recommended 
instead of on-bead digestion.18
12. When a ‘wild-type’ cell line (the parental cell line that was used to generate the 
transgenic cell line) is not available, it is possible to use the nuclear extracts from cells 
expressing the GFP-tagged transgene in combination with blocked agarose beads 
(BAB) as a negative control. These BAB are commercially available (see section 2.5). 
This may also be necessary when expression of the GFP-tagged transgene significantly 
changes the growth rate and/or morphology of the parental cell line. In this case, the 
experimental set-up changes. Instead of four different cultures, only the GFP-tagged 
cell line is labeled light and heavy but expanded to twice the amount. Four affinity 
purifications are then performed as follows: light and heavy nuclear extracts incubated 
with GFP-binder beads and light and heavy nuclear extracts incubated with BAB. The 
forward experiment becomes heavy GFP-binder pull-down + light BAB pull-down and 
the reverse experiment becomes light GFP-binder pull-down + heavy BAB pull-down.
13. Note that the buffer C* used for affinity purification contains 300 mM NaCl as opposed 
to the buffer C (420 mM NaCl) used for nuclear extraction. At the last step of nuclear 
extraction, addition of two volumes of buffer C with 420 mM NaCl to the crude nuclei 
results in a final salt concentration of approximately 300 mM. Since the protein 
concentrations of different batches of nuclear extracts may vary, the volume of nuclear 
extract to be used for affinity purification may also vary (in order to use the same 
amount of protein). By using a buffer with 300 mM salt for the GFP pull-down, the final 
salt concentration is kept equal in all affinity purifications. 
14. Using 1 mg of nuclear extract is usually sufficient to identify the bait and interactors. 
For low-expressed bait proteins or when using whole cell lysates, this amount can be 
increased to a maximum of 5 mg. The amount of beads used during the pull-down 
need not be changed. 
15. Using ethidium bromide is very critical to eliminate DNA-mediated indirect interactions. 
Although the bulk of the DNA ends up in the insoluble chromatin fraction during 
nuclear extraction, the nuclear extract still contains a fair amount of double-stranded 
DNA. In the absence of ethidium bromide, the pull-downs are more “noisy” and more 
proteins are identified as interactors of the bait, many of which are false positive, DNA-
mediated secondary interactions (see Figures 2 and 3). As an alternative, DNA and 
RNA in the extract can be digested with an endonuclease such as MNase prior to the 
pull-down. 
16. The amount of detergent and salt in the wash buffer may be altered. To identify 
low affinity or sub-stoichiometric interactors, the final NP-40 concentration can be 
decreased to 0.2%; to identify very strong interactors, it can be raised to 1%. The 
key point is to find a balance between specificity and sensitivity and this may vary 
depending on the bait. 
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     Abstract
   MBD5 and MBD6 are two members of the methyl-CpG binding domain (MBD) family 
of proteins that are poorly characterized. Studies performed thus far have failed to show 
binding of the MBD5 and MBD6 MBD domain to methylated DNA. Here, we show that 
both MBD5 and MBD6 interact with the mammalian PR-DUB Polycomb protein complex 
in a mutually exclusive manner. Strikingly, the MBD domain of MBD5 and MBD6 is both 
necessary and sufficient to mediate this interaction. ChIP analyses reveal that MBD6 and 
FOXK2/PR-DUB share a subset of genomic target genes, suggesting a functional interaction 
in vivo. Finally, we show that MBD6, but not MBD5, gets recruited to sites of DNA damage 
in a PR-DUB independent manner. Our study thus implies a shared function for MBD5 and 
MBD6 through an interaction with PR-DUB, as well as an MBD6-specific recruitment to sites 
of DNA damage. 
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     Introduction
   DNA methylation is a stable epigenetic mark found in vertebrate and plant genomes. 
In mammals, the fifth carbon position of cytosine is methylated throughout the genome 
and mostly in a CpG dinucleotide context (5-meCpGs) [1, 2]. 5-meCpGs in the promoter of 
genes are generally associated with their repression and are involved in processes such as 
regulating the expression of imprinted genes, X chromosome inactivation and higher order 
chromatin compaction [3]. The molecular pathways via which DNA methylation mediates 
transcriptional silencing are not completely understood. One important mechanism is 
thought to involve the specific recruitment of transcriptionally-repressive protein complexes 
to methylated CpG dinucleotides [2, 3]. Initially, three classes of proteins were found to 
interact with 5-meCpG: the Methyl-CpG Binding Domain (MBD) family of proteins, Kaiso 
and Kaiso-like proteins (ZBTB38 and ZBTB4), and SET and Ring finger Associated (SRA) 
domain proteins (UHRF1 and UHRF2)[3]. More recently, it was shown that other proteins 
not belonging to these three protein classes can interact with methylated CpG containing 
DNA. Examples include certain homeobox proteins and proteins carrying a winged helix 
domain [4, 5]. 
   The first discovered member of the MBD family of proteins is MeCP2 [6]. The domain 
within MeCP2 responsible for binding to methylated CpGs was narrowed down and named 
the methyl-CpG-binding domain [7]. Later on, based on sequence homology, more members 
of the MBD family of proteins were identified, which were designated MBD1-6. In addition, 
four other proteins carry an MBD domain (SETDB1, SETDB2, BAZ2A and BAZ2B) (Figure 1A). 
However, biochemical studies have revealed that not all members of the MBD family are 
capable of binding to 5-meCpG. MBD5 and MBD6 represent two such examples of MBD-
containing proteins that cannot bind 5-meCpG [1, 3, 8].
  MBD5 has two isoforms: a long isoform carrying a PWWP domain near its carboxy-
terminal, and a shorter isoform lacking this domain. MBD6 has no other annotated domains 
in addition to the MBD. MBD5 and MBD6 localize to heterochromatin foci in mouse nuclei 
in a DNA methylation independent manner [9]. A microdeletion syndrome including part 
of the Mbd5 locus has been associated with neurological disorders [10]. Furthermore, 
Mbd5 knock-out mice show deregulation in glucose homeostasis, growth retardation and 
ultimately, preweaning lethality [11]. A detailed functional and biochemical characterization 
of these proteins is still lacking.
    Here, we show that MBD5 and MBD6 interact with the human Polycomb repressive complex 
PR-DUB. PR-DUB was first identified in Drosophila melanogaster and the complex catalyzes 
deubiquitination of H2A at lysine 118 (119 in mammals) [12]. The mammalian counterpart 
of the complex is known to consist of BAP1, ASXL1/2, KDM1B, FOXK1/2 and HCFC1[13-15]. 
We find these proteins to co-purify with MBD5 and MBD6. Interestingly, the MBD domain of 
MBD5 and MBD6 is necessary and sufficient for the interaction with the PR-DUB complex, 
showing the first example of an MBD acting as a protein-protein interaction domain. MBD5 
and MBD6 interact with the PR-DUB complex in a mutually-exclusive manner. Using ChIP, we 
find that MBD6 co-localizes to a subset of genomic FOXK2 and BAP1 target genes, suggesting 
a functional link between these proteins in vivo. Finally, we find that MBD6, but not MBD5, 
gets recruited to sites of DNA damage in a PR-DUB independent manner, thus revealing a 
functional distinction between MBD5 and MBD6. 
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     Materials and methods
     Cell culture and SILAC labeling
     293T cells and HeLa cells were cultured in DMEM (high glucose, 4.5 g/l) with L-glutamine 
(Lonza) supplemented with 10% FBS (Thermo Scientific) and 550 units of penicillin-
streptomycin (Lonza). For SILAC labeling, cells were cultured for at least 8 doublings in heavy 
and light SILAC medium (SILAC DMEM (PAA), 10% v/v dialyzed FBS (Gibco), 1 unit/ml of 
penicillin-streptomycin (Gibco) and 2 mM L-glutamine and either light or heavy forms of 
arginine and lysine at a final concentration of 27 mM and 66 mM, respectively), before 
expanding them to the desired amounts. 
   
     Transient transfection and nuclear extraction
    15 mL of SILAC DMEM (without supplements) was mixed with 450 µl of PEI (1 mg/ml) 
and 150 µg of plasmid encoding for the protein of interest tagged with eGFP. This mixture 
was vortexed for 15 seconds and then incubated at room temperature for 25 minutes. Next, 
5x15 cm dishes of light labeled and 5x15 cm dishes of heavy-labeled 293T or HeLa cells were 
transfected with 1.5 ml of the transfection mixture and incubated at 37°C for 36-40 hours. 
As a control, 5 light labeled 15 cm dishes and 5 heavy labeled 15 cm dishes of 293T or HeLa 
cells were mock transfected. Nuclear extracts were generated as described [16].
   MBD5 isoform 1, isoform 2 and MBD6 were amplified from plasmids with gateway-
compatible recombination arms [9]. Destination vectors resulting in N-terminal eGFP 
tagging (pcDNA5/FRT/TO), were prepared according to the manufacturer’s instructions 
(Invitrogen). The destination vectors were then transfected into HeLa cells with a single FRT 
site (referred to as HeLa FRT cell line) along with the pOG44 recombinase (Invitrogen). Cells 
were selected for stable incorporation of the construct of interest into the FRT site using 
hygromycin (Roche). Stable cell lines were tested for expression of the transgene by western 
blotting for GFP. 14-16 hours prior to harvesting cells to generate nuclear extracts, 1 µg/ml 
of doxycycline was added to culture medium to induce protein expression. 
   
     Stable knock-down of BAP1 in MBD6-GFP HeLa FRT line
       BAP1 knock-down using shRNA constructs against BAP1 and a scrambled shRNA construct 
as a control in the MBD6-GFP HeLa FRT cell line was performed essentially as described [17]. 
   
     GFP Immunoprecipitation, on-bead digestion of proteins and mass spectrometry
      Depending on the nuclear extracts used, i.e. from SILAC labeled cells or non-labeled cells, 
the GFP pull-down set-up can be seen in Figure 2a or Figure 4a, respectively. 
In the case of SILAC extracts, 4 different IPs were performed using GFP nanotrap beads 
(Chromotek) and 4 different extracts (light non-transfected; light transfected; heavy non-
transfected; heavy transfected). In the case of label-free extracts, 3 specific pull-downs were 
performed with GFP beads and 3 control pull-downs using non-GFP beads (Chromotek) using 
the same GFP extract. 1-2 µg of extract was used for each IP. IPs and subsequent on-bead 
digestion, LC-MS/MS analysis and data analysis were performed essentially as described 
[18]. Data was analyzed using the MaxQuant software [19].
  
     Chromatin Immunoprecipitation
     Approximately 20 million cells (one confluent 150 mm culture dish) were crosslinked by 
adding 10% vol/vol Buffer A (0.1 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Hepes, freshly 
added before use: 11% final concentration formaldehyde) and rocking at room temperature 
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for 10 minutes. Crosslinking was quenched by the addition of 0.125 M glycine. After this 
step the dishes were kept on ice. Cells were scraped and collected in PBS following 1 PBS 
wash and then pelleted by centrifugation (1600xg, 7 minutes, 4°C). 5 ml of lysis buffer (10 
mM Tris-HCl (pH 7.5), 10 mM NaCl, 0.2% NP-40, 0.2% Triton-X, 1 mM EDTA, 0.5 mM EGTA) 
was added to the cell pellet, followed by centrifugation (1600xg, 5 minutes, 4°C). 5 ml of 
buffer C (0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Hepes) was added to the cell pellet 
and the cell suspension was incubated at 4°C for 10 minutes on a rotating wheel, followed 
by centrifugation (1600xg, 5 minutes, 4°C). The pellet was resuspended in 900 µl of ChIP 
incubation buffer (0.2% SDS, 1% Triton-X, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM 
Tris-HCl (pH 8)) and sonicated for 28 cycles (Diagenode Bioruptor, setting high; 30 seconds 
on, 30 seconds off). The sonicated cell suspension was cleared by centrifugation (3500xg, 
20 minutes, 4°C) and the supernatant was snap-frozen as the chromatin fraction. For each 
ChIP, 300-400 µl from the chromatin fraction was incubated with protein A/G agarose beads 
(Santa Cruz), bovine serum albumin dissolved in Milli Q, ChIP incubation buffer, protease 
inhibitor cocktail and 2-3 µg of antibody overnight at 4°C on a rotating wheel. The next 
day beads were washed twice with wash buffer 1 (0.1% SDS, 0.1% NaDOC, 1% Triton-X, 
0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl (pH 8)), once with wash buffer 
2 (0.1% SDS, 0.1% NaDOC, 1% Triton-X, 0.5 M NaCl, 1 mM EDTA, 10 mM Tris-HCl (pH 8)), 
once with wash buffer 3 (0.25 M LiCl, 0.5% NaDOC, 0.5% NP-40, 1 mM EDTA, 0.5 mM EGTA, 
10 mM Tris-HCl (pH 8)) and twice with wash buffer 4 (1 mM EDTA, 0.5 mM EGTA, 10 mM 
Tris-HCl (pH 8)) in a volume of 200 µl. Each wash consisted of 5 minute incubation on a 
rotating wheel at 4°C followed by centrifugation (2000xg, 1 minute, 4°C). After the final 
wash, immunocomplexes were eluted off the beads by the addition of elution buffer (1% 
SDS, 0.1 M NaHCO3) and incubation at room temperature on a rotating wheel for 15 minutes 
followed by centrifugation. The supernatant was collected and one more round of elution 
was performed on the beads, after which the collected supernatant was added to the first 
(final volume 250 µl). 10 µl of 5M NaCl was added to the samples after which samples were 
decrosslinked at 65°C for 4 hours / overnight, shaking at 1400 rpm. After decrosslinking, 10 
mM EDTA, 40 mM of Tris-HCl (pH 6.5) and 20 µg of proteinase K (Roche) were added to the 
samples followed by incubation for 1 hour at 45°C, shaking at 1400 rpm. After this step, DNA 
was purified using PCR purification kit (Qiagen) and eluted in 200 µl Milli Q. Input DNA and 
immunoprecipitated samples were analyzed using qPCR. Primer sequences are available 
upon request. 
   
     Local laser irradiation and live microscopy
   Cells were seeded on 12 mm round coverslips and sensitized for microirradiation by 
incubation with 10 µM BrdU for 20–24h at 37°C. Microirradiation was carried out with a 405 
nm laser diode (30 mW) coupled into a LSM710 confocal microscope (Zeiss) equipped with a 
thermostated chamber. Laser was focused through a Plan-Apochromat 63X/1.4 oil objective 
to locally irradiate preselected lines of 1 µm in width within the nucleus, using the following 
settings: 40% power, 50 iterations, scan speed 12.6 μsec/pixel. For live-cell imaging, confocal 
image series of one mid z-section were taken before and after microirradiation at several 
time intervals using 488 nm and 514 nm Argon laser lines (25 mW), with a pixel size of 90 
nm. Images were adjusted for brightness and contrast using Fiji (Fiji Is Just ImageJ) software.
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   Results
   MBD5 and MBD6 interact with the human PR-DUB complex
   To investigate which proteins interact with MBD5 and MBD6, we transfected GFP-tagged 
full length cDNA clones of these proteins into SILAC-labeled 293T cells. Forty hours after 
transfection, nuclear extracts were prepared and these were subjected to GFP pull-downs 
followed by on-bead digestion and LC-MS/MS (Figure 2A). Both GFP-MBD5 and GFP-MBD6 
were found to co-purify with subunits of the human PR-DUB complex (BAP1, ASXL2 and 
KDM1B) (Figure 2B and 2C). Interestingly, MBD5 was not detected in the MBD6 pull-down 
and vice versa. Importantly, this association with the PR-DUB complex was not observed 
for other MBD proteins we tested (MeCP2, MBD1, MBD2, MBD3, MBD4, data not shown). 
Next, we generated HeLa Kyoto cells stably expressing PR-DUB subunits (BAP1 and ASXL2) 
with a C-terminal GFP tag at near endogenous levels and including naturally occurring splice 
variants using BAC TransGenOmics technology [20]. These cell lines were subsequently 
SILAC-labeled and subjected to GFP affinity enrichments coupled to quantitative mass 
spectrometry as described previously [18]. Endogenous MBD5 and MBD6 were found to 
co-purify with BAP1-GFP and ASXL2-GFP (Figure 2D and 2E). Most of the other interactors 
observed in the pull-downs such as FOXK1/FOXK2 and HCFC1 are known PR-DUB interactors 
[13, 14, 21]. In summary, these results clearly establish MBD5 and MBD6 as novel interactors 
of the mammalian Polycomb group protein complex PR-DUB. 
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Figure 1. The mammalian family of MBD 
proteins. A. Schematic overview of the 11 
human proteins that are known to contain 
an MBD or MBD-like domain. Other known 
domains in each of these proteins are also 
indicated. B. Sequence alignment of the 11 
mammalian MBD domains.
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Figure 2. MBD5 and MBD6 both interact with the human PR-DUB complex. A. Schematic overview 
of the workflow. Light and heavy-labeled 293T cells were transiently transfected with GFP-MBD5 
(B) or GFP-MBD6 (C) and subjected to single affinity purifications in a ‘forward’ and ‘reverse’ 
pull-down using GFP nanotrap beads. As a control, light and heavy-labeled 293T cells were mock 
transfected. In the figures, the ratio of all the proteins in the forward pull-down (X axis) is plotted 
against their ratio in the reverse pull-down (Y axis). MBD5 and MBD6 associated proteins appear 
in the upper right quadrant of Figure 2B and 2C, respectively, showing a high ratio in the forward 
and a low ratio in the reverse pull-down. Boxplot statistics was applied to determine statistically-
significant interactors. Non-specific proteins appear around the origin of the figures (ratio ~ 1 in 
both pull-downs). HeLa cells stably expressing BAP1-GFP (D) or ASXL2-GFP (E) were also subjected 
to SILAC-labeling and single affinity purification as described above. 
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    MBD5 and MBD6 interact with the human PR-DUB complex via their MBD
    Having established that MBD5 and MBD6 both interact with the human PR-DUB complex, 
we were interested to determine the region within MBD5 and MBD6 that mediates this 
interaction. Two isoforms for MBD5 are known to exist, the second of which contains a 
substantial C-terminal truncation [9]. This shorter MBD5 isoform (amino acids 1-851) still 
interacts with the PR-DUB complex (data not shown). This suggests that the C-terminus 
of the full-length MBD5 protein is not mediating the interaction with PR-DUB. In support 
of this observation, a deletion mutant of MBD5 containing only the first 94 amino acids 
of the protein still maintained its interaction with the PR-DUB complex (Figure 3A). This 
N-terminal fragment of the MBD5 protein mainly contains the MBD domain. Similar results 
were obtained for MBD6 (data not shown). Finally, we were not able to observe interactions 
between PR-DUB and MBD5 or MBD6 when using constructs lacking the MBD domain 
(Figure 3B and data not shown). Based on these observations, we conclude that both 
MBD5 and MBD6 interact with the PR-DUB complex through their highly homologous MBD 
domains. This is the first example of an MBD domain mediating a protein-protein interaction 
as opposed to protein-DNA and protein-RNA interactions, which have been observed for 
other members of the MBD family of proteins [22, 23]. 
   
  
Figure 3. The MBD domain of MBD5 is both necessary and sufficient to mediate an interaction 
with the human PR-DUB complex. Light and heavy labeled 293T cells were transiently transfected 
with MBDonly_MBD5-GFP (A) or deltaMBD_MBD5-GFP (B) and subjected to single GFP affinity 
purifications as described in Figure 2. 
     MBD6 co-localizes with BAP1 to a subset of FOXK2 target genes
    GFP-based purifications of the mammalian PR-DUB complex consistently resulted in the 
co-purification of FOXK1 and FOXK2. These proteins are part of the Forkhead box transcrip-
tion factor family, all of which contain a Forkhead box DNA binding domain, also known as 
a winged helix. None of the other PR-DUB subunits contain a clear DNA binding domain. 
These two proteins are therefore candidates for recruiting the PR-DUB complex to target 
genes in the genome. Interestingly, FOXK1/2 have recently been shown to interact with 
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methyl cytosine and its oxidized derivatives [5, 24]. In addition to being part of the human 
PR-DUB complex, FOXK proteins have previously also been linked to the Sin3/HDAC complex 
[25-27]. To investigate the interaction between FOXK2 and PR-DUB in more detail, we per-
formed label-free quantification of FOXK2 interactors using a stable and inducible HeLa FRT 
cell line expressing GFP-tagged FOXK2 [28]. Nuclear extracts from control and GFP-tagged 
cells were subjected to GFP affinity enrichment in triplicate, followed by on-bead trypsin 
digestion and LC-MS/MS. The GFP-tagged bait, specific interaction partners and background 
proteins were plotted in a volcano plot (Figure 4A and B, Supplementary Figure 1A). For 
stoichiometry estimations, the iBAQ algorithm was used [18, 29]. A large number of proteins 
were found to co-purify with FOXK2, including subunits of the Sin3/HDAC, NCOR, PR-DUB 
and NSL complexes. Stoichiometry analysis revealed that roughly equal amounts of Sin3/
HDAC and N-CoR/SMRT complex co-purify with FOXK2 whereas somewhat lower levels of 
PR-DUB/MBD6 and NSL complex are detected (Figure 4C). Using a stable HeLa FRT cell line 
expressing GFP-tagged MBD6, we performed GFP chromatin immunoprecipitation followed 
by targeted qPCR for genes that are known to be FOXK2 targets and regulated by both BAP1 
and FOXK2 [15, 30]. Out of several target loci tested, CGGBP1, PHB2 and JRK show clear 
MBD6 enrichment in the MBD6-GFP HeLa FRT cells compared to the negative control, emp-
ty HeLa FRT cells (Figure 4D). These results therefore establish a physical and functional link 
between PR-DUB, FOXK2, and MBD6 in vivo.
   MBD6 is recruited to sites of DNA damage in a PR-DUB independent manner
   The experiments described thus far have shown that MBD5 and MBD6 both interact with 
the mammalian PR-DUB complex through their MBD domain. The C-terminus of MBD5 and 
MBD6, however, is not highly conserved between the two proteins, suggesting that MBD5 
and MBD6 may have specific functions that are not overlapping. As ubiquitination / deubiq-
uitination signaling, and thus DUB proteins –including BAP1– are crucial for the assembly 
and disassembly of repair proteins at sites of DNA damage, we tested a potential involve-
ment of MBD5 and MBD6 in this context [15, 31-33]. We observed that upon laser microir-
radiation, MBD6 was recruited to sites of laser-induced DNA damage; the recruitment was 
rapid (less than 30 seconds), and was visible for 5 to 10 minutes (Figure 5A and Supple-
mentary Figure 2). We never observed recruitment of MBD5 isoforms to laser-induced DNA 
damage sites (Figure 5A), even though the cells did contain DNA lesions, as evidenced by 
positive 53BP1 labeling after irradiation (Figure 5B). As BAP1, a key component of PR-DUB, 
was recently shown to be involved in the DNA damage response, we investigated whether 
the recruitment of MBD6 to sites of DNA damage is dependent on BAP1[34]. We repeated 
the microirradiation experiment in a BAP1 knock-down background (Supplementary figure 
1B), and observed that MBD6 localization to sites of DNA damage persisted in the absence 
of BAP1, albeit with possibly slower kinetics (Figure 5C). Next, we tested the deltaMBD de-
letion mutant of MBD6 that does not interact with PR-DUB. As shown in Figure 5D, this 
protein lacking its MBD was still efficiently recruited to sites of DNA damage. Therefore, it is 
the C-terminus of MBD6 (aminoacids 85-1003), and not its MBD, that distinguishes it from 
MBD5 and recruits it to DNA lesions. It remains to be seen whether the C-terminal-depen-
dent recruitment of MBD6 to DNA damage sites coordinates the recruitment of PR-DUB to 
damage sites in an MBD domain-dependent manner. 
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Figure 4. FOXK2 interacts with PR-DUB and MBD6 co-occupies a subset of FOXK2/PR-DUB target 
genes. A. Schematic overview of the workflow. B. Volcano plot showing GFP-FOXK2 interactors as 
revealed by label free quantitative mass spectrometry-based proteomics. Significant interactors 
of FOXK2-GFP are identified by permutation-based FDR corrected T-test (threshold: p=0.0001, 
S0=10). The LFQ intensity of the GFP pull-down relative to the control is plotted against the –
Log10 of the p-value. The red line indicates the permutation-based FDR threshold. C. Visualization 
of the stoichiometry values in the FOXK2-GFP pull-down. Proteins that were identified as signif-
icant FOXK2 interactors but with a stoichiometry value relative to FOXK2 of < 1% were omitted 
from this figure, with the exception of KDM1B and MBD6. D. ChIP-qPCR analysis of GFP-MBD6 
binding to a subset of FOXK2 target genes. Error bars show the standard deviation between tech-
nical triplicates.
Figure 5. MBD6, but not MBD5, is recruited to sites of DNA damage in a PR-DUB independent 
manner. A. MBD6, but not MBD5, is recruited to sites of laser-induced DNA damage. Live-cell 
imaging of laser-microirradiated HeLa FRT cells stably expressing GFP-MBD5 isoform 1, GFP-MBD5 
isoform 2 or GFP-MBD6. B. MBD5 is not recruited to the regions of damaged DNA labeled by 
53BP1. Cells were transfected with GFP-tagged MBD5 and MBD6 constructs as in A. Cells were 
also transfected with RFP-53BP1. Scale bars, 5µm.
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    Discussion
   Here, we have shown that two relatively uncharacterized members of the MBD family 
of proteins, MBD5 and MBD6, interact with the human Polycomb group protein complex 
PR-DUB through their MBD domain. Furthermore, we show that FOXK2/PR-DUB and MBD6 
share a subset of genomic target genes. Finally, we show that MBD6, but not MBD5, gets 
recruited to sites of DNA damage upon microirradiation in a PR-DUB-independent manner. 
Recently, PR-DUB subunits have received a lot of attention given their seemingly broad 
involvement in a number of human malignancies. For example, BAP1 is proposed to cause 
a cancer syndrome characterized by predisposition to uveal melanoma and mesothelioma 
[21, 35]. BAP1 has also been linked to renal cell carcinoma and cutaneous melanoma [21, 
35, 36]. Furthermore, conditional BAP1 knock-out mice display splenomegaly and develop 
myeloid malignancies [14]. Likewise, ASXL1 is mutated in a subset of myeloid malignancies 
[37]. In agreement with this emerging link between PR-DUB and cancer, both BAP1 and 
ASXL1 were recently reported as one of 138 human ‘driver’ genes that are frequently 
mutated and/or deregulated in cancer [38]. In addition to this tumorigenesis link, BAP1 
interacts with HCFC1 and this interaction is known to regulate cell cycle progression [15, 39-
41]. MBD5 and MBD6 have thus far not been linked to cancer. Further studies are needed 
to elucidate the molecular mechanisms underlying the association between deregulated 
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Figure 6. MBD6 recruitment to laser-induced DNA 
damage sites is not BAP1-dependent. A. Live-cell 
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PR-DUB and cancer/cell cycle progression. 
   The Methyl-CpG binding domain family of proteins consists of 7 members (MeCP2 
and MBD1-6). In addition, four other proteins are known to harbor an MBD-like domain 
(SETDB1A/B and BAZ2A/B). This more inclusive superfamily is also known as the TAM family 
(TTF-IIP5/ARBP/MeCP2) [1, 42, 43]. Within the human MBD family, only MeCP2, MBD1, 
MBD2 and MBD4 have been shown to bind to methylated DNA. In other vertebrates such as 
zebrafish, MBD3 also binds methylated DNA (M.V., manuscript in preparation). In mammals, 
two mutations in the MBD3 MBD have resulted in a loss of high affinity methyl- CpG binding 
[44]. Interestingly, several eukaryotes such as Drosophila melanogaster and Caenorhabditis 
elegans do not have high levels of CpG methylation yet they do contain MBD proteins. 
The question therefore is whether the MBD domain evolved as a bona fide methyl-CpG 
binding domain or whether the domain originated as having a different function and later 
acquired methyl-CpG binding activity. Detailed structural analysis suggests that the MBD 
domain originally evolved as a methyl-CpG binding domain and that in most cases, such 
as C. elegans, loss of methyl-CpG binding co-evolved with a loss of CpG methylation while 
general DNA binding affinity was not affected [43]. The conserved similarity/homology 
between MBD sequences indicates that while meCpG binding function was not conserved 
for some members of the family, the domain was nevertheless retained, possibly evolving to 
function in other ways. MBD5 and MBD6 represent two good examples of this as their MBD 
domains seem to have evolved, following a loss of meCpG binding activity, as a protein-
protein interaction module. A better understanding of this evolutionary process could come 
from analyzing MBD5 and MBD6 across different species. The few known members of the 
family that are present in invertebrates, such as flt-1 in C.elegans and Toutatis in Drosophila 
melanogaster, are considered homologues of MBD2/MBD3, which is considered the 
ancient MBD protein [1, 43]. It is possible that more homologues of the mammalian MBDs 
are yet to be discovered, such as the recently reported orthologue of MBD5 in Drosophila 
melanogaster, sba [1, 45]. Thus far, however, an interaction between sba and the Drosophila 
PR-DUB complex has not been reported.
    In summary, the results described in this study have revealed both shared and specific 
functions for MBD5 and MBD6. Both proteins interact with PR-DUB through their MBD 
domain. Furthermore, MBD6 gets recruited to sites of DNA damage in a PR-DUB independent 
manner, something which was not observed for MBD5. Several key questions still remain. 
What is the exact function of MBD5 and MBD6 in relation to PR-DUB? What are the 
molecular mechanisms underlying the link between MBD5/PR-DUB and brain function? Is 
there functional redundancy between MBD5 and MBD6, and if there is, has this redundancy 
resulted in a tissue-specific expression pattern for MBD5 and MBD6? How is MBD6 recruited 
to sites of DNA damage and what is its exact role in DNA repair? Further studies are required 
to answer these questions.
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     Supplementary Material 
Supplementary figure 1A. GFP-FOXK2 interactors visualized in a volcano plot. GFP-FOXK2 inter-
actors are localized in the right part of the figure. 1B. Validation of  shRNA mediated BAP1 knock-
down in GFP-MBD6 HeLa FRT cells by qPCR (left) and Western blotting (right) . 
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Supplementary figure 2. Detailed kinetics of MBD6 recruitment to sites of laser-induced DNA 
damage. Live-cell imaging of laser-microirradiated HeLa FRT cells stably expressing GFP-MBD6 at 
the indicated time points.
Supplementary Table 1: Proteingroups output tables (Maxquant) of the SILAC and label-free 
based GFP affinity purifications and LC-MS/MS analyses. For the SILAC-based pull-downs (MBD5-
GFP, MBD6-GFP, BAP1-GFP, ASXL2-GFP, MBDonly_MBD5-GFP , deltaMBD_MBD5-GFP), proteins 
are sorted according to the normalized forward SILAC ratio. For the label-free pull-down (FOXK2-
GFP) according to their LFQ intensity (GFP1). 
Available online: http://onlinelibrary.wiley.com/doi/10.1002/pmic.201400013/suppinfo
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    Abstract
    Part I
    Polycomb complexes are highly expressed and functional in mouse embryonic stem cells, 
i.e. they repress genes that should be activated later in development1. The chromatin marks 
that are catalyzed by the two major Polycomb complexes, PRC1 and PRC2, are Histone 
H3K27me3 and Histone H2AK119Ub1. These marks are present abundantly in the mouse 
ESC genome2,3. Here we set out to investigate whether the complex that deubiquitinates 
Histone H2AK119Ub1, the PR-Dub complex, is also present in mESCs and also in a more 
differentiated lineage that is the neural progenitor cells (mNPCs). We characterize the PR-
Dub complex in both settings and show that the interactions observed in purifications from 
HeLa cells are retained in pluripotent and multipotent cells.  
    Part II
    In the previous chapter, we show that MBD6 is recruited to sites of damaged DNA. Here 
we investigate whether there are novel interactions induced by DNA damage using a mass 
spectrometry-based approach.
3MBD5 and MBD6 interact with the PR-Dub
85
    Part I: Characterization of the PR-Dub complex in mouse embryonic stem cells and      
    neural progenitor cells
    Introduction
   The components of the human, mouse and Drosophila PR-Dub complexes have recently 
been identified and reported4–6. In our group, we have purified the human PR-Dub complex 
in HeLa cells stably transfected with a GFP-tagged BAP1 BAC and a GFP-tagged ASXL2 BAC 
as shown in chapter 3. We further wished to characterize the mouse PR-Dub complex in 
embryonic stem cells (mESCs) and neural progenitor cells (mNPCs). We stably transfected 
the BAP1 BAC that is recombined to express a C-terminally GFP-tagged fusion BAP1 protein7 
into mES cells. The same method was used for generating mESCs that stably express ASXL2-
GFP fusion protein. Nuclear extracts generated from these lines were subjected to GFP 
affinity purification followed by mass spectrometry analysis (GFP AP-ms). NonGFP agarose 
beads were used in the control purification. Label-free quantitation algorithm was used to 
determine interactors (see figure 4A in the previous chapter for an overview of the method).
    Results
      Both human BAP1 protein and human ASXL2 proteins that are GFP-tagged are incorporated 
into the mouse ESC PR-Dub complex as a clear enrichment for interactors is observed 
in Figure 1. For BAP1, there are 2 potential novel interactors: Poldip2 and Fhl3. Poldip2 
is a polymerase delta-interacting protein and Fhl3 may be a protein involved in muscle 
development8. Whether these proteins are true interactors of the mESC PR-Dub complex 
is unknown. To address this question, these proteins should be enriched reproducibly 
and specifically in subsequent PR-Dub subunit purifications. Interestingly, Fhl3 protein is 
enriched as a PR-Dub interactor in mouse NPCs as well (Figure 2) and its stoichiometry 
slightly increases in mNPCs (Figure 3). 
     The ASXL2-GFP AP-ms shows additional interactors (Figure 1B): Nr0b1, Nrip1 and Nanog. 
Nr0b1 and Nrip1 are proteins involved in nuclear receptor signaling8. ASXL2 is reported 
to be involved in peroxisome proliferator-activated receptor and retinoic acid receptor 
signaling9,10. Therefore, it is plausible that ASXL2 interacts with other proteins and complexes 
involved in these signaling pathways. It should be noted that the stoichiometry values for 
these proteins are rather low (<10%, data not shown) suggesting that ASXL2 is found most 
predominantly in the PR-Dub complex. An interaction between Nanog and ASXL2 has not 
been reported, however, Nr0b1 interacts with Nanog11. It is possible that ASXL2 indirectly 
interacts with Nanog via Nr0b1. Finally, as mentioned in chapter 3, ASXL1 and ASXL2 seem 
to be mutually-exclusive within the PR-Dub complex as ASXL1 is only identified in BAP1 
purifications but not in ASXL2 purifications.
    In summary, in this section we show the PR-Dub complex in mESCs using BAP1-GFP and 
ASXL2-GFP fusion proteins as baits. In addition, we show the PR-Dub complex in mNPCs 
using BAP1-GFP as a bait. Although there are candidate novel interactors in the three AP-
ms experiments shown in Figure 1 and 2, the interactors with the highest stoichiometry do 
not change: Bap1, Asxl1, Asxl2, Kdm1b, Foxk1/2, Hcfc1, Ogt and Mbd6 (Figure 3). Mbd5 is 
consistently identified as an interactor albeit with low stoichiometry. The enrichment for 
Hcfc1 and Ogt show variation between experiments (not detected in ASXL2-GFP AP-ms and 
close to the background cloud in BAP1 AP-ms experiments (Figure 1 and 2)), however the 
stoichiometry for Hcfc1 is consistently high. For Ogt, the stoichiometry seems to decrease 
in mNPCs (Figure 3). Finally, based on the PR-Dub stoichiometry data in mESCs and mNPCs, 
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PR-Dub complex dynamics during differentiation seem to be more stable in comparison to 
PRC1 dynamics (S.L. Kloet, unpublished observations; 12).
   
Figure 1: GFP affinity 
purification of PR-Dub 
subunits in mouse 
embryonic stem cells.
Panel A shows the 
interactors of BAP1-
GFP and Panel B shows 
the interactors of 
ASXL2-GFP in mESCs. 
The GFP tagged baits 
are shown in green. 
X-axis shows the ratio 
of enrichment between 
the specific and control 
affinity purifications. 
Y-axis shows the 
reproducibility of 
quantification between 
three replicates.
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Figure 2: GFP affinity 
purification of BAP1-GFP in 
mouse neural progenitor cells.
Figure 3: The stoichio-
metry of BAP1 interactors 
in mouse ESCs (A) and 
mouse NPCs (B). The stoi-
chiometry plots are based 
on the affinity purification 
experiments shown in Fi-
gure 1A and Figure 2. The 
stoichiometry values of 
interactors are normalized 
to the bait and the stoichio-
metry of the bait is set to 1. 
“4932438A13Rik” protein 
observed in Figure 2 is exc-
luded from stoichiometry 
calculations shown in pa-
nel B due to low number of 
peptide counts (n=2). Some 
interactors (e.g. Foxk1 and 
2) are collapsed due to 
the contribution of shared 
peptides to stoichiometry 
values.
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     Materials and methods
    R1 mESCs were cultured in DMEM high glucose, FBS, LIF, pen/strep, L-glutamine and 2i 
inhibitors. Human BAP1 and ASXL2 BACs recombined to express a GFP-tagged fusion protein 
were transfected into R1 mESCs using Lipofectamine 2000, according to manufacturer’s 
instructions. 200 ug/mL Geneticin was used to select for cells stably expressing the fusion 
protein. mESCs expressing BAP1-GFP (referred to as BAP1-GFP mESCs) were differentiated 
into mNPCS (referred to as BAP1-GFP mNPCs) in N2B27 medium. After differentiation, 
mNPCS were cultured in NSA medium with 1% L-glutamine, 1x N2 supplement, 10 ng/mL 
bFGF and 10 ng/mL EGF13. Nuclear extraction, GFP affinity purification, mass spectrometry 
measurement and analysis were performed as decribed in chapter 3. Stoichiometry analysis 
was performed as described in Smits et. al14.
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    Part II: A mass spectrometry-based approach for investigating DNA damage-specific 
    interactors of MBD6
    Introduction
   MBD6 localizes to microirradiated sites on DNA as shown in the previous chapter. While 
we have shown that this localization does not depend on BAP1, we do not have further 
information on the interactors of MBD6 at damage sites and whether any novel interactions 
are induced upon DNA damage. Is there a novel interactor that recruits MBD6 to sites of 
DNA damage? Are there novel interactors that MBD6 recruits to sites of DNA damage? To 
try to address these questions, we performed quantitative interaction proteomics in gamma 
irradiated MBD6 HeLa FRT cells.  
    Results
      MBD6-GFP expression was induced in all four groups of SILAC-labeled MBD6 HeLa FRT cells. 
One heavy labelled and one light labelled group of cells were subjected to 10 Gys of gamma 
irradiation for 10 minutes (see Figure 4A for an overview of the workflow). Subsequent 
steps of nuclear extraction and GFP AP-ms were performed as described in chapter 2. In this 
experimental set-up, the bait (MBD6-GFP) and interactors (PR-Dub) observed under normal 
conditions (no induction of DNA damage) would end up in the background cloud in the origin 
of the scatter plot as the GFP-tagged protein is present in all 4 groups. Only DNA damage-
specific interactors would be enriched in the right upper quadrant with a high forward and 
low reverse ratio. As seen in Figure 4B, there are no novel, irradiation-specific interactors 
detected in this screen. The dots that stand out in the left upper quadrant correspond to 
contaminant proteins.
   In summary, we could not detect any damage-specific interactors when we performed 
AP-ms using MBD6-GFP as a bait after exposing the cells to gamma irradiation. It is possible 
that the subsequent steps of preparing nuclear extracts and performing GFP AP following 
gamma irradiation hinder the detection of interactions formed transiently after DNA damage 
induction. As seen in chapter 3, the dynamics of MBD6 recruitment to and dissociation from 
sites of irradiated DNA may be too fast for capturing damage-induced interactions with the 
methodology that we use.  
     Materials and methods
   Inducible MBD6-GFP HeLa FRT cells were created as described in van Nuland et al.15. 
MBD6-GFP HeLa FRT cells were cultured in DMEM (high glucose), 1% pen-strep, 10% FBS. 
Approximately ~15 hours before gamma irradiation, the expression of MBD6-GFP was 
induced by the addition of doxycycline (1 ug/ml final) to culture medium. Half of the cells 
were exposed to 10 Grays of gamma irradiation for 10 minutes. Nuclear extraction and GFP 
AP-ms were performed as described in chapter 2.  
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Figure 4: A quantitative interaction screen for MBD6-GFP upon DNA damage
Panel A shows the overview of the protocol. Half of SILAC labeled MBD6-GFP HeLa FRT cells were 
exposed to gamma irradiation. In this set-up, only the damage-induced interactors would stand 
out from the background cloud. Panel B shows the SILAC scatterplot. MBD6-GFP and other known 
interactors are in the background cloud. There are no specific, DNA-damage induced interactions.
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     Abstract
    A key step in gene repression by Polycomb is trimethylation of lysine 27 in histone H3 
(H3-K27me3) by PRC2.  H3-K27me3 provides a binding surface for PRC1.  We show that 
monoubiquitination of histone H2A (H2Aub) by PRC1-type complexes in turn creates a 
binding site for Jarid2-Aebp2-containing PRC2 and promotes H3-K27me3 deposition on 
H2Aub nucleosomes.  Jarid2, Aebp2 and H2Aub thus constitute components of a positive 
feedback loop that establishes H3-K27me3 chromatin domains.
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    Nucleosomes constitute the building block of eukaryotic chromosomes. They consist of 
a core of histone proteins around which DNA is wrapped in two helical turns. The post-
translational modification of histones is a key step for the regulation of diverse processes 
that occur on nucleosomal DNA.  Specific histone modifications often decorate arrays of 
nucleosomes that comprise many kilobases of DNA, but how such extended stretches of 
chromatin become modified is not well understood.  A paradigm for a long-range chromatin 
modification mechanism is transcriptional repression by Polycomb protein complexes1, 2. 
The Polycomb system generates two distinct histone modifications: methylation of lysine 
27 in histone H3 (H3-K27me) and monoubiquitination of lysine 119 in histone H2A (H2Aub) 
in vertebrates and at the corresponding lysine 118 in Drosophila H2A. Polycomb Repressive 
Complex 2 (PRC2) catalyzes mono-, di- and tri-methylation at H3-K27 (H3-K27me1/2/3)1, 2. 
At inactive Polycomb target genes, H3-K27me3 typically decorates nucleosomes across the 
entire upstream, promoter and coding region  (www.modencode.org) and is essential for 
their repression3.  The H3-K27me3 modification is recognized by Polycomb (Pc), a subunit 
of the canonical Polycomb repressive complex 1 (PRC1) and is thought to promote PRC1 
interaction with chromatin across the entire length of repressed genes. PRC1 has been 
proposed to repress transcription through chromatin compaction and also through its 
ubiquitin ligase activity for H2A monoubiquitination1,2. To gain insight into the function of 
H2Aub, we set out to identify interactors of this modification.
   We reconstituted arrays of four nucleosomes (referred to as oligonucleosomes) with 
recombinant Drosophila or Xenopus histones and monoubiquitinated H2A in these templates 
using appropriate recombinant enzymes (Supplementary Figure 1). We then used Drosophila 
H2A-K118ub oligonucleosomes and the corresponding unmodified oligonucleosome control 
template for affinity purification of H2A-K118ub binding proteins from Drosophila embryo 
nuclear extracts (Figure 1a).  In parallel, we used Xenopus H2A-K119ub and unmodified 
control oligonucleosomes to identify vertebrate H2A-K119ub interactors in nuclear extracts 
from mouse embryonic stem cells (Figure 1b).  In both experiments, quantitative mass 
spectrometry analyses identified PRC2 subunits as or among the most highly enriched 
H2Aub interactors (Figure 1a, b).  Jarid2 and Aebp2 were the PRC2 subunits showing highest 
enrichment in both cases (Figure 1a, b).
     The identification of PRC2 as an H2Aub interactor in both flies and vertebrates prompted 
us to analyze PRC2 histone methyltransferase (HMTase) activity on H2Aub nucleosomes. 
We reconstituted recombinant human PRC2 containing EED, EZH2, SUZ12, RBBP4 (here 
referred to as PRC2) and assemblies of the same complex that in addition contained AEBP2 
(AEBP2–PRC2), or JARID2 (JARID2–PRC2) or both JARID2 and AEBP2 (JARID2–AEBP2–PRC2 
(Supplementary Figure 2a). As substrates we used Xenopus mononucleosomes that were 
either unmodified or monoubiquitinated at H2A-K119 (Supplementary Figure 2b), and in all 
cases we used western blot analyses with antibodies against H3-K27me1 and H3-K27me3 
to monitor PRC2 activity. We first performed a time course experiment to compare the 
activity of PRC2 and JARID2–AEBP2–PRC2 on H2A and H2Aub nucleosomes. Consistent with 
earlier reports4,5, we found that the catalytic activity of PRC2 alone is largely unchanged on 
H2Aub nucleosome templates (Figure 2a lanes 1-8). As expected6-9, inclusion of JARID2 and 
AEBP2 in PRC2 resulted in stronger activity for H3-K27 methylation already on unmodified 
nucleosome templates (Figure 2a, compare lanes 9-12 with lanes 1-4; see also refs. 6-9). 
However, we observed a much stronger increase in H3-K27me3 formation when we used 
JARID2–AEBP2–PRC2 for HMTase reactions on H2Aub nucleosomes (Figure 2a, compare 
lanes 13-16 with lanes 9-12). We estimate that JARID2–AEBP2–PRC2 tri-methylates H3-K27 
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in H2Aub nucleosomes with 25-fold higher efficiency compared to PRC2 (Figure 2a, compare 
lanes 4 and 16; see also Supplementary Figure S2c,d). To assess the contributions of JARID2 
and AEBP2 to this stimulation of HMTase activity, we next compared the catalytic activity of 
all four forms of PRC2 on H2A and H2Aub nucleosome substrates (Figure 2b). JARID2–PRC2 
showed higher H3-K27 methyltransferase activity than PRC2 on unmodified nucleosomes, as 
previously reported9, but this was not any further increased on H2Aub nucleosomes (Figure 
2b, compare lanes 5-8 and lanes 21-24). In contrast, AEBP2–PRC2 methylated H3-K27 in 
H2Aub nucleosomes with considerably higher efficiency than in unmodified nucleosomes 
(Figure 2b, compare lanes 9-12 with lanes 25-28). This suggests that AEBP2 is critical for 
the specific activation of PRC2 by H2Aub, whereas JARID2 has a more general function in 
boosting PRC2 HMTase activity, independently of the H2A modification state.
    The work reported here uncovers that Jarid2-Aebp2-containing PRC2 binds to H2Aub 
nucleosomes and demonstrates that H3-K27 tri-methylation by this complex is strongly 
enhanced on H2Aub nucleosomes. This establishes H2Aub, Aebp2 and Jarid2 as components 
of a positive feedback loop where H2Aub promotes PRC2 binding and H3-K27me3 deposition, 
and in turn H3-K27me3 promotes binding of the canonical PRC1 via the chromodomain 
of Polycomb (Figure 2c). It is currently not clear whether canonical PRC1 indeed has E3 
ligase activity for H2A monoubiquitination, or whether this modification is only generated 
by forms of PRC1 lacking Pc (e.g. refs. 10, 11). Intriguingly, in ES cells, we also identified the 
PRC1-type complexes, PRC1.1 and PRC1.6 (refs. 12, 13), as H2Aub interactors (Figure 1b), 
suggesting an additional feedback loop for H2Aub deposition in vertebrates. The positive 
feedback loop for H3-K27me3 formation by H2Aub uncovered here provides a rationale 
for how extended domains of Polycomb-repressed chromatin could be generated in both 
Drosophila and vertebrates (Figure 2c). Our findings could explain why H3-K27me3 levels 
at Polycomb target genes are reduced in murine embryonic stem cells where H2A-K119ub 
has been depleted14. However, we previously found that bulk H3-K27me3 levels were 
undiminished in late stage Drosophila larvae where bulk H2Aub levels had been depleted15, 
suggesting that maintenance of H3-K27me3-modified chromatin domains does not strictly 
depend on H2Aub. The H2Aub-mediated feedback loop may thus primarily be required for 
the initial formation of H3-K27me3 chromatin domains when Polycomb repression is first 
established during the early stages of embryogenesis.
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Figure 1: H2Aub 
n u c l e o s o m e s 
bind Jarid2–
Aebp2–PRC2
(a) Jarid2–
A e b p 2 – P R C 2 
is the major 
H2Aub interac-
tor in Drosophi-
la.  Left: Proteins 
from Drosophila 
embryo nuclear 
extracts, affini-
ty-purified with 
unmodified (left 
lane) or H2Aub 
(right lane) nu-
cleosomes were 
separated on a 
16% polyacryl-
amide gel and 
visualized by 
coomassie stain-
ing; Supplemen-
tary Figure S3 
shows all lanes 
of the triplicate 
pull-down re-
actions. Right: 
H2Aub interac-
tors were iden-
tified by mass 
spect rometr y 
using permuta-
tion-based FDR 
corrected T-test 
(threshold: p=0.05 & S0=1). The LFQ intensity of proteins in the H2Aub pull-down over the H2A 
control is plotted against the –Log10 (p-value) of the T-test in a volcano plot. The blue line indicates 
the permutation-based FDR threshold. Esc, E(z) and Jarid2 were identified as significant H2Aub in-
teractors.
(b) Jarid2–Aebp2–PRC2 is an H2Aub interactor in mammalian cells.  Left: as in (a) but with proteins 
from mouse embryonic stem cell nuclear extracts that were stable isotope labeled by amino acids 
in cell culture (SILAC)16; Supplementary Figure S3 shows all lanes of the SILAC pull-down. Right: 
Proteins identified by mass spectrometry in the H2A/H2Aub pull-downs were plotted by their log2 
transformed normalized SILAC-ratios in the forward (x-axis) and reverse (y-axis) experiment (see 
Online Methods). Note that apart from PRC2, also PRC1.1 and PRC1.6 subunits and Dnmt1 were 
identified as specific H2Aub interactors (see also Supplementary table 1).
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Figure 2: Aebp2 and Jarid2 stimulate H3-K27 methylation by PRC2 on H2Aub nucleosomes
(a) Western blot analysis of H3-K27me1 and -me3 formation in HMTase reactions with PRC2 (134 
nM, lanes 1-8) or JARID2–AEBP2–PRC2 (134 nM, lanes 9-16) on unmodified (lanes 1-4 and 9-11) or 
H2Aub (lanes 5-8 and 13-16) mononucleosomes (460 nM) after indicated reaction times; histone 
H4 signal served as loading control. JARID2–AEBP2–PRC2 shows higher activity for H3-K27me3 
formation on H2Aub than on unmodified nucleosomes (compare lanes 13-16 with 9-12) whereas 
PRC2 activity is comparable on both substrates (compare lanes 5-8 with 1-4); see also (b).
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(b) Western blot analysis as in (a) of HMTase reactions with increasing amounts of the indicated 
PRC2 complexes on unmodified (lanes 1-16) or H2Aub (lanes 17-32) mononucleosomes (460 
nM); reaction time was 90min in all cases. Comparison of H3-K27 methylation by each complex 
on H2Aub versus unmodified nucleosomes shows that only AEBP2–PRC2 and JARID2–AEBP2–
PRC2 show higher activity on H2Aub nucleosomes. Supplementary Figures S2c,d shows results on 
oligonucleosome substrates and Supplementary Figure S4 shows original blots.
(c) Positive feedback loop model for generating Polycomb-repressed chromatin. Monoubiquitination 
of H2A by PRC1-type complexes promotes Jarid2–Aebp2–PRC2 binding and H3-K27me3 deposition; 
H3-K27me3 in turn promotes binding of canonical PRC1 via its Polycomb (Pc) subunit (solid green 
and magenta arrows). PRC1.1 and PRC1.6 are additional H2Aub interactors (Figure 1b) and PRC2 
binds to and is stimulated by H3-K27me3 (refs 1,2), suggesting additional positive feedback loops for 
H2Aub and H3-K27me3 formation (dashed arrows).
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Supplementary Material
Supplementary Figure 1:
Recombinant proteins used for in vitro ubiquitination and methylation of nucleosomes.
(a) Coomassie-stained 4-12% polyacrylamide gel showing purified recombinant human ubiquitin 
activating enzyme UBE1 (lane1), human ubiquitin-conjugating enzyme UBCH5C (lane 2), mouse 
ubiquitin ligase Ring1b1-130/Bmi11-109 (lane 3) and Ubiquitin (lane 4).
(b) Reconstituted recombinant Drosophila or Xenopus oligonucleosomes were subjected to 
ubiquitination (+ Ring1b1-130/Bmi11-109, lane 2 in both cases) or mock (– Ring1b1-130/Bmi11-
109, lane 1 in both cases) reactions and products were visualized by Coomassie staining after 
separation on denaturing 16% Tris-Glycine polyacrylamide gels (top) Note the size shift of the 
unmodified H2A band in lanes 1 and 3 to the monoubiquitinated H2A band in lanes 2 and 4, 
respectively; in both cases, a very small fraction appears to become di-ubiquitinated (H2Aub2). 
The band marked by an asterisk is a contaminant that sometimes is observed in UBE1 preparations.
Bottom: Western blot analysis of the same reactions shown above with antibody against 
unmodified histone H2A. Reaction products were separated on 4-12% BT MES polyacrylamide 
gels. Note the size shift of the unmodified H2A band in lanes 1 and 3 to the monoubiquitinated 
H2A band in lanes 2 and 4, respectively.
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Supplementary Figure 2:
Recombinant proteins and nucleosomes used for HMTase assays on mono- and oligonucleosomes
(a) Coomassie stained polyacrylamide gels with purified recombinant PRC2 (left), AEBP2-PRC2 
(middle) and JARID2 (right). Recombinant purified PRC2 consisting of EZH2, SUZ12, EED, RBBP4 
(left). AEBP2-PRC2 additional contains AEBP2 (middle). These PRC2 complexes and JARID2 were 
used for the experiments shown in Fig. 2 and Figure S2.
(b) Non-ubiquitinated and ubiquitinated mononucleosomes after coupling to streptavidin coated 
Dynabeads (M-280).
(c) and (d) JARID2 and H2Aub stimulate H3-K27 methyltransferase activity of AEBP2-PRC2. (c) 
Western blot analysis of H3-K27me1 and -me3 formation in HMTase reactions performed with 
AEBP2-PRC2 (134 nM, lanes 3-6) in the absence (lanes 3, 4) or presence of JARID2 (120 nM, lanes 
5,6) on recombinant Xenopus mononucleosomes (460 nM) that were unmodified (lanes 1, 3, 5) 
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or contained H2Aub (lanes 2, 4, 6) (see Figure S1); histone H4 signal served as loading control. 
Histogram shows quantification of H3-K27me3 chemiluminescence signal by ImageJ; no signal 
is detected in lanes 1, 2 (asterisk).  Note the increase of H3-K27me3 tri-methylation when H2A 
is monoubiquitinated and JARID2 is added to the reaction. The reduction of H3-K27me1 signal 
in lane 6 suggests that most H3-K27 residues became di- or tri-methylated. (d) as in (c) but with 
recombinant Xenopus 4-mer oligonucleosomes (460 nM) as substrate. The reaction contained 67 
nM AEBP2-PRC2 and 60 nM JARID2.  Supplementary Figure S5 shows original blots.  
Supplementary Figure 3:
Original Coomassie gels for pull-down reactions.
Left: Full gel image of the triplicate pull-down reactions from Drosophila nuclear extracts.  Area of 
the gel boxed in blue is shown in Figure 1a.  
Right: Full gel image of the SILAC pull-down experiment from mouse embryonic stem cell nuclear 
extracts.  Area of the gel boxed in blue is shown in Figure 1b.
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Supplementary Figure 4:
Full-size scans of western blot membranes shown in Figure 2. Scans are arranged in the same 
order as shown in Figure 2a,b and cropped portions are boxed in blue.
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Supplementary Figure 5:
Full-size scans of western blot membranes shown in Figure S2. Scans are arranged in the same 
order as shown in Figure S2c,d and cropped portions are boxed in blue.
Supplementary Table 1:
Identification and quantification of proteins detected in two SILAC-based H2A vs H2Aub 
nucleosome pulldowns. Available online: 
http://www.nature.com/nsmb/journal/v21/n6/full/nsmb.2833.html#supplementary-information
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     Abstract
  The Nucleosome Remodeling and Deacetylase (NuRD) complex is an evolutionary 
conserved chromatin-associated protein complex. Although the subunit composition of 
the mammalian complex is fairly well characterized, less is known about the stability and 
dynamics of these interactions. Furthermore, detailed information regarding protein-protein 
interaction surfaces within the complex is largely still lacking. Here, we show that the NuRD 
complex interacts with a number of substoichiometric zinc finger-containing proteins. Some 
of these interactions are salt sensitive (ZNF512B, SALL4), whereas others (ZMYND8) are not. 
The stoichiometry of the core subunits is not affected by high salt, indicating that the core 
complex is stabilized by hydrophobic interactions. Interestingly, the RBBP4 and -7 proteins 
are sensitive to high non-ionic detergent concentrations during affinity purification. In a 
subunit exchange assay using SILAC labeled nuclear extracts, the RBBP4 and -7 proteins are 
identified as dynamic core subunits of the NuRD complex, consistent with their proposed 
role as histone chaperones. Finally, using cross-linking mass spectrometry, we uncover novel 
features of NuRD molecular architecture that complement our AP-MS/MS data.  Altogether, 
these findings extend our understanding of MBD3/NuRD structure and stability.
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    Introduction 
    The Nucleosome Remodeling and Deacetylase (NuRD) complex is a conserved chromatin-
associated protein complex that was first purified and characterized from Xenopus laevis 
and human cells in the late 1990s [1-3]. As the name implies, the NuRD complex contains 
both histone deacetylase (HDAC) and ATP-dependent chromatin remodeling activity. In the 
human complex, HDAC activity is catalyzed by HDAC1 and HDAC2. The large CHD3 and CHD4 
subunits contain ATPase activity, which is used to move the position of nucleosomes on DNA. 
In addition to these enzymatic activities, the NuRD complex contains a number of other core 
subunits: MTA1-3, GATAD2A and –B, MBD2-3, RBBP4 and -7 and CDK2AP-1 [4, 5]. Some of 
these proteins, such as MBD2 and MBD3, are mutually exclusive within the NuRD complex. 
For GATAD2A/B, RBBP4 and -7 and MTA1-3, it is currently not known whether these proteins 
exclusively form heterodimers/trimers or mutually exclusive homodimers/trimers. In 
addition to the well-described core subunits, a large number of proteins have been reported 
to interact with the NuRD complex. Examples include SALL4, FOG1 and ZMYND8 [6-8]. These 
proteins may recruit the NuRD complex to its target sites in the genome. 
  Due to the presence of HDACs, which are generally associated with gene silencing, the 
NuRD complex has long been thought of as a transcriptional co-repressor complex. 
Indeed, in luciferase assays, NuRD subunits repress transcription of reporter constructs 
[4]. Furthermore, the methyl CpG binding protein MBD2 links MBD2-containing NuRD to 
methylated CpG islands and induces gene silencing [9]. However, recent genome wide 
profiling studies have revealed that NuRD complexes, such as MBD3/NuRD, are also found at 
active enhancers and promoters, indicating that NuRD-mediated regulation of transcription 
is more diverse than previously thought [10, 11].  Further functional experiments have 
revealed an important role for the NuRD complex in regulating cell fate decisions [12, 13]. 
These different biological functions of the NuRD complex may be driven by subtle changes 
in subunit composition. 
  Recently, a number of mass spectrometry-based methods were developed which can 
be used not only to confidently identify protein-protein interactions, but also to obtain 
information about the stoichiometry, dynamics and the interaction surfaces between 
subunits [14-16].  Here, we applied these different methods to gain further insight into 
the structure and dynamics of the MBD3/NuRD complex in HeLa cells. We applied label 
free quantitative mass spectrometry to investigate the stoichiometry of the MBD3/NuRD 
complex using different buffer stringencies during affinity purification. A SILAC-based subunit 
exchange assay was used to show that the RBBP4 and -7 proteins are dynamic core subunits 
within NuRD.  Finally, cross-linking mass spectrometry was used to identify inter-protein 
contacts within MBD3/NuRD. Altogether, these experiments increase our understanding of 
the stability, dynamics and architecture of the NuRD complex. 
    Results
    RBBP4 and -7 interaction with NuRD is salt stable but detergent sensitive
     To facilitate the purification of MBD3/NuRD, we created a stable cell line with doxycycline-
inducible GFP-tagged MBD3.  Cells were incubated for 16 hours in the presence or absence 
of doxycycline.  Expression of GFP-MBD3 occurs only after addition of doxycycline (dox) 
to the medium (Figure 1A).  Nuclear extracts from this cell line were used for GFP affinity 
purifications combined with label-free LC-MS/MS analysis.  Briefly, triplicate pulldowns 
were performed with GFP-Trap_A beads and GFP-MBD3-containing nuclear extracts (+Dox). 
Simultaneously, triplicate pulldowns were performed with GFP beads on control nuclear 
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extracts (-Dox).  Proteins that bind specifically to GFP-MBD3 will be enriched in the GFP 
pulldowns and appear on the right side of the plot.  Proteins that bind nonspecifically to the 
GFP beads will appear in the background cloud.
   
Figure 1: Label-free proteomics reveal RBBP4 and -7 interaction with NuRD is NP-40 sensitive
(A) An anti-MBD3 Western blot of GFP-MBD3 HeLa cells after 16 hours incubation with Doxycycline 
(+Dox) or without (-Dox).  Nonspecific bands are marked with an *.  (B-D)  Volcano plots from label-
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free GFP pulldowns of GFP-MBD3 HeLa nuclear extracts with varying salt and NP-40 concentration. 
Statistically enriched proteins in the GFP-MBD3 pull-down are identified by a permutation-based 
FDR-corrected t-test. The LFQ intensity of the GFP pull-down over the control (fold change (FC), 
X axis) is plotted against the –log 10 transformed p-value of the t-test (Y axis). The proteins in the 
upper right corner represent the bait and its interactors. (E) Stoichiometry of NuRD core subunits. 
The iBAQ value of each protein group is divided by the iBAQ value of the GFP-MBD3 bait, which 
was set to 2.  (F)  Stoichiometry of NuRD complex interactors relative to the GFP-MBD3 bait using 
the same data as in (E) but with a differently scaled axis.
   To determine the stability of the NuRD complex, several NP-40 and NaCl concentrations 
were used during the affinity purifications (Figure 1B-D). In each of these pull-downs, 
known NuRD core subunits were identified. In addition, several previously described 
NuRD interactors were also detected, including ZMYND8, ZNF592, and SALL4 [8, 14, 17]. 
Interestingly, we did not pulldown LSD1 in any of our MBD3-GFP purifications. LSD1 has 
previously been reported as a putative subunit of the NuRD complex [18] but our data 
on MBD3/NuRD does not agree with this observation. Next, the intensity-based absolute 
quantification (iBAQ) values were compared between all NuRD subunits and interactors. 
The iBAQ algorithm normalizes the total mass spec intensity for each protein according 
to the number of theoretically observable peptides [19].  This allows estimation of the 
relative abundance of large and small proteins detected in affinity purifications.  Since the 
NuRD complex contains many paralogs that overlap at the peptide level, iBAQ values were 
summed for all paralogs (Table S1). Comparison of the iBAQ values relative to the GFP-
MBD3 bait revealed that most core subunits of NuRD remain tightly bound to each other 
and to MBD3 despite the presence of high salt (1M NaCl) and NP-40 concentration (0.5%) in 
the wash steps (Figure 1E).  Surprisingly, the core RBBP4 and -7 subunits were very sensitive 
to NP-40.  Increasing the NP-40 concentration from 0.15% to 0.5% led to a decrease in the 
amount of RBBP4 and -7 associated with the complex (stoichiometry of 5.5 reduced to 4).
   In addition, the association of several zinc finger domain-containing proteins with NuRD 
was very sensitive to high salt concentrations.  The association of ZNF512B decreased 
nearly 8-fold when the salt concentration in the wash was increased from 300mM to 1M 
NaCl (Figure 1F).  A reduction in SALL4 binding was also observed with increased salt.  In 
contrast, other substoichiometric interactors such as ZMYND8 and KPNA2 remained tightly 
associated with the core complex under increased salt and NP-40 concentration. Together, 
these results suggest that the core NuRD complex is very stable when challenged by high salt 
concentrations, indicating that interactions within the NuRD complex are at least partially 
driven by hydrophobic interactions. The partial dissociation of RBBP4 and -7 observed at 
high NP-40 concentration may suggest that these proteins are less tightly associated to the 
rest of the core complex. Finally, although other detected interactors have a low iBAQ value 
relative to the core complex (1-2% relative to the core subunits), some of these interactions 
are very stable under high salt and NP-40 concentrations, suggesting a functional role for 
these proteins in relation to the NuRD complex. 
   
     RBBP4 and RBBP7 partially dissociate from the NuRD complex in a subunit exchange     
     assay
   To further study the potential dynamics of NuRD subunit interactions, a SILAC-based 
subunit exchange assay was used (Figure 2A) [15]. HeLa cells expressing GFP-CDK2AP-1 were 
labeled in culture with heavy amino acids (Forward) or light amino acids (Reverse).  Similarly, 
WT HeLa cells were also labeled with light or heavy amino acids.  GFP pulldowns were 
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performed immediately after mixing the nuclear extracts (T
0
) or after overnight incubation 
(T
ON
). Proteins that are more dynamically associated with NuRD will dissociate from the 
complex during the overnight incubation step and may be replaced by proteins from the 
other, differentially labeled extract. This eventually results in a decrease of detected SILAC 
ratios, where dynamic core subunits and/or interactors will move towards the background 
cloud in the scatter plot.
   At T
0
, all NuRD core subunits are significantly enriched according to boxplot statistics 
(Figure 2B). However, after overnight incubation, RBBP4 and -7 clearly separate from the 
other NuRD subunits and migrate towards the background cloud (Figure 2C).  To more 
directly compare the 2 scatter plots, the difference in forward and reverse ratios between 
the plots was visualized in a graph (Figure 2D). A protein with no change in ratios between 
experiments would have a value of 0. This graph clearly shows that RBBP4 and -7 are the 
most dynamic NuRD core subunits. These observations are in agreement with recent 
structural studies, which suggest that MTA and histone H4 compete for RBBP binding [20]. 
Furthermore, RBBP4 and -7 are part of many different protein complexes other than NuRD 
(Sin3 complex, PRC2), which also could explain their observed dynamic behavior [21, 22].       Cross-linking mass spectrometry reveals novel architectural features of the human      
     NuRD  complex       To further characterize the structural interactions between NuRD complex core subunits, 
we conducted cross-linking mass spectrometry to identify inter-protein interaction surfaces 
(Figure 3A). NuRD complex was isolated from HeLa nuclear extracts using tandem affinity 
purification with a GFP-His-MBD3 bait and subsequently cross-linked with BS3 for LC-MS/
MS analysis. Crosslinking was monitored by silver staining to ensure complete cross-linking 
of all NuRD subunits (Figure 3B). High confidence cross-linked peptides (FDR <0.05) were 
then identified by pLink using default settings and searching against a database of NuRD 
core components (Figure 3C and 3D) [23]. In total, 336 spectra matching with high confi-
dence to 16 non-ambiguous inter-protein cross-links, 87 non-ambiguous intra-protein cross-
links, and 46 ambiguous cross-links encompassing a variety of homo- or heteromers or in-
tra-protein cross-links were identified (Table S2).
    Structural validation was confounded by lack of overlap between the few existing NuRD 
crystal structures and our identified cross-links. For example, although 5 HDAC1 and 11 
HDAC2 intra-protein cross-links as well as 4 ambiguous HDAC1/2 cross-links were identified, 
all of them were located in the undetermined region of the known HDAC1 crystal structure 
(PDB 4BKX). However, seven cross-links mapping to the CHD4 chromodomain-ATPase region 
(residues 500-1298) were identified, which has a yeast CHD1 ortholog with known structure 
(PDB 3MWY). To our knowledge, this represents the highest number of mappable cross-links 
from our data set to any single structure. Structural validation of our CHD4 chromodomain-
ATPase cross-links was performed using a homology modelling approach. The human CHD4 
sequence was aligned to the yeast CHD1 template using HHPred and homology models were 
constructed using Modeller (Human CHD4 Uniprot: Q14839) [24-27]. In ten overlapping 
homology models, well-ordered regions from the crystal structure yield consistently low 
divergence models, while short alignment gaps or structurally undetermined loops are 
clearly disordered (Figure 3E). All homology models were highly similar except for very 
small, flexible regions, so one model was chosen as representative and cross-links were 
validated by calculating solvent accessible surface (SAS) distance using Xwalk [28]. All seven 
cross-links showed an SAS under 30 Å, as expected from the maximum length of the BS3
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Figure 2: RBBP4 and -7 are the most dynamic NuRD core subunits
(A) Schematic representation of the SILAC subunit exchange assay.  (B,C)  Scatter plots of GFP-
CDK2AP-1 forward and reverse pulldowns immediately after extract mixing (B, T
0
) and after 
overnight incubation (C, T
ON
).  The SILAC ratio for each protein in the forward pulldown is plotted 
against the ratio in the reverse pulldown. Boxplot statistics were used to determine statistically 
significant GFP-CDK2AP-1 interactors. The arrow and circle in (C) illustrate the movement of 
RBBP4 and -7 towards the background cloud, indicating that these proteins exchange between 
the heavy and light extract (D) Bar graph showing the difference in forward and reverse SILAC 
ratios between T
0
 and T
ON
.
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Figure 3: Cross-linking mass spectrometry offers insight into NuRD molecular architecture
(A) MBD3-NuRD was obtained by tandem affinity purification (GFP affinity enrichment, TEV 
cleavage and Ni-NTA enrichment) and cross-linked on-bead with BS3. Proteolytic digestion and 
analysis by AP-MS/MS was followed by identification and validation of high-confidence cross-linked 
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peptides (FDR < 0.05) using pLink.  (B) NuRD complex purification and cross-linking was monitored 
by silver staining to ensure complete cross-linking of all complex components.  Note that after the 
cross-linking reaction, NuRD subunits migrate at an apparent higher molecular weight in the SDS 
PAGE gel. (C) High confidence spectra were matched to putative cross-links using a target-decoy 
approach in pLink. Representative FDR curves are shown for cross-links of charge state +3 and 
+4.  (D) An annotated high-scoring spectrum from a CHD4 intra-protein cross-link, K959-K969. 
(E) Structural validation was performed using a human CHD4 chromodomain-ATPase homology 
model aligned to a yeast CHD1 ortholog template structure. Yeast CHD1 is colored in red with ten 
overlapping CHD4 homology models in blue. Validated cross-links are indicated in purple. Below 
the homology models are close-up views of seven CHD4 cross-links in the Chromodomain-ATPase 
region using a representative CHD4 homology model; the lower left image shows crosslinks 
between K959-K969, K959-K1189, and K969-K1189 in a well ordered region, while the lower right 
image shows crosslinks between K690-K693 and K693-K696 in a gapped region and cross-links 
between K833-K838 and K833-839 in a structurally undetermined region.  (F) Cross-link map for 
human NuRD subunits. Subunits connected by at least one unambiguous cross-link are indicated 
by a solid line, while subunits connected only by ambiguous cross-links are indicated by a dashed 
line. In our data, all ambiguous cross-links are ambiguous for peptides from a paralogous subunit. 
The relative number of inter- or intra-protein cross-links is designated by the area of gray shading 
surrounding that link.
cross-linker. Three cross-links mapped to a well-ordered region, and four mapped to a 
disordered region that likely possesses a highly flexible structural conformation. Therefore, 
all seven CHD4 chromodomain-ATPase cross-links seem to be structurally plausible, and we 
conclude that our cross-linking data is of good quality. 
   Few NuRD subcomplexes have resolved structures, most notably the MBD2-GATAD2A 
coiled-coil subcomplex, the RBBP4-MTA1 subcomplex, and the HDAC1-MTA1 subcomplex 
[20, 29, 30]. None of these studies describe comprehensive protein structures for both 
binding partners, so the complete interaction interfaces remain unknown. As such, our 
inter-protein cross-linking data reveal novel features of the NuRD complex architecture 
and extend our understanding of NuRD structure-function relationships (Figure 3F). For 
example, robust contacts were observed between MTA1-3 and RBBP4 and -7 subunits. Our 
data cannot discern whether these RBBP4 and -7 cross-link sites indicate binding of a single 
MTA paralog or a multimer, nor can we distinguish between potentially dynamic or paralog-
specific interactions at each site. However, mapping cross-linked residues onto the known 
RBBP4 structure shows K25 and K307 fall on either side of the known MTA1 interaction 
interface (PDB 4PC0 [20], Figure 4A). As RBBP4 K25 maps relatively close to the known MTA1 
binding pocket while K307 sits across a large, adjacent hydrophobic region, these cross-links 
could outline the opposite ends of the MTA1-3 binding platform (Figure 4B). Intriguingly, 
this would explain our observation that MTA1-3 binding to RBBP4 and -7 is stabilized by 
hydrophobic interactions under high salt conditions. Similarly, although the MBD3 structure 
is not known, we identified a short MBD3 region (residues 92-124) that contained 5 cross-
links with GATAD2A/B, two of which represented unique cross-links for GATAD2A, one which 
was unique for GATAD2B and two of which were ambiguous for the GATAD2A/B peptide 
(Figure 4C). The MBD2 and -3 sequences were aligned in EBI’s Clustal Omega in order to map 
any MBD3-GATAD2A crosslinks to the solved MBD2-GATAD2A coiled-coil structure (PDB 
2L2L, [30, 31]). Only two cross-linked lysine residues could be mapped to a representative 
conformer GATAD2A structure (K163 and K178), but no crosslinks could be mapped to the 
MBD2 structure (Figure 4D).  Furthermore, one GATAD2A cross-link site, K178, was located 
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at the tail end of the conformer, which exhibited a highly flexible conformation and thus 
offers little structural information. It is possible we observe low cross-link coverage within 
the MDB2-GATAD2A coiled-coil domain because, as the authors of that study note, this 
interaction hides at least 1,337 Å² of solvent accessible area, potentially hindering BS3 
accessibility. Thus, our cross-links may outline an interaction interface rather than reveal 
a binding footprint. However, in agreement with previous work, our data depict a single 
binding interface between MBD3 and GATAD2A/B paralogs. Overall, this cross-linking 
mass spectrometry data greatly improves our understanding of the NuRD complex subunit 
architecture and will help direct future structural studies.
    Discussion
  Here we have used a variety of mass spectrometry-based methods to increase our 
understanding of the dynamics, stability and architecture of the MBD3/NuRD complex. 
GFP-based affinity purifications combined with a label-free method to estimate protein 
complex stoichiometry revealed that the RBBP4 and -7 core subunits of the NuRD complex 
are sensitive to high detergent concentration. Increasing the NP-40 concentration from 
0.1 to 0.5% in the wash buffer resulted in a reduction of RBBP4 and -7 co-purified with 
MBD3. This result illustrates an important limitation of AP-MS experiments, namely that 
part of the interactions that occur in vivo may be lost during affinity purification. Conversely, 
interactions can be formed in the extract that may not occur in vivo. To overcome these 
limitations, cross-linking prior to cell lysis can be used as an alternative approach.  However, 
this approach is technically very challenging due to experimental and computational issues. 
  Except for MBD3 and HDAC1/2, the stoichiometry values we obtained in our GFP-
MBD3 purifications are generally in good agreement with our previously published NuRD 
stoichiometry results [14] [32]. Previously, we made use of a BAC GFP-MBD3 HeLa cell line, 
which expresses MBD3 with a GFP tag at near endogenous levels. In the current study we 
used a doxycycline-inducible GFP-MBD3 cell line. This cell line may be expressing MBD3 at 
slightly higher levels, which may result in slightly different MBD3 and HDAC1/2 stoichiometry 
values. It is important to note that the final stoichiometry values we obtained represent an 
average value based on a large number of potentially heterogeneous complexes. Based on 
our data, we cannot be sure whether paralogous proteins such as MTA1-3 or GATAD2A-B are 
present within the same complex or whether these proteins are in fact mutually exclusive 
as we have previously shown for MBD2 and-3 [33]. It is highly likely that a large number 
of distinct NuRD complexes exist. However, our cross-linking data cannot distinguish 
unambiguously between homomeric and heteromeric interactions for HDAC1/2, MTA1-3 
and GATAD2A-B. Interestingly, we were able to detect unambiguous interprotein crosslinks 
for CHD3 and CHD4, indicating that these proteins may form a heterodimer.  Nevertheless, 
NuRD complex heterogeneity most likely creates a significant challenge towards high-
resolution determination of the NuRD molecular architecture. 
    In addition to the core NuRD subunits, a number of substoichiometric interactors were 
identified in the MBD3-GFP purifications. Interestingly, these interactors showed differential 
sensitivity to salt and detergent. ZMYND8 and ZNF532/592/687 co-purified with GFP-MBD3 
even when challenged with 1 M NaCl and 0.5% NP-40. The stability of this interaction 
indicates that it may be functionally relevant. Interestingly, these proteins have previously 
been described to interact with each other as a central hub in a large transcriptional network
[34]. Given the presence of a large number of putative DNA binding zinc fingers in the 
ZMYND8/ZNF module, we hypothesize that this module may recruit the NuRD complex to a
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Figure 4: Structural analysis of cross-linked residues reveals novel features of NuRD subcomplex 
interactions (A) Twelve identified cross-links between RBBP4 and -7 and MTA1-3 map to two 
residues on RBBP4, K25 and K307 (K24 and K306 on RBBP7). (B)  Residues from (A) are mapped 
onto the known crystal structure for RBBP4.  These residues surround the binding site of the 
MTA1 peptide. RBBP4-K25 sits near the MTA1 binding site, while RBBP4-K307 lies across a large 
hydrophobic region representing a potential MTA1 binding platform. Hydrophobic regions are 
indicated in red, while hydrophilic regions are indicated in blue. (C)  Five cross-links identified 
between MBD3 and GATAD2A/B map to MBD3 residues K92, K109, and K124. (D) Coiled-coil 
conformer model of GATAD2A and MBD2.  The GATAD2A coil is colored in light red and the MBD2 
coil is colored in blue. All lysine resides are colored dark red, while the cross-linked residues are 
indicated and colored in yellow.
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subset of its target genes. The same holds true for other detected substoichiometric 
interactors. Further work is needed to determine the functional significance of the detected 
ZMYND8/ZNF – NuRD interaction.
   Materials and Methods
   Cloning
   A tandem affinity purification (TAP) tag was cloned into pcDNA5 FRT/TO.  This tag consists 
of eGFP followed by 2 TEV protease cleavage sites and a 6xHis tag.  The TEV sites and His tag 
were added to eGFP via PCR.  MBD3 was amplified using BamHI and XhoI and was cloned 
into the MCS of pcDNA5 FRT/TO.      Cell Culture and SILAC Labeling
   HeLa FRT cells were transfected with pcDNA5 FRT/TO TAP-MBD3 using Lipofectamine LTX 
Plus (Invitrogen).  Cells underwent selection for 10 days with hygromycin, and single colonies 
were picked, expanded and screened for expression of TAP-MBD3.  TAP-MBD3 expression 
was induced with 1ug/mL doxycycline treatment for 16 hours. SILAC labelling of HeLa cells 
was done as described [35].
   
   Nuclear extracts
  Nuclear extracts were prepared essentially according to Dignam et al. [36].  Cells were 
harvested with trypsin, washed with PBS 2x and centrifuged at 400xg for 5 min at 4˚C.  Cells 
were swelled for 10 min at 4˚C in 5 volumes of Buffer A [10mM Hepes KOH pH 7.9, 1.5mM 
MgCl2, 10mM KCl] and then pelleted at 400xg for 5 min at 4˚C.  Cells were resuspended in 
2 volumes Buffer A plus protease inhibitors and 0.15% NP-40 and transferred to a dounce 
homogenizer.  After 30-40 strokes with a Type B pestle, the lysates were spun at 3900 rpm 
for 15 min at 4˚C.  The nuclear pellet was washed 1x with PBS and spun at 3900 rpm for 5 
min at 4˚C.  The nuclear pellet was resuspended in Buffer C [420mM NaCl, 20mM Hepes KOH 
pH 7.9, 20% v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA] with 0.1% NP-40, protease inhibitors 
and 0.5mM DTT.  The suspension was incubated with rotation for one hour at 4˚C, then spun 
at 14000rpm for 15 min at 4˚C.  The supernatant was aliquoted and stored at -80°C until 
further usage.
   
   Label free pulldowns and cross-linking mass spectrometry
    Label-free GFP pulldowns, LC-MS/MS and data analysis were done essentially as described 
[14].  For cross-linking mass spectrometry, 8 mL of HeLa nuclear extract (5 mg/mL plus 50 
microgram/mL ethidium bromide) containing doxycycline induced TAP-MBD3 was incubated 
with 400 microliters of GFP-trap beads (Chromotek) for 2 hours at 4°C in a rotation wheel. 
Beads were then washed three times with 10 mL wash buffer (300 mM NaCl, 0.5% NP-40, 
20 mM Hepes KOH pH 7.9, 0.5 mM DTT, 2 mM MgCl2, 0.2 mM EDTA and complete protease 
inhibitors) and twice with 5 mL of TEV cleavage buffer (150 mM NaCl, 10 mM Tris-HCl pH 8.0, 
0.1% NP-40 and 1 mM DTT). Beads were then resuspended in 0.5 mL TEV cleavage buffer 
containing 100 units GST-TEV protease (US Biological) and incubated overnight at 4°C in a 
rotation wheel. The supernatant was collected and GST-TEV was removed from the eluate 
by adding 10ml GST beads and incubating for 15 minutes 4 °C in a rotation wheel. The eluate 
was then incubated with 20 ml Ni-NTA beads (Qiagen) for 45 minutes at 4 °C in a rotation 
wheel. Beads were washed once with 1 mL TEV cleavage buffer and three times with 1 mL 
cross-linking buffer (25 mM Hepes KOH pH 7.9, 300 mM KCl, 5% glycerol, 0.05% Tween-20). 
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Beads were then resuspended in 50 ml cross-linking buffer containing 250 mM BS3 cross-
linker (Sigma) and incubated for 30 min at 37°C in a thermoshaker (1100 rpm). The cross-
linking reaction was quenched by adding 7 ml 0.5 M ammonium bicarbonate and incubating 
for 5 minutes at RT. Finally, beads were washed twice with 0.5 mL PBS after which bound 
cross-linked proteins were digested overnight using on-bead LysC/trypsin digestion. Tryptic 
peptides were desalted and purified using stagetips prior to LC-MS/MS analysis. 
   
     Analysis of cross-linking mass spectrometry data
   Thermo RAW MS files were converted to .mgf format using the MSConvert tool from 
ProteoWizard and analyzed using pLink with default settings for HCD using BS3 as a cross-
linking agent [23, 37]. Cross-linked peptides matched to spectra with an FDR <0.05 were 
considered high confidence and were used for further analysis. Spectra were visually 
analyzed and annotated using the pLabel software [38]. Template structures for homology 
modelling were searched using HHPred, and homology models were built using the Modeller 
interface in UCSF Chimera [24, 26, 39]. Yeast CHD1 chromodomain and ATPase residues 38-
800 (PDB 3MWY) were used as a template for residues 500-1298 from human CHD4 (Uniprot 
Q14839) for homology modelling [27]. RMSD calculations were performed in UCSF Chimera. 
Solvent accessible surface distances were calculated for a representative CHD4 model using 
Xwalk. xiNET was used to visualize high-confidence intra- and inter-protein cross-links in 
network form (Rappsilber Lab--crosslinkviewer.org). All protein structure visualizations were 
produced using UCSF Chimera. 
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Supporting Information
Supplementary Table 1: iBAQ values used to calculate NuRD subunit stoichiometry. 
For a more comprehensive version including the iBAQ values of proteins from each affinity 
purification, see: http://onlinelibrary.wiley.com/doi/10.1111/febs.12972/suppinfo
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Supplementary Table 2: Overview of all assigned cross-links with FDR <0.05 as calculated in pLink.
sp|O94776|MTA2_HUMAN 460 sp|O94776|MTA2_HUMAN 504
sp|O94776|MTA2_HUMAN 460 sp|O94776|MTA2_HUMAN 508
sp|O94776|MTA2_HUMAN 492 sp|O94776|MTA2_HUMAN 504
sp|O94776|MTA2_HUMAN 501 sp|O94776|MTA2_HUMAN 508
sp|O94776|MTA2_HUMAN 504 sp|O94776|MTA2_HUMAN 559
sp|O94776|MTA2_HUMAN 508 sp|O94776|MTA2_HUMAN 539
sp|O94776|MTA2_HUMAN 508 sp|O94776|MTA2_HUMAN 559
sp|O94776|MTA2_HUMAN 522 sp|O94776|MTA2_HUMAN 539
sp|O94776|MTA2_HUMAN 531 sp|O94776|MTA2_HUMAN 539
sp|O94776|MTA2_HUMAN 531 sp|O94776|MTA2_HUMAN 559
sp|O94776|MTA2_HUMAN 533 sp|O94776|MTA2_HUMAN 539
sp|O94776|MTA2_HUMAN 533 sp|O94776|MTA2_HUMAN 559
sp|O94776|MTA2_HUMAN 539 sp|O94776|MTA2_HUMAN 559
sp|O94776|MTA2_HUMAN 539 sp|O94776|MTA2_HUMAN 592
sp|O94776|MTA2_HUMAN 559 sp|O94776|MTA2_HUMAN 592
sp|O94776|MTA2_HUMAN 611 sp|O94776|MTA2_HUMAN 618
sp|O95983|MBD3_HUMAN 46 sp|O95983|MBD3_HUMAN 68
sp|O95983|MBD3_HUMAN 92 sp|O95983|MBD3_HUMAN 109
sp|O95983|MBD3_HUMAN 129 sp|O95983|MBD3_HUMAN 142
sp|Q09028|RBBP4_HUMAN 156 sp|Q09028|RBBP4_HUMAN 215
sp|Q12873|CHD3_HUMAN 288 sp|Q12873|CHD3_HUMAN 295
sp|Q12873|CHD3_HUMAN 839 sp|Q12873|CHD3_HUMAN 843
sp|Q13547|HDAC1_HUMAN 438 sp|Q13547|HDAC1_HUMAN 444
sp|Q13547|HDAC1_HUMAN 444 sp|Q13547|HDAC1_HUMAN 451
sp|Q13547|HDAC1_HUMAN 451 sp|Q13547|HDAC1_HUMAN 457
sp|Q13547|HDAC1_HUMAN 466 sp|Q13547|HDAC1_HUMAN 476
sp|Q13547|HDAC1_HUMAN 469 sp|Q13547|HDAC1_HUMAN 476
sp|Q14839|CHD4_HUMAN 123 sp|Q14839|CHD4_HUMAN 126
sp|Q14839|CHD4_HUMAN 263 sp|Q14839|CHD4_HUMAN 273
sp|Q14839|CHD4_HUMAN 266 sp|Q14839|CHD4_HUMAN 273
sp|Q14839|CHD4_HUMAN 266 sp|Q14839|CHD4_HUMAN 285
sp|Q14839|CHD4_HUMAN 266 sp|Q14839|CHD4_HUMAN 287
sp|Q14839|CHD4_HUMAN 266 sp|Q14839|CHD4_HUMAN 290
sp|Q14839|CHD4_HUMAN 284 sp|Q14839|CHD4_HUMAN 287
sp|Q14839|CHD4_HUMAN 284 sp|Q14839|CHD4_HUMAN 289
sp|Q14839|CHD4_HUMAN 285 sp|Q14839|CHD4_HUMAN 290
sp|Q14839|CHD4_HUMAN 285 sp|Q14839|CHD4_HUMAN 295
sp|Q14839|CHD4_HUMAN 287 sp|Q14839|CHD4_HUMAN 290
sp|Q14839|CHD4_HUMAN 287 sp|Q14839|CHD4_HUMAN 295
sp|Q14839|CHD4_HUMAN 290 sp|Q14839|CHD4_HUMAN 297
sp|Q14839|CHD4_HUMAN 290 sp|Q14839|CHD4_HUMAN 304
sp|Q14839|CHD4_HUMAN 290 sp|Q14839|CHD4_HUMAN 501
sp|Q14839|CHD4_HUMAN 295 sp|Q14839|CHD4_HUMAN 304
sp|Q14839|CHD4_HUMAN 297 sp|Q14839|CHD4_HUMAN 504
sp|Q14839|CHD4_HUMAN 690 sp|Q14839|CHD4_HUMAN 693
sp|Q14839|CHD4_HUMAN 693 sp|Q14839|CHD4_HUMAN 696
sp|Q14839|CHD4_HUMAN 833 sp|Q14839|CHD4_HUMAN 838
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sp|Q14839|CHD4_HUMAN 833 sp|Q14839|CHD4_HUMAN 839
sp|Q14839|CHD4_HUMAN 969 sp|Q14839|CHD4_HUMAN 1189
sp|Q14839|CHD4_HUMAN 1390 sp|Q14839|CHD4_HUMAN 1396
sp|Q14839|CHD4_HUMAN 1390 sp|Q14839|CHD4_HUMAN 1454
sp|Q14839|CHD4_HUMAN 1660 sp|Q14839|CHD4_HUMAN 1664
sp|Q14839|CHD4_HUMAN 1687 sp|Q14839|CHD4_HUMAN 1693
sp|Q14839|CHD4_HUMAN 1687 sp|Q14839|CHD4_HUMAN 1723
sp|Q14839|CHD4_HUMAN 1690 sp|Q14839|CHD4_HUMAN 1723
sp|Q14839|CHD4_HUMAN 1693 sp|Q14839|CHD4_HUMAN 1723
sp|Q16576|RBBP7_HUMAN 155 sp|Q16576|RBBP7_HUMAN 214
sp|Q16576|RBBP7_HUMAN 159 sp|Q16576|RBBP7_HUMAN 214
sp|Q86YP4|P66A_HUMAN 178 sp|Q86YP4|P66A_HUMAN 204
sp|Q86YP4|P66A_HUMAN 204 sp|Q86YP4|P66A_HUMAN 233
sp|Q86YP4|P66A_HUMAN 349 sp|Q86YP4|P66A_HUMAN 459
sp|Q86YP4|P66A_HUMAN 451 sp|Q86YP4|P66A_HUMAN 459
sp|Q86YP4|P66A_HUMAN 459 sp|Q86YP4|P66A_HUMAN 503
sp|Q86YP4|P66A_HUMAN 459 sp|Q86YP4|P66A_HUMAN 507
sp|Q86YP4|P66A_HUMAN 487 sp|Q86YP4|P66A_HUMAN 507
sp|Q86YP4|P66A_HUMAN 499 sp|Q86YP4|P66A_HUMAN 507
sp|Q86YP4|P66A_HUMAN 503 sp|Q86YP4|P66A_HUMAN 507
sp|Q86YP4|P66A_HUMAN 550 sp|Q86YP4|P66A_HUMAN 585
sp|Q86YP4|P66A_HUMAN 576 sp|Q86YP4|P66A_HUMAN 585
sp|Q8WXI9|P66B_HUMAN 15 sp|Q8WXI9|P66B_HUMAN 30
sp|Q8WXI9|P66B_HUMAN 15 sp|Q8WXI9|P66B_HUMAN 44
sp|Q8WXI9|P66B_HUMAN 44 sp|Q8WXI9|P66B_HUMAN 52
sp|Q8WXI9|P66B_HUMAN 147 sp|Q8WXI9|P66B_HUMAN 157
sp|Q8WXI9|P66B_HUMAN 281 sp|Q8WXI9|P66B_HUMAN 462
sp|Q8WXI9|P66B_HUMAN 353 sp|Q8WXI9|P66B_HUMAN 462
sp|Q8WXI9|P66B_HUMAN 454 sp|Q8WXI9|P66B_HUMAN 462
sp|Q92769|HDAC2_HUMAN 413 sp|Q92769|HDAC2_HUMAN 439
sp|Q92769|HDAC2_HUMAN 440 sp|Q92769|HDAC2_HUMAN 451
sp|Q92769|HDAC2_HUMAN 444 sp|Q92769|HDAC2_HUMAN 452
sp|Q92769|HDAC2_HUMAN 451 sp|Q92769|HDAC2_HUMAN 452
sp|Q92769|HDAC2_HUMAN 458 sp|Q92769|HDAC2_HUMAN 468
sp|Q92769|HDAC2_HUMAN 458 sp|Q92769|HDAC2_HUMAN 478
sp|Q92769|HDAC2_HUMAN 462 sp|Q92769|HDAC2_HUMAN 468
sp|Q92769|HDAC2_HUMAN 462 sp|Q92769|HDAC2_HUMAN 478
sp|Q92769|HDAC2_HUMAN 466 sp|Q92769|HDAC2_HUMAN 478
sp|Q92769|HDAC2_HUMAN 468 sp|Q92769|HDAC2_HUMAN 478
sp|Q92769|HDAC2_HUMAN 468 sp|Q92769|HDAC2_HUMAN 481
sp|O94776|MTA2_HUMAN 41 sp|O95983|MBD3_HUMAN 46
sp|O94776|MTA2_HUMAN 639 sp|Q12873|CHD3_HUMAN 1067
sp|O94776|MTA2_HUMAN 539 sp|Q16576|RBBP7_HUMAN 214
sp|O94776|MTA2_HUMAN 639 sp|Q8WXI9|P66B_HUMAN 462
sp|O95983|MBD3_HUMAN 92 sp|Q86YP4|P66A_HUMAN 178
sp|O95983|MBD3_HUMAN 109 sp|Q86YP4|P66A_HUMAN 204
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  Inter-­‐protein	  Links
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sp|O95983|MBD3_HUMAN 92 sp|Q8WXI9|P66B_HUMAN 193
sp|Q12873|CHD3_HUMAN 116 sp|Q14839|CHD4_HUMAN 123
sp|Q12873|CHD3_HUMAN 1199 sp|Q14839|CHD4_HUMAN 1865
sp|Q12873|CHD3_HUMAN 1385 sp|Q86YP4|P66A_HUMAN 27
sp|Q12873|CHD3_HUMAN 14 sp|Q8WXI9|P66B_HUMAN 15
sp|Q13330|MTA1_HUMAN 532 sp|Q14839|CHD4_HUMAN 266
sp|Q13330|MTA1_HUMAN 532 sp|Q14839|CHD4_HUMAN 290
sp|Q13330|MTA1_HUMAN 686 sp|Q14839|CHD4_HUMAN 1390
sp|Q14839|CHD4_HUMAN 1844 sp|Q86YP4|P66A_HUMAN 349
sp|Q14839|CHD4_HUMAN 1865 sp|Q86YP4|P66A_HUMAN 503
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    Abstract
   A multitude of post-translational modifications take place on histones, one of the best 
studied being acetylation on lysine residues, which is generally associated with gene 
activation. During the last decades, several so-called co-repressor protein complexes that 
carry out the reverse process, histone deacetylation, have been identified and characterized, 
such as the Sin3, N-CoR/SMRT and NuRD complexes. Although a repressive role for these 
complexes in regulating gene expression is well established, accumulating evidence also 
points to a role in gene activation. Here, we argue that integration of various state-of-the-
art technologies, addressing different aspects of transcriptional regulation, is essential to 
unravel this apparent biological versatility of ‘co-repressor’ complexes.
6Versatility of the Co-repressors
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      Introduction
    To facilitate the packaging of DNA into the cell nucleus, four types of histone proteins 
(H2A, H2B, H3 and H4) together form an octamer around which 147 base pairs of DNA is 
wrapped. This complex of histones and DNA is called the nucleosome. Both the core domains 
and the N-termini of histones, the so-called histone tails, contain a large number of amino 
acid residues that can be post-translationally modified. Because of their proximity to DNA, 
these modifications can influence gene expression. An important and frequent modification 
that occurs on histone tails is acetylation, in which an acetyl group (COCH3) is covalently 
coupled to a lysine residue (K). Already in the 1960s, histone acetylation was proposed 
to be associated with gene activation1, an assumption that has been supported by many 
findings since (e.g.2). The acetyl group can neutralise the positive charge of the histone, 
thus disrupting higher-order chromatin structure by weakening the interaction between the 
histone octamer and DNA3. In general, this leads to enhanced gene transcription in cis. In 
addition, acetylated histones are recognized by bromodomain-containing activator proteins4. 
Many proteins have been identified that have the ability to acetylate histones; these 
enzymes are called histone acetyltransferases (HATs, reviewed in3). Most protein complexes 
containing HATs are thus known transcriptional activators. In contrast, histone deacetylases 
(HDACs) remove acetyl groups from histones and these proteins are therefore thought to 
have a repressive effect on gene expression. Indeed, several complexes containing HDACs 
were described to induce transcriptional repression, such as the Sin3A/B, N-CoR/SMRT 
and NuRD complexes5–11. Although a repressive role for the these complexes in regulating 
gene expression is well established, accumulating evidence has revealed that co-repressor 
complexes also localize to actively transcribed genes and are sometimes required for their 
activation. In this perspective, we discuss some examples where the Sin3A/B, N-CoR/SMRT 
and NuRD complexes are associated with gene activation (for a more comprehensive review, 
refer to 12). We also discuss recent technological advances that need to be further developed 
and integrated to decipher the molecular mechanisms behind the apparent biological 
versatility of ‘co-repressor’ complexes. 
     When co-repressors activate
   Early on it was shown that upon inhibition or depletion of HDACs, an approximately 
equal number of genes are up- and downregulated13–16. While these observations may be 
attributed to indirect effects, subsequent studies proved otherwise17. Pioneering mechanistic 
studies in yeast clearly showed that the Sin3/Rpd3 complex is required for activation 
of some of its target genes upon osmostress and heat shock in a histone deacetylation-
dependent manner18,19. The development of new genomics technology also brought about 
new perspectives on the function of histone acetylation and deacetylation, both in yeast 
(ChIP-on-chip) and mammals (ChIP-sequencing). The first global localization study for Rpd3, 
interestingly, showed enrichment both near repressed and active genes20. Similarly, in 
mammals, the genome-wide localization of several HATs and HDACs showed that binding of 
HATs as well as HDACs positively correlates with gene expression, RNA Polymerase II binding 
and acetylation levels21. The authors proposed that at active genes, the function of HDACs 
may be to remove acetyl groups during transcription, so that chromatin is ‘reset’ for the next 
round of transcription22. This suggests that the role of HDACs may not be solely repressive, 
but can in fact also support active gene expression.    Indeed, targeted studies focusing on individual HDAC-containing complexes provided 
further support for these initial observations. The mammalian orthologues of Sin3, Sin3A 
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and B, were shown to be enriched in the proximity of genes that are activated as myoblasts 
differentiate into myotubes23.  A subset of these genes is downregulated upon Sin3A/B 
depletion, further implying the activating effect of Sin3 proteins on these genes. It is 
noteworthy that Sin3A/B target genes that are repressed during myoblast differentiation 
are also enriched for the transcription factor E2F4. Relevant to this observation, in a more 
recent report by the same group, Sin3A was reported to be enriched at promoters of active 
genes with high levels of H3K4me3, along with the H3K4me3 interactor ING124. Another 
set of genes that are Sin3A targets were also enriched for E2F4. Upon perturbation of the 
H3K4me3/me1 ratio at the promoter proximal regions, decreased binding of both ING1 and 
Sin3A was observed in the former set of genes, whereas Sin3A/E2F4 targets were insensitive 
to the H3K4me3/me1 ratio. These observations classify Sin3 targets depending on different 
co-factors and/or the chromatin marks that are present in cis. Thus, recruitment of Sin3 to 
chromatin by different co-factors possibly results in different transcriptional outputs. 
    For the nuclear receptor co-repressors, it was first observed in 2000 that N-CoR was 
required for transcriptional activation mediated by the retinoic acid receptor-specific 
ligand (LG550). This ligand failed to activate target genes in N-CoR-/- MEFS and  exogenous 
expression of N-CoR restored activation25. Similarly, the closely related SMRT co-repressor 
was observed to mediate full estrogen-dependent ER-alpha transcriptional activation, albeit 
in a cell type-specific manner26. In addition, a recent ChIP-sequencing study revealed that 
N-CoR and SMRT colocalize with known activators at Vitamin D3-activated gene enhancers. 
The genome-wide binding profile of N-CoR showed high correlation with the Vitamin D 
receptor binding upon Vitamin D3 stimulation, suggesting an activating role for N-CoR27. 
While most of the evidence for an activating role of N-CoR and SMRT is based on correlation, 
it is clear that gene regulation mediated by these co-repressors is more complex than 
originally described (reviewed in 28).
    For the NuRD complex, a number of studies have suggested a correlation with active 
transcription. For example, when the genome-wide localisation of the NuRD subunit MBD3 
was studied in MCF-7, MDA-231 and mES cells, it was found that MBD3 preferentially 
localises to the active part of the genome, i.e. active enhancer regions, active promoters 
and gene bodies of actively transcribed genes29,30. Together with the finding that the 
NuRD subunit Mi-2β localises mainly to transcriptionally active genes31, this suggests an 
activating role for the NuRD complex at these loci. Also in the haematopoietic system, an 
activating role for the NuRD complex was described. FOG-1, which itself is a co-factor for 
the haematopoietic factor GATA-1 and is required for regulation of most GATA-1 dependent 
genes, is known to bind to the NuRD complex and recruit it to FOG-1 target genes32. While 
the NuRD complex is present at target genes of GATA-1 and FOG-1 that are repressed, it 
is also recruited to some other GATA-1 and FOG-1 targets where it mediates activation. 
Indeed, it was shown that NuRD occupancy at these genes remained high or even increased 
upon FOG-1-dependent activation. Additionally, a construct containing a FOG-1-dependent 
reporter gene could no longer be activated by FOG-1 when the NuRD subunits MTA1-3 were 
knocked down, indicating that NuRD is directly required for transcriptional activation32. By 
studying mice homozygous for a mutated form of FOG-1 that is unable to interact with 
the NuRD complex, an activating role for NuRD was suggested for some FOG-1/GATA-1 
target genes also in vivo32. Together, these findings show that the NuRD complex is directly 
involved in activation of gene expression in multiple instances, indicating that this may be a 
more general role than previously thought.
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   Data interpretation and future directions
  When studying transcriptional regulation by multi-subunit protein complexes, there are 
many factors that need to be considered that are generally overlooked in genome-wide 
sequencing based approaches. Below we describe these factors, and discuss several 
methods and technologies that we think are required, in an integrative manner, to solve 
the molecular mechanisms underlying the apparent biological versatility of ‘co-repressor’ 
complexes (see Figure 1). 
  First of all, most genome-wide profiling studies such as ChIP-sequencing require large 
amounts of cells. Heterogeneity within a certain cell population that is used for the 
experiment may compromise correct interpretation of the data. In large heterogeneous 
cell populations, opposing individual signals may be averaged out and therefore escape 
notice. Also, signals present in a minority of cells may be lost due to overruling signals from 
the majority. Finally, proteins that appear to co-occupy certain genes in a ChIP-sequencing 
experiment, may actually bind to the same genes but in a mutually exclusive manner. It is 
thus important to realise that population effects can strongly affect data output and result 
in false, generalizing conclusions concerning individual cells.
  Asynchronous cell populations cause another layer of heterogeneity. Cells that are in 
different phases of the cell cycle differ in the genes they express and the epigenetic marks 
that are present on their chromatin. Thus, pooling asynchronous cells possibly masks 
some cell cycle specific patterns. A 2003 study using synchronized cell populations showed 
alternating enrichment of factors driving waves of expression33. This led to the model of 
cyclical regulation of transcription, which was a remarkable leap from the analogy that 
visualizes transcriptional control as an on/off switch28. DNA methylation has also been 
shown to vary cyclically and thereby regulate gene expression34,35. These experiments in 
synchronized cells thus revealed that cyclical variation may be a more general phenomenon 
in the regulation of gene expression and that conclusions drawn from the analysis of 
asynchronous cell populations may not represent all regulatory patterns equally well. 
   An additional point that needs to be emphasised is that correlation does not necessarily 
mean causation. When two proteins or epigenetic marks are found to colocalise at a specific 
locus, this could indeed mean that the presence of one led to recruitment of the other, 
or that both interacted already before binding at the locus together. However, proteins or 
marks could also be attracted to the same site independently of each other, for example 
through binding other proteins. Other scenarios are also imaginable, such as one protein 
or mark actually causing repulsion of the other, but that this event had not yet taken place 
at the time of analysis. When examining correlation studies we therefore need to take 
these different possibilities into account, and appreciate the different conclusions they 
may propose. Information on the duration of the binding of factors may vastly add to the 
interpretation of correlation studies. It was first shown in 2000 that regulatory factors are 
not statically bound at the their target regulatory sites upon stimulation, but are rather in a 
state of constant exchange36. Additionally, in the 2003 study mentioned above, the dynamics 
and co-occurrence of factors on the estrogen-responsive pS2 gene promoter were identified 
over a series of time course experiments33. Knowing the dynamics of factor binding at target 
sites provides a more detailed picture of the in vivo situation and allows us to decipher the 
cause within the correlation. 
   Essential to keep in mind is the structural heterogeneity of the Sin3A/B, N-CoR/SMRT 
and NuRD complexes. Each complex consists of multiple core subunits, many of which have 
orthologues, resulting in a large number of possible complex compositions28,37–39. Evidence is 
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emerging that similar but distinct core subunits have different biological functions, implying 
that the exact subunit composition influences the activity of the complex23,40,41. In addition, 
various substoichiometric, often cell-type specific interactors have been identified39. These 
proteins also have the ability to alter the behaviour of the complex, for example by directing 
the complex to specific targets. Identifying the exact composition of the complexes in 
different contexts should also shed light on their functional heterogeneity. An additional 
variation on complex composition concerns different post-translational modifications 
(PTMs) of the subunits. For example, for the NuRD complex, progressive acetylation of 
HDAC1 was shown to block its catalytic activity during erythropoiesis42–44. The complex is 
hypothesized to switch function from repression to activation as the HDAC subunits lose 
their catalytic activity and the only chromatin modifying activity the complex can perform 
is remodelling. This example shows that PTMs contribute to the functional switch by 
modulating the catalytic activities of the complexes. In addition, PTMs could affect complex 
composition by influencing interactions with other subunits or interactors. Yet another layer 
of complication regarding the study of multisubunit complexes concerns potential complex-
independent functions of the subunits. Therefore it may be inaccurate to extrapolate from 
data obtained by studying only one subunit to the whole complex.
   Another area of transcriptional regulation that needs to be considered is at the stage of 
RNA Polymerase II (Pol II) elongation. For a long time, general transcription factors recruiting 
Pol II machinery was considered sufficient to generate transcriptional output, which is an 
assumption that mostly holds true for transcriptional control in Saccharomyces cerevisiae. 
Notably, chromatin modifying complexes do interact with the elongating Pol II, affecting 
its processivity in Saccharomyces cerevisiae; however this usually takes place on the gene 
bodies and increasingly toward the 3’ end of genes45. In metazoans, on the other hand, 
there had been indications of extra levels of regulation between the recruitment of Pol II 
and the initiation of productive transcription at the 5’ ends of genes. With the genome-wide 
maps of Pol II localization, the extent of paused versus elongating Pol II could be observed 
more globally46,47. Further work elucidated the presence of positive and negative elongation 
factors that strictly regulate transcriptional elongation by Pol II. So far, a link between Pol 
II stalling/elongation and various chromatin complexes has been shown for the NuRD and 
Sin3B complexes via specific interactors, IKAROS and PHF12 respectively48,49. NuRD positively 
regulates elongation via its remodeling activity whereas the presence of Sin3B/HDAC1 is 
suggested to block elongation due to histone deacetylation. More examples of this type of 
regulation undertaken by these chromatin complexes are expected to emerge and possibly 
clarify the context-dependency of their activating or repressing function. 
  Novel technology to investigate nuclear organization in three dimensions has revealed 
many new insights regarding regulation of transcription. Especially the generation of ‘C 
technologies’ consisting of chemical crosslinking of DNA followed by deep sequencing 
provided a genome-wide picture of chromosomal architecture50,51. There is a strong 
correlation between the position of a gene within the nucleus (peripheral or central) and its 
activity (silent or active respectively)51, but the exact cause and effect relationship between 
the two aspects is not yet known. There are a few examples demonstrating enhanced 
transcription upon induced chromatin looping52,53, but more data on different loci is required 
to fully address the causality question. However, classifications have emerged that qualify 
certain looping events such as permissive looping versus instructive looping50. As such, it is 
now conceivable that the cause and effect relationship between looping and transcription 
is not unilateral and can change context- or locus-dependently. A recent report showed that 
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decondensation of chromatin was sufficient for a locus to move from the nuclear periphery 
to a more central nuclear position, suggesting that the change in chromatin compaction 
is driving the change in location within the nucleus, and hence, the 3D organization54. 
This study is exemplary in integrating multiple levels of regulation: chromatin compaction 
regulating the potential for transcription and, at the same time, affecting the position of 
the locus in question. For the purposes of understanding the function of the chromatin 
complexes (Sin3A/B, N-CoR/SMRT and NuRD), the next step would be to look at their global 
3D distribution within the nucleus and see whether they affect the genome architecture in 
any way. 
     At the population level, an established approach that has given many insights as mentioned 
above is ChIP re-ChIP33. Whereas ChIP assays are designed to identify the DNA targets of a 
certain protein of interest, re-ChIP or sequential ChIP allows for the identification of proteins 
that are concomitantly binding to the same DNA sequence. Although this technically 
challenging method has been shown to yield qualitatively good data (e.g.33,35), it is restricted 
in the sense that it is a targeted approach, where proteins of interest are known in advance. 
Further advances may therefore mainly lie in unbiased single cell and even single locus 
approaches. Indeed, gene expression has been revealed as an essentially stochastic process, 
resulting in cell-to-cell variations in mRNA and protein levels55. Single cell biology, although 
a relatively young field, has already yielded many promising methods that have provided 
insights into the variability of cell populations, and many researchers are working on 
even more advanced techniques to look into single cell dynamics56,57. The stochasticity of 
transcription observed in single cell studies provides a very intriguing viewpoint, suggesting 
that there may be far more levels of regulation in play that lead to the deterministic pattern 
of expression observed at the population level58,59. In addition, effort has been put into 
developing methods facilitating unbiased identification of proteins and histone marks at a 
single genomic locus, although these approaches are still constrained to using populations 
of cells to obtain enough material60–63. Both single cell and single locus approaches have the 
potential to offer more details about the behaviour of the Sin3A/B, N-CoR/SMRT and NuRD 
complexes. This detailed insight seems indispensable for elucidating the apparent versatility 
of the complexes and for thoroughly explaining the different contexts of their function.
   In an ideal world, we would be able to look at the exact complex composition on a single 
locus in a single cell, identify all other proteins present on the locus and their binding 
dynamics, know the 3D location of the locus within the nucleus, know the state of Pol II and 
the transcriptional output. By putting all this information together, we can study all aspects 
of transcriptional control at the single cell level as well as the population level, pinpoint 
the contribution of stochastic versus deterministic processes, and refine the concepts of 
activation and repression by ‘co-repressor’ complexes. 
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Figure 1: Brief overview of discussed methods
Panel (A) depicts the apparent versatility of the co-repressor complexes. In the panels below, 
different methods of addressing this question are shown. The read-out of these methods is in-
fluenced by the con-
text characterized by 
differential interactors, 
the interaction with a 
paused or elongating 
Pol II and nuclear local-
ization. (B) The action 
of the co-repressor 
complexes depends on 
association with differ-
ent interactors which 
could be specific to 
cell type, to the phase 
of the cell cycle or to a 
subset of targets. Due 
to the heterogeneity 
of the cell population 
(e.g. different phases 
of the cell cycle and/
or slight differences in 
developmental stage) 
the opposite outcomes 
mediated by differen-
tial interactors are not 
observed, i.e. the ma-
jority of the population 
of cells masks the op-
posite effect observed 
in the minority of cells. 
(C) The co-repressor 
complexes could be 
involved in regulating 
transcription elongation. In the presence of a specific interactor, the 
co-repressor complexes facilitate the release of paused RNA Polymerase 
II, resulting in transcriptional elongation, while in the absence of such an 
interactor the target gene is not transcribed. Serine 2 phosphorylation 
(S2-P) represents elongating RNA Polymerase II (Pol II), Serine 5 phos-
phorylation (S5-P) represents the stalled Pol II. (D) The observed activity 
of the co-repressor complexes can also depend on nuclear localization. 
When a target gene bound by a complex is located at the nuclear periphery it is silenced, while the 
same gene bound by the same complex could be activated when located more centrally in the nu-
cleus. This instance of regulation could be explained by the repressive versus permissive chroma-
tin context within the nucleus. (E) In summary, the caveats of the currently used methods prevent 
us from predicting the outcome of the action of the ‘co-repressor’ complexes as the activating and 
repressing functions are dependent on as yet ill-defined contexts. Technology integration could 
resolve the differential action of co-repressors and help in defining the contextual differences that 
cause the different outcomes in the first place.
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Techniques
Chromatin immunoprecipitation is an immunoprecipitation technique that is used to 
study pro     tein-DNA interactions in the context of the chromatin. The basic steps include 
crosslinking proteins  and chromatin, after which the DNA is cut into small fragments. An 
antibody for a specific protein is then used to immunoprecipitate this protein together 
with the associated DNA. Finally, the crosslinks are reversed, the DNA is purified and can 
be subjected to a number of techniques. In ChIP-seq, the DNA is sequenced by massively 
parallel DNA sequencing. Alternatively, the DNA can be hybridised to a DNA microarray 
(ChIP-on-chip), another method to identify the fragments that were enriched by ChIP.
In ChIP-reChIP, immediately after the first immunoprecipitation the sample is subjected 
to a second round of immunoprecipitation with a different antibody. This approach is used 
to study the colocalisation of proteins.
C technologies are a collection of technologies that use chromatin conformation 
capture to study the 3D organisation of DNA inside the nucleus. Usually the protocol 
includes crosslinking followed by restriction digestion and intramolecular ligation. After 
the crosslinks are reversed, there are several methods to analyse the sample, typically 
containing an amplification and quantitation step. 
RNA-sequencing is a method used to study the transcriptome of cells. Generally, RNA 
is isolated from cells and reverse-transcribed into cDNA, which is then subjected to 
sequencing. This provides information on the transcription status of genes at a particular 
time. Recently, the development of single-cell RNA-sequencing made it possible to study 
the transcriptome of individual cells.
Single-cell technologies cover a plethora of techniques, including methods to visualize 
transcription (e.g. RNA-FISH), histone modifications (e.g. ISH-PLA), individual protein 
localization (e.g. FRAP), or protein-DNA interactions (e.g. DamID) at the single-cell level. 
Single locus proteomics aims to identify all the proteins associated with a single locus, 
however, this technique is not yet applicable to single cells.
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Discussion
Chapter 7
“When life itself seems lunatic, who knows where madness lies? Perhaps to be
 too practical is madness. To surrender dreams - this may be madness.
Too much sanity may be madness - and maddest of all: 
to see life as it is, and not as it should be!” 
Cervantes, Don Quixote (1605, 1615)
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   Regulation of transcription is an essential process in driving life forward. It is involved in 
regulating cell metabolism via sensing intracellular metabolites and integrating extracellular 
signals provided by signaling pathways in both multicellular and single cell organisms. In 
addition, activation and repression of different transcriptional programs is essential for 
proliferation and differentiation in multicellular organisms. Hence, the appropriate response 
to environmental changes and the maintenance of tissue homeostasis are mediated by 
modulation of transcription. 
    As a complex and multistep process, the various steps of transcription, i.e. initiation, 
elongation and termination, are relatively well described with most of the components 
biochemically characterized. As DNA is wrapped around histone octamers in eukaryotic cells, 
transcriptional regulation requires alteration of the chromatin environment. A reciprocal 
correlation between ‘chromatin density’ and amenability to transcription dates back to 
1920s1. However, the characterization of the transcription machinery preceded studies 
revealing the properties of chromatin around active transcription sites. This sequence of 
discoveries is mostly due to the technological challenges of studying chromatin and partly to 
the underestimation of the influence of chromatin components on DNA accessibility. 
   The chromatin environment, as introduced in chapter 1, affects all DNA-templated 
processes. In this thesis, well-known transcriptional regulatory complexes, NuRD, PRC1 and 
PRC2 as well as the relatively recently characterized PR-Dub complex, are the subject of study. 
The mammalian PR-Dub complex composition and the functional implication of MBD6 in 
DNA damage response are presented in chapter 3. Novel insight into the interplay between 
PRC1 and PRC2 complexes provided by the biochemical characterization of nucleosomal 
H2AK118/119Ub interactors is presented in chapter 4. Attempts at characterizing the 
stability of the NuRD complex, along with some novel interaction data, are presented in 
chapter 5. Chapter 2 outlines the method we utilize in our laboratory to characterize nuclear 
protein-protein interactions. Chapter 6 is a general perspective on chromatin regulatory 
complexes that were originally characterized as repressors. 
   In the following section, various questions raised by the work described in this thesis and 
several general points regarding the epigenetics field are discussed.
    Polycomb targeting
   As introduced in chapter 1, PcG and TrxG proteins are instrumental in maintaining the 
repressed or active state of chromatin respectively2–4. Both groups represent epigenetic 
regulators as they lay down the chromatin marks that have come to define active and 
repressed states. However, how these complexes are recruited to their tissue-specific targets 
remains an unanswered and critical question. In Drosophila melanogaster, the finding that 
there are Polycomb Response Elements (PREs), specific sequences with which some PcG 
proteins interact (via TFs), was critical as it presented a mechanism for sequence-specific 
targeting5. Interestingly, TrxG proteins are also found to be associated with some PREs, 
invoking the question of what mediates specificity at these shared PRE/TRE elements6. 
   In the mammalian system, the number of PcG complex core subunits and interactors 
increase substantially compared to Drosophila melanogaster (see table 1 and 2 in chapter 
1). In addition, PREs appear to be absent in mammals (with a few exceptions7). Instead, 
specific interactions between PcGs and various long non-coding RNAs have been observed 
in addition to interactions with some TFs3. Therefore, in the mammalian system, targeting 
could be mediated by various interactors (especially if the expression of the interactor is 
tissue-specific) and long non-coding RNAs. 
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  This hypothesis holds true for some targeting events in the genome, but it seems 
insufficient to explain all the loci that PcGs are found at that are revealed by genome-
wide assays. However, taking another factor that is characteristic of mammalian genomes 
into account provides a lot of insight: ~60% of the mammalian promoters overlap with 
CpG islands (CpGIs). It was first proposed in 2008 that CpGIs could be the mammalian 
equivalent of PREs8. However, for PcG recruitment, the absence of any activating factor is 
a pre-requisite. In line with this observation, subsequent studies utilizing ectopic CpGI-like 
sequences inserted into the mESC genome have shown recruitment of both TrxG (CFP1) and 
PcG (PRC2) proteins to CpGIs9,10. Based on these studies, an alternative hypothesis is now 
emerging in the field which envisions the targeting of PcGs (as wells TrxGs) as ‘responding’ 
to chromatin environment as opposed to ‘instructing’ it11,12. The epigenetic regulators are 
hypothesized to ‘sample’ chromatin via specific interactors, and depending on the pre-
existing chromatin state (activating or repressing marks and/or factors), their recruitment is 
stabilized or lost. This sampling is, as exemplified so far, mainly driven by CpG-rich promoters 
and the CXXC zinc finger-containing proteins that interact with unmethylated CpGs: KDM2B 
and CFP1 both have a CXXC zinc finger domain. KDM2B interacts with and recruits variant 
PRC1 complexes to unmethylated CpGs13 and CFP1 is a subunit of the SET1 complex4. Since 
neither PRC1 nor SET1 is found at all unmethylated CpGIs, what seems to be determining 
whether their recruitment is maintained or not is the chromatin environment. For example, 
the presence of active transcriptional machinery could negatively affect PRC1 recruitment 
and result in its dissociation whereas a dense nucleosome environment may favor PRC1 
activity and recruitment (as shown for PRC214). On the other hand, for TrxG proteins, CFP1 
could be sampling chromatin for active marks and activating factors to set the stage for 
activation. This is how ‘chromatin sampling’ by PcG and TrxG proteins may be mediated via 
CXXC-bearing interactors and complex subunits (figure 1). 
   It is important to note that the presence of factors on chromatin that may positively 
or negatively affect PcG recruitment are not necessarily mutually exclusive. The best 
examples are the so-called bivalent chromatin domains in which H3K4me3 co-localizes 
with H3K27me315. Bivalent domains, found most predominantly in mESCs, are thought to 
prime genes for activation and most bivalent domains are resolved (i.e. either activated or 
repressed with the corresponding mark taking over) upon differentiation. While it was shown 
that the presence of H3K4me3 hinders PRC2 activity on the same histone H3 molecule16, the 
existence of bivalent marks was proven by showing that nucleosomes can be asymmetrically 
modified: One Histone H3 molecule bearing the active mark and the other H3 within the 
same nucleosome carrying the repressive mark17. At bivalent domains, the predominance of 
the either histone mark and the proteins it recruits may be effective in tipping the balance 
towards activation versus repression. For example, H3K4me3 could recruit TFIID which 
would facilitate the recruitment of more TrxG proteins and amplify the H3K4me3 signal, 
which would recruit more TFIID and promote PIC formation18,19. Conversely, H3K27me3 
may recruit PRC1 which monoubiquitinates Histone H2AK11920–22. Indeed, the PRC1 subunit 
RING1B is found at a subset of bivalent domains8. In chapter 4 of this thesis along with some 
recent reports23,24, data that show H2AK119Ub recruiting PRC2 have been presented which 
form the basis of a mutual positive feedback loop between PRC1 and PRC2, facilitating the 
amplification of repressive signals from both sides by both complexes.
   An integration of various genome-wide data sets has revealed that H3K4me3 is found 
mostly on CpG-promoters8,25,26. Co-occurence of H3K4me3 and H3K27me3 was exclusively 
observed on CpG-promoters in pluripotent cells (i.e. mESCs and iPSCs), an observation 
7Discussion
149
Figure 1: Chromatin environment affects the recruitment of epigenetic regulators. Panel A 
shows the co-existence of H3K4me3 and H3K27me3 on the same nucleosome, hence a bivalent 
region. Panel B shows the recruitment of the SET1 complex via an interaction between CFP1 and 
unmethylated CpGs. Panel C shows the recruitment of PRC1 by KDM2B, also interacting with 
unmethylated CpGs. Panel D shows the recruitment of the PRC1 complex via an interaction 
between CBX proteins and H3K27me3. Panel E shows Polycomb domain formation by the 
mechanisms described in panel C and D, in addition to the recruitment of PRC2 via an interaction 
with H2AK119Ub. Note that the histone tails depicted in this figure are only H3 N-terminal tails 
and H2A C-terminal tails.
that links bivalent marks and chromatin sampling mediated by proteins with CXXC domains. 
Therefore, how chromatin may be ‘sampled’ by PRC1 and SET1 complexes at nonCpG 
promoters remains to be determined. In addition, while PRC2 recruitment to CpG promoters 
has been reported8,10,26,27, a detailed mechanism with an intermediary interactor or subunit 
is not characterized yet for the PRC2 complex (like KDM2B and PRC1). At the moment, three 
components of chromatin sampling have been identified: unmethylated CpG promoters, 
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CXXC domain-containing proteins and the complexes that they recruit (PRC1 and SET1). 
Different contexts involving PRC2 and CpG promoters in addition to all the complexes (PcGs 
and TrxGs) at nonCpG promoters need to be investigated further. Interestingly, despite the 
conservation of PcG and TrxG proteins between Drosophila melanogaster and vertebrates, 
the Drosophila melanogaster genome lacks DNA methylation and hence CpG islands. In that 
case, sampling may be taking place at the PREs and other promoter elements. It is expected 
that different promoter elements and the factors that they recruit direct chromatin sampling 
at nonCpG promoters in the mammalian system as well.
   In the DNA methylation section in chapter 1, a different interpretation of a subset of 
DNA methylation events was introduced as ‘responding’ to TF occupancy as opposed to 
instructing transcription28. Chromatin modifiers that put on marks associated with activation 
and transcription are also hypothesized to sample chromatin as discussed above11,12. 
Depending on the chromatin environment (i.e. marks and/or other proteins already 
present) their recruitment is stabilized or lost. This hypothesis presenting epigenetic factors 
as responding to chromatin environment and then proceeding to ‘lock’ the pre-existing state 
(and possibly amplify activating/repressing signals to fulfill some threshold requirements 
for both processes) seems to solve the specificity problem inherent in the hypothesis in 
which epigenetic factors instruct transcription. The emerging picture of transcriptional 
regulation is that the TFs lay down the initial regulatory signals, which are then amplified 
and maintained by the epigenetic machinery.   
   
     A closer look at the interplay between PRC1 and PRC2
        As mentioned above, before the recruitment of PRC1 to CpGIs via KDM2B was characterized 
in detail in 2012, multiple studies reported PRC2 recruitment to CpGIs in the absence of 
active marks and/or activating factors8,10,26. The finding that the CBX proteins of PRC1 have 
an affinity for the H3K27me3 mark catalyzed by PRC2 precedes this observation20–22. In light 
of all this information, the hierarchical model for Polycomb recruitment is straightforward: 
PRC2 is recruited to target sites in the genome by 1. specific interactions with certain TFs 
or 2. long noncoding RNAs or 3. by the genetic component that are the CpGIs. Once PRC2 
is recruited, it catalyzes the methylation of Histone H3K27. This mark serves as a recruiter 
of both PRC1 (via CBX proteins) and more PRC2 (via EED)29,30, and more H3K27 methylation 
in addition to monoubiquitination of Histone H2AK119 is catalyzed. This model offers a 
stepwise explanation for how the two major PcG complexes are recruited to chromatin. 
   However, genome-wide binding profiles for PRC1 and PRC2 contradict this model in 
that the sites the complexes occupy do not fully overlap31,32. H2AK119Ub levels in the 
absence of PRC2 persist32–34. We and others have shown the hierarchical model could in 
fact be a mutual recruitment model in that the presence of H2AK119Ub engages PRC2 
just as H3K27me3 engages PRC1 (chapter 4,23,24). The latest findings are interesting in this 
sense and reveal an extra layer of regulation of PcG recruitment. However, it should be 
kept in mind that, just as the H2AK119Ub mark is still present in the absence of PRC2 (and 
H3K27me3), H3K27me3 levels are not totally disrupted in Ring1 knock-out mESCs that lack 
H2AK119Ub34,35. Therefore, Histone H2AK119Ub serving as a recruiter for PRC2 seems to 
have regulatory symmetry with Histone H3K27me3 recruiting PRC1: Both mechanisms are 
at play at a subset of PRC1 and PRC2 targets. It may well be that the affinity of one complex 
for the mark laid by the other serves as another example of chromatin sampling by both 
complexes and may be effective mostly in the formation of Polycomb domains, but it is 
not the means of all targeting events of the either complex. That is to say, in addition to 
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the target genes they repress in a coordinated manner31,34, PRC1 and PRC2 have targets on 
chromatin that they occupy independently of one other. For these ‘individual’ target sites, 
the means of recruitment could involve all the aforementioned targeting mechanisms other 
than recognizing the chromatin mark catalyzed by the other PcG complex. 
  Another important aspect to consider is the difference between establishing and 
maintaining the Polycomb domains. The positive feedback loop the two PRC complexes 
generate for each other with the histone marks they catalyze may be critical in establishing 
Polycomb domains in the genome at a specific developmental window. Maintaining these 
domains in successive cell divisions may not require the agonistic crosstalk as vigorously. 
    Another level of complexity is presented by different complex compositions. Clearly, the 
PRC1 complexes that can be recruited by H3K27me3 are those that contain CBX proteins. For 
PRC2, our in vitro interaction screen suggests AEBP2 and JARID2, known PRC2 interactors, 
as the key factors in H2AK119Ub recognition. Therefore, the PRC2 that could be recruited 
by H2AK119Ub could be a subset of all PRC2 that stably interacts with JARID2 and AEBP2. 
Very recently, the activity of PRC2 was shown to be stimulated by the methylation of JARID2 
by PRC2, which is an intriguing instance of a complex post-translationally modifying an 
interactor to modulate its own activity36.
    
      An intriguing chromatin mark: Histone H2A(K119) monoubiquitination
      As introduced in chapter 1, H2A monoubiquitination is associated with several process-
es: transcriptional regulation, cell cycle progression and the DNA damage response. 
      In the context of transcriptional regulation, 
  H2AK119Ub is catalyzed by the PRC1 complex and mediates gene silencing37,38. 
Monoubiquitination of H2A catalyzed by BRCA1 mediates the silencing of microsatellite 
repeats in the genome39; however the ubiquitination sites on Histone H2A by BRCA1 are on 
different lysines (K127 and K129)40.  It would be of interest to know whether the different 
functional associations observed for some PTMs depending on the site of the modification 
on the same histone molecule (for example methylation (15 daltons x2/3 for me2/3) on 
Histone H3K4 vs H3K9) are also observed for a PTM as bulky as ubiquitination (~7 000 
daltons).
     There are a few reports showing that H2AK119Ub mediated by PRC1 or another E3 ligase, 
2A-HUB, function in blocking the elongation of RNA Pol II. The catalytic subunit of PRC1, 
RING1B, was shown to be present in bivalent promoters in mESCs8. It was proposed that 
the RNA Pol II machinery present at these promoters is kept from elongating due to the 
activity of the PRC1 complex41. H2AK119Ub catalyzed by 2A-HUB was shown to be critical 
in repressing transcriptional elongation at a subset of chemokine genes in macrophages by 
inhibiting FACT recruitment42. The FACT complex facilitates transcriptional elongation via 
displacing nucleosomes43. As various genome-wide assays are generated, also for profiling 
paused versus elongating RNA Pol II, it would be interesting to see whether most instances 
of repression linked to H2AK119Ub are cases of RNA Pol II arrest at promoter proximal 
sites. At least a subset of PRC1-mediated repression events could indeed be the inhibition 
of elongation as there is a mild to moderate enrichment of RPII18 (a subunit of all RNA 
polymerases found in Drosophila melanogaster) in the chromatin fraction defined by the 
presence of PcGs in the model organism Drosophila melanogaster44. 
     With the characterization of the PR-Dub complex in Drosophila melanogaster, a surprising 
finding was that removal of H2AK118Ub seemed necessary for transcriptional repression45. 
At first it was not exactly clear how PR-Dub contributed to repression: it was one of the 
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possibilities discussed in the original paper that the repression of the hox genes may be 
mediated by a temporal ubiquitination-deubiquitination cycle mediated by PRC1 and PR-
Dub45. A follow-up paper from the same group further classified target genes of PRC1: The 
genes that required the H2A ubiquitin ligase activity of Sce (D.m. homologue of Ring1b) 
were called Class I genes and those that did not need H2A ubiquitination for repression were 
called Class II46. PR-Dub-mediated deubiquitination was necessary to ensure repression of 
Class I genes. A possible scenario is that the PR-Dub may be removing ubiquitin from non-
target sites (Class II) to provide enough ubiquitin molecules to be utilized by PRC1 for the 
repression of Class I genes. Alternatively, a specific H2AK118Ub-binding repressor could 
be sequestered upon aberrant Histone H2A ubiquitination. PR-Dub, via deubiquitinating 
non-target sites, could be restoring this unknown repressor levels to be re-directed to 
correct target sites (Class I). In both of these scenarios, it seems that the PR-Dub complex 
is functioning to correct for targeting defects in play regarding PRC1 H2A ubiquitin ligase 
activity (which is only required at Class I targets). However, how such specific targeting of PR-
Dub activity to Class II H2AK118Ub would be mediated is not known as genome-wide binding 
profiles for Sce and Calypso (D.m. Bap1) overlap at both Class I and II target genes. Other 
possible scenarios are that the H2AUb levels need to be tightly regulated locally for accurate 
repression and PR-Dub may be adjusting the concentration of H2AUb levels at specific loci. 
Or, as mentioned above, PR-Dub and PRC1 temporally regulate H2AK118Ubn levels. For a 
more detailed discussion of these scenarios, see Scheuermann et al47. Characterizing the 
exact nature of the repression mediated by H2AUb will possibly shed more light on PRC1/
PR-Dub dynamics.
     The mammalian PR-Dub activity on Histone H2A has been reported to result in an increase 
in local H2AK119Ub levels, but the exact effect of this increase on transcription was not 
clear48. In another study, H2A deubiquitination was reported to repress gene transcription, 
but in a PRC1-dependent manner49. That is, the derepression observed in BAP1 knock-down 
is lost in the absence of RING1b-BMI E3 ligases for H2AK119. This study claims that RING1-
BMI is mediating gene activation and under normal conditions PR-Dub is antagonizing 
this activation effect. However, this observation of RING1 depletion compensating the 
upregulation observed upon BAP1 depletion was shown for 3 target genes (of both RING1b 
and BAP1). Therefore whether the proposed interplay between RING1 and BAP1 is valid at 
more sites or whether this is an isolated observation remains to be seen.
     In the context of DNA damage,
    H2A mono and polyubiquitination on various lysines have been reported to recruit DDR 
proteins and promote foci formation50. All deubiquitinases of H2A studied in this context, 
expectedly, were reported to negatively affect foci formation with the exception of BAP151. 
However, a recent screen showed that depletion of 2A-DUB and BRCC36 resulted in DSB 
repair defects as well, suggesting that these two Dubs of H2AUb are also promoting DSB 
repair like BAP152. BAP1 has been reported to localize to DNA damage sites by multiple 
studies and its presence positively affects foci formation53,54. Some possible explanations for 
these unexpected observations could be: 1. These three Dubs deubiquitinate H2AK119Ub on 
nucleosomes that are ‘less proximal’ to the damage site to supply ubiquitin for nucleosomes 
closer to the damage site. 2. Deubiquitination of H2AK119Ub facilitates nucleosome eviction 
to promote the recruitment of DDR machinery. 3. The Dubs target other DDR proteins and 
enhance their activity.  4. The presence of the Dubs at damage sites is independent of their 
deubiquitinase activity and serves another purpose to facilitate the damage response. 
     In chapter 3, our data showed that MBD6 recruitment to sites of irradiation is independent 
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of its interaction with BAP1. Whether BAP1 is recruited to irradiated loci via MBD6 is still 
unclear in our assays either due to BAP1 recruitment being more dynamic than we can 
capture or the eGFP signal being diffused throughout the nucleus obscuring the signal at 
sites of damage. An alternative explanation is that BAP1 is not recruited to sites of irradiated 
DNA in our assays using the HeLa cell line. 
    Finally, in the context of cell cycle progression,
  Deubiquitinases for H2A monoubiquitin that are implicated in cell cycle regulation 
(USP16, USP3 and USP22) are required to make sure H2A is ubiquitin-free for chromosome 
compaction prior to metaphase51,55. Although the effect of BAP1 on the cell cycle has been 
studied by multiple groups due to the tumor suppressor function of BAP156–58, it has not 
been shown to effect the progression of the cell cycle in this context. 
   
     The mammalian PR-DUB: subunits and activities beyond deubiquitination of H2AK119Ub
   The catalytic subunit of the mammalian PR-Dub complex, BAP1, has evolved to include 
an HCFC1-binding domain. HCFC1 is a multifunctional regulatory protein, interacting with 
various TFs and TrxG proteins, and reported to regulate the progression of the cell cycle59,60. 
It is reported to be deubiquitinated by BAP1, although whether this deubiquitination affects 
the stability of HCFC1 is not clear56,57. Interestingly, HCFC1 needs to undergo proteolysis 
to reach maturation. O-linked beta-N-acetylglucosamination (O-GlcNAcylation) by OGT 
is essential for proteolysis61,62 and OGT activity was reported to be regulated by BAP1 
deubiquitinating OGT63. This complex network of interactions and the addition/removal of 
PTMs between the 3 proteins need to be clarified in more detail (figure 2).
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    OGT is an enzyme of increasing popularity due to the emerging findings that O-GlcNAc 
seems to be a rather abundant modification on chromatin and other proteins (chromatin 
associated and otherwise)64,65. As mentioned above, at least in the case of HCFC1, the 
regulatory consequence of O-GlcNAcylation is remarkable. In addition, O-GlcNAcylation 
metabolism in cancer cells is deregulated66. Therefore, O-GlcNAc and the protein responsible 
for the modification (OGT) are of interest in cancer epigenetics67.     
     More links to cancer for PR-Dub subunits are provided  by BAP1 and ASXL1. As mentioned 
in chapter 1, BAP1 and ASXL1 are characterized as driver genes of cancer in a study that 
screened mutations in a number of different malignancies68. Both proteins are categorized 
as tumor suppressors. ASXL1 is mostly mutated in myeloid malignancies as opposed to 
various solid cancers in which BAP1 is mutated69–71. 
     The mammalian PR-DUB complex has, in addition to BAP1 and OGT, one more chromatin 
modifier that is KDM1B (this thesis, 57,58,63). The catalytic activity of this lysine demethylase 
has been shown to be directed to H3K4 mono- and dimethylation, chromatin marks found 
at enhancers and active transcription units72,73. It could be that KDM1B is demethylating this 
Figure 2: The regulatory circuit within the PR-
Dub complex. Reported enzymatic activities of 
PR-Dub subunits on one another are shown. 
Crosstalk or a possible sequential relationship 
between these activities is not yet elucidated.
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mark at sites where BAP1 is mediating H2AK119Ub deubiquitination. Additionally, KDM1B 
has a CW-type zinc finger and a SWIRM domain, and both were shown to be required for 
the demethylase activity74. Whether these domains also mediate the recruitment of PR-
Dub to chromatin will be interesting to find out. Another possibility is that the presence of 
KDM1B within the PR-Dub complex is required to act on other complex members and not 
on chromatin at target sites (or, possibly, it does both).
     In total, there are two erasers (BAP1, KDM1B) and one writer (OGT) as chromatin modifiers 
in the PR-Dub complex. BAP1 is a tumor suppressor, along with another protein within the 
complex that does not have any enzymatic activity (that we know of), ASXL1. An important 
question to address is to what extent the reported tumor suppressor activities of BAP1 and 
ASXL1 and the putative oncogenic link of OGT are within the PR-Dub complex context. If a 
remarkable extent of subunit activities is conducted within the complex, targeting of only 
one protein could rescue the consequences of deregulated PR-Dub activity. If all/some of the 
proteins have complex-independent functions, individual targeting of enzymatic activities 
may be required. Either way, the cancer-related and enzymatic activity–bearing subunits of 
the PR-Dub complex present possibilities to extend the scope of epigenetic drugs.
    Novel PR-Dub subunits/interactors: MBD5 and MBD6
   It is of note that the neurological disorders associated with mutations in the Mbd5 gene 
and microdeletion/duplication of the loci encompassing Mbd5, are all neurodevelopmental 
disorders, i.e. they are not the neurological illnesses that surface later in the life of an 
adult75–77. This observation is indicative of the fact that the neural differentiation program is 
compromised in the absence of (or in the dysfunctioning of) MBD5. Polycomb complexes are, 
as mentioned before, essential for the correct setting of differentiation. The fly homologue 
of MBD5, sba, was not found to interact with the fly PR-Dub complex(45, Jürg Müller personal 
communication). Therefore, any study looking into the potential involvement of PR-Dub 
in the Mbd5-related neurological defects should be designed using a mammalian system. 
Interestingly, knocking out the Mbd5 gene in a mammalian system, i.e. mice, resulted not 
only in neurodevelopmental defects, but also in disturbed glucose homeostasis78. Therefore, 
tissue-specific interactors and activities of MBD5 are of particular interest (see next section).
    As mentioned in chapter 1, there is one report showing the expression profile of Mbd5 
and Mbd6 in various mouse tissues79. The second isoform of MBD5 is highly expressed in 
oocytes. This finding is intriguing in light of the study that reports KDM1B is functionally 
linked to maintaining the maternal imprints in oocytes80. It would be interesting to see if 
this function of KDM1B is within the context of the PR-Dub complex and whether and how 
MBD5 contributes to the maintenance of maternal imprints. 
      MBD6 was observed to be highly expressed in testes and brain. Although the heterogeneity 
of these tissues in the expression profiling should be taken into account, it is curious that 
MBD6 is expressed highly in the brain considering that we show it localizes to DSBs in 
chapter 3 in this thesis. The DDR machinery is most often studied in proliferating cells and 
it is intricately linked with cell cycle checkpoints (G1, G2, mitotic checkpoints) which are 
not active in postmitotic neurons (G0)81. All DNA damage response proteins and pathways 
are nonetheless present in postmitotic cells, albeit in lower levels81. However, the exact 
mechanisms of DDR are not as clear due to lack of data. Upon DNA damage, re-entry into G1 
and S phases has been shown for postmitotic neurons, but no division follows the S phase 
entry. It seems the neurons are more likely to undergo apoptosis if the re-entry to G1 extends 
into the S phase as well82,83. It would be of interest to find out how MBD6 contributes to the 
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DDR and whether the PR-Dub interaction is involved: Although we have convincingly shown 
that the recruitment of MBD6 to DNA damage sites is PR-Dub-independent, we still do not 
know if MBD6 recruits PR-Dub to sites of damage. There are reports in literature claiming 
that PR-Dub localizes to IR sites, but our preliminary results are inconclusive in this aspect. 
Another possibility to consider is that MBD6 may have other functional roles that have not 
been characterized yet.
   
    Challenges of studying multisubunit complexes  
   With high quality interaction proteomics, the subunits and interactors of multisubunit 
complexes are relatively easy to identify as presented in chapters 3 and 5. Of note, for some 
proteins in some of the complexes, which protein is a subunit of the complex and which is 
an interactor of the complex is not an easy distinction to make. To address this question, 
complex compositions in different cell types could be compared to identify tissue-specific 
interactors. In addition, if available, information on the relative stoichiometry of proteins 
within the complex could serve as a criterion for distinguishing subunits from interactors. 
    Possibly a more pressingly necessary distinction that is required concerns the function of 
proteins of a complex that are a) in the context of the complex and b) independent of the 
complex. This is a rather difficult question to tackle. Conventionally, the effect of deleting 
the domain on the protein of interest mediating the interaction with the complex of interest 
is observed. However, there is always the possibility that the deletion of a domain disrupts 
all functionality of the protein. In addition, the domain that mediates interaction with the 
complex could also be functional in a complex-independent context. Therefore, while this 
experimental set-up does provide some insight into the possible complex-independent 
functions of proteins, it has its caveats. For chromatin regulatory complexes, the overlap 
of binding profiles of various subunits on chromatin is informative in that if there’s overlap 
between the subunits, it is highly likely that those sites are targeted by the complex of 
interest and not by particular subunits individually. The most informative method will be to 
identify all proteins on a locus of interest to see the co-localization of proteins (and hence 
complex composition as a whole) using methods such as ChIP-ms or derivatives.
     Another interesting question is the tissue-specific interactors and functions of chromatin 
complexes. With the generation of CRISPR-Cas genome targeting, it has become significantly 
more feasible to manipulate the genomes of higher eukaryotes84. What would be an 
interesting experimental set-up is to knock-out various subunits or interactors of a complex 
one by one in an inducible manner. The induction of the knock-out could be driven by a 
tissue-specific promoter. When applied to multiple subunits one by one or in combination, 
these experiments can shed light on the function of tissue-specific interactors in addition 
to tissue-specific functions of the chromatin regulatory complexes like those studied in 
this thesis that are found abundantly in many tissue types and highly conserved among 
metazoans. 
     Mass Spectrometry-based Proteomics for Epigenetics
    Mass spectrometry-based proteomics technologies have facilitated the investigation of 
many aspects of chromatin biology in a high-throughput and accurate manner. Particularly 
the generation of reliable quantification methods has enhanced interaction proteomics in 
such a way that the specificity of interactions are detected at an unprecedented accuracy. In 
affinity purification experiments, stretches of DNA or histone peptides bearing a modification 
of interest can be used as baits along with unmodified versions to serve as control85,86. 
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Incubation of modified and unmodified baits with a cellular extract will provide an unbiased 
screen of all proteins that specifically interact with or are repelled by the modification 
of interest. While this methodology does not distinguish between direct and indirect 
interactors, many reader proteins and complexes for various chromatin marks have been 
discovered in these screens87,88. For protein-protein interactions (PPIs), affinity purifications 
for a tagged protein of interest can be performed along with a nonspecific purification 
as control and thus the specific interactors of the protein of interest are enriched. In this 
thesis, a detailed method for identifying PPIs using quantitative interaction proteomics has 
been described in chapter 2. This method has been applied to various proteins of interest. 
In addition, various readers and interactors of a chromatin mark, i.e. Histone H2AK119Ub 
in a nucleosomal setting have been characterized. Identification of novel interactors has 
provided functional clues for proteins of interest and extra layers of regulation concerning 
the chromatin mark in question.
   Other epigenetic questions of interest are 1. the identification of histone PTMs, either 
of known PTMs at novel sites or of novel PTMs altogether. 2. Quantification of histone 
PTMs 3. The combination of PTMs on histones 4. Characterization and quantification of 
histone variants. Bottom up proteomics could be used to investigate the first and second 
questions, but the third and fourth questions require middle-down or top-down techniques. 
To investigate the combination of histone marks, it is obviously necessary to detect PTMs on 
the same peptide species, which is why middle-down proteomics would be the preferred 
method to look into this question87,88. Histone variants are rather difficult to quantify using 
bottom up proteomics due to the number of shared peptides: peptides that could be used 
to distinguish between variants and for quantification of variants decrease in number if 
the protein sequences are very similar, which is the case for histone variants. This is why 
top-down proteomics is more suitable to study histone variant dynamics91–94. However, 
compared to bottom-up proteomics, both middle-down and top-down techniques have 
remarkable difficulties regarding all steps of mass spectrometry-based proteomics, i.e. 
sample preparation, ionization and detection, and data analysis95,96. Therefore, further 
advances in middle-down and top-down techniques are very valuable for studying the main 
protein component of the chromatin environment that is histones. 
      A number of recent methods have been generated in the field to characterize and quantify 
the protein content on certain loci in the genome97–100. These methods are groundbreaking 
in the sense that they give a snapshot of the in vivo situation at a locus with all the associated 
proteins. At this stage, the technical challenges limit the use of these methods for loci in 
single cells. However, even if it may be only at the population level, it is rather exciting to 
think that soon we may be able visualize the whole chromatin landscape with all the protein 
components at a database like ENSEMBL (for visualizing genes and transcripts) in different 
cell types and under different conditions.
   Another aspect of chromatin biology that should be considered is the PTMs found on 
chromatin regulatory complexes. Although some PTMs are reported on individual members 
of various chromatin complexes, a combinatorial PTM screening is yet to be reported for any 
complex. If and how different PTMs affect complex formation and function is an area that has 
not been explored yet due to technical challenges. It is up to the mass spectrometry-based 
proteomics field to overcome these challenges and shed light on this area of regulation 
where possibilities are too high in number to be tackled by any other method than one that 
is high throughput. 
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    Emerging and evolving concept: Epigenetics, controversy and more controversy
   Epigenetics refers to all heritable information stored on chromatin that is not contained 
within the DNA sequence. Depending on how conservatively interpreted, it could refer to 
information that is passed over cell divisions and/or across generations - or not passed on at 
all (which in fact goes against the definition of the term). Originally, the term was conceived 
by Conrad Waddington in 1942 to comprise the processes of genotype interpretation leading 
to a specific phenotype101. The implication of heredity (across generations as well as cell 
divisions) was linked to the term later on, especially in light of DNA methylation studies102. In 
2000, Strahl and Allis suggested the term ‘the histone code’ to refer to the information stored 
in chromatin in the form of specific combinations of histone PTMs103. They claimed that the 
histone code is instrumental in phenotype formation. In a review in 2001, Jenuwein and Allis 
further postulated that the histone code is, just like DNA methylation, a very important player 
in epigenetic mechanisms and it is, like DNA methylation, (most likely) heritable across cell 
divisions104. In this review, the only mention of transgenerational inheritance of the histone 
code is in the context of imprinted genes: The authors propose that the imprinted regions 
may harbor histone PTMs in addition to methylated DNA, forming another combination 
(code) to make sure imprinted regions are faithfully transmitted across generations. A rather 
bold proposition of the review is ‘that a “histone code” exists that may considerably extend 
the information potential of the genetic (DNA) code.’ Eventually, the strong implication that 
epigenetics presents other levels of information as opposed to presenting mechanisms of 
interpretation of the genetic information raised a lot of controversy in the field105,106, especially 
since the hereditary aspects (across cell divisions and generations) of these marks were 
rather unknown. In 2007, Adrian Bird described epigenetics as ‘the structural adaptation of 
chromosomal regions so as to register, signal, or perpetuate altered activity states’107. While 
this definition accommodates the functional implications and consequences of epigenetic 
marks, the nature of the ‘perpetuation of altered activity states’ remains unclear for the 
most part and most marks. In 2009, a group of scientists proposed what they called an 
operational definition of epigenetics as: “An epigenetic trait is a stably heritable phenotype 
resulting from changes in a chromosome without alterations in the DNA sequence’’ and 
specified that the inheritance could be via mitosis or meiosis108.
   It is important to make distinctions between the three phenomena that are claimed, 
at one point or another, to be covered by epigenetics. 1. Does epigenetics refer to all the 
information on top of DNA that enable/disable a certain DNA-templated process? (e.g. 
acetylation of promoter nucleosomes before transcription.) 2. Does epigenetics refer to all 
the information mentioned in (1) only when it is stably maintained across cell divisions? 
3. Does epigenetics refer to information mentioned in (1) only when it is inherited across 
generations? 
    From the most conservative perspective, if epigenetics, by definition, stands to include 
all 3 factors mentioned above, then it needs to perpetuate the altered activity state in 
the absence of the initial, causative signal across generations. Examples fulfilling this 
criterion, (i.e. transgenerational inheritance), have been well-documented in plants and 
Caenorhabditis elegans in mechanisms involving DNA methylation and long noncoding 
RNAs109,110. However, in mammals, these examples are refrained to the case of imprinted 
genes111. Less conservative interpretations of the term epigenetics (i.e. definition (1) above) 
encompass all changes on chromatin induced by intra or extracellular signaling pathways by 
cis or trans-acting mechanisms regardless of inheritance (intercellular or intergenerational). 
Even within this limited description, there has been some discussion calling into question 
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the cause versus consequence relationship between epigenetic marks and regulatory 
processes. This confusion mostly stems from equating the presence of an epigenetic mark 
to functional outcomes without accounting for other regulatory factors such as TFs and the 
regulatory loops that they initiate. 
  Transcription factors (TFs) are the undoubted master regulators of transcription. The 
literature is full of examples where the expression of transcription factors overrules the effect 
of chromatin marks112,113,114. One of the best and possibly the most revolutionary example of 
this phenomenon is the ectopic expression of OCT4, SOX2, KLF4 and MYC TFs being able to 
reprogram differentiated cells back into a pluripotent state115. In addition, TFs (by definition) 
have specific DNA sequences that they recognize and bind which confers them specificity – 
a property essential in regulation and lacking in chromatin regulatory proteins. Chromatin 
remodeler and modifiers depend on TFs for recruitment for their activities to be targeted. 
     However, numerous elegant studies from model organisms are accumulating in literature, 
emphasizing the importance of epigenetic mechanisms in establishing various phenotypes. 
For example, in honeybees, changing DNA methylation patterns affected the developmental 
fate of bees in becoming a worker versus queen bee116. In Drosophila melanogaster, a 
particular histone mark (H3K27me3) was shown to be responsible for all the repression 
mediated by Ez2 as the mutation of the histone perpetuated the Ez2 knock-out phenotype117. 
Conversely, another study in D. melanogaster resulted in viable flies when total Histone H3 
in the organism was replaced with a mutant that cannot be methylated at the K4 position118. 
The mutant flies did display some developmental defects and in fact this observation could 
be used by both sides of the argument: One claiming that the mark is not that critical as 
the organism survives, the other side claiming that the mark is obviously functional due to 
the observed developmental difference. Such functional studies are yet to be performed in 
higher eukaryotes.
     With increased emphasis on epigenetics, the Roadmap Epigenomics Project was launched 
in 2008 with the aim of mapping epigenetic marks in different human tissues. Some scientists 
expressed their concern about such ambitious projects being misdirected in their huge 
invesment in epigenetic information119. They felt that the  mechanisms of gene regulation 
undertaken by TFs and the feedback loops that they generate (mechanisms already well-
described decades ago) are being overlooked in an attempt of better characterizing the 
developmental expression profile regulation. 
    In my opinion, taking the argument to extremes is doing disservice to both sides of the 
discussion. Clearly, epigenetic mechanisms cannot be considered independently of the 
underlying DNA sequence and the regulatory circuits that are directed by sequence-specific 
elements. However, some chromatin marks are also emerging to be instrumental in regulatory 
pathways initiated by TFs. How they are put on chromatin, how they are interpreted and 
how specificity is mediated are questions that need to be answered in more detail. These 
answers will not devalue the already elucidated gene regulatory mechanisms, they will only 
reveal more mechanisms of how the genetic material is interpreted at different loci and 
during different developmental phases. As functional studies on chromatin marks increase 
in number and include more model organisms, we will appreciate better which marks are 
critical, to what extent exactly and which are just circumstantial to biological processes. I do 
expect more causal evidence to be discovered on the epigenetics side - when the term is 
considered within the sense that Waddington proposed. However, in the sense that includes 
transgenerational inheritance, I do expect less likeness to mechanisms observed in lower 
eukaryotic model organisms considering the waves of ‘resetting’ chromatin in the germline 
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of mammals102,111,120. 
  As for the proposition of Jenuwein and Allis that a combinatorial histone code drives 
differentiation and maybe even exists alongside DNA methylation in imprinted regions 
across generations: they were right that numerous histone marks have been discovered and 
strongly linked to certain biological processes and outcomes. However, insofar as we know, 
the combinatorial complexity is not at all high considering the mathematical possibilities121. 
More accurately, the combinatorial complexity has been shown to be high to a certain 
extent, but the functional implications remain unresolved for the co-occurence of more 
than, approximately, 3 marks89. That is to say, the functional difference –if there is one- 
between H3K9me2K14acK23acK27me3 and H3K9me1K14acK23acK27me3 is not yet clear. 
Jenuwein and Allis were right that imprinted regions do contain some certain histone marks 
(H3K9me3) that seem to recruit certain reader proteins in mammals122. On the other hand, 
the mechanisms involved in the propagation of histone marks, across mitosis and meiosis, 
are not fully elucidated yet and remain an intense area of investigation123–125. 
    On a more clinical note, many epigenetic regulators are dysregulated in cancer68. Before the 
exact (causative) functions of the epigenetic regulators are described, multiple epigenetic 
drugs have passed clinical trials and are in use today. Some examples that act on epigenetic 
writers are histone deacetylase inhibitors, DNA methyltransferase inhibitors, histone 
methyltransferase inhibitors and drugs that block epigenetic readers such as Bromo-domain 
inhibitors126–130. From the perspective of molecular biology, this development is bizarre in 
that only the global effect of these drugs is known but not exactly the individual targets and 
the specific outcomes at those sites. From a medical perspective, it is quite usual that the 
exact molecular mechanisms of drugs in use are unknown.
   Interestingly, or rather expectedly, the controversy surrounding how much regulation 
could be ascribed to epigenetic information as well as how heritable it is has spread to the 
field of evolution: In the October 8 2014 issue of the journal Nature, a comment article 
containing opposing arguments from 2 different camps of scientists was published as the 
pinnacle of this disagreement131. One group proposed that in light of all the research of the 
past half-century, the standard evolutionary theory (SET), with its ‘gene-centric focus’, needs 
a make over which they called the extended evolutionary synthesis (EES). The additional 
factors within EES are listed as: ‘how physical development influences the generation of 
variation (developmental bias); how the environment directly shapes organisms’ traits 
(plasticity); how organisms modify environments (niche construction); and how organisms 
transmit more than genes across generations (extra-genetic inheritance).’ Three out of 
these listed four factors (developmental bias, plasticity and extra-genetic inheritance) are 
-at least partially- epigenetic phenomena. The opposing group of scientists acknowledged 
the importance of all the listed phenomena in evolution and claimed that all of these are 
already studied intensively as part of the SET. They refused to treat these phenomena as 
newly emerging revolutionary mechanisms. While recognizing their value and contribution 
to evolution, they cautioned against putting these factors on par with the most powerful 
force in evolution that is genetic change. 
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   Concluding Remarks
   Many gene regulatory mechanisms have been characterized in detail in the past decades. 
The role chromatin plays in transcriptional regulation has been revealed to a large extent. 
However, many questions remain, especially regarding the combinatorial activity of 
transcriptional and epigenetic regulators and the dynamics of the in vivo situation in cells. 
More advances in genomics and proteomics technologies and an integration of the two 
areas will provide more answers.
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Summary
Humans are in the animal kingdom within the eukaryotic domain. In eukaryotes, the 
genetic material (genome) is stored in a compartment within cells that is called the 
nucleus. Extremely sophisticated mechanisms have evolved to replicate and interpret the 
information stored in the genome. The relatively novel branch of science that is Molecular 
Biology has been addressing these mechanisms for the past century with increasingly more 
elegant tools and techniques.
Genetic information is utilized via gene expression: Genes are expressed to form functional 
agents called proteins that perform a plethora of structural and functional roles inside and 
outside of cells. Proteins can be categorized according to their function and/or structure 
as well as their location. This thesis focuses on proteins that function within the nucleus, 
playing roles in controlling gene expression via specific or non-specific interactions with 
the genome. Proteins very rarely act on their own: Specific and stable protein-protein 
interactions make up groups of proteins, referred to as protein complexes.
Chapter 1 of this thesis is an introduction to the eukaryotic genome, present in the form of 
chromatin. Components and several properties of chromatin along with various chromatin-
interacting protein complexes are described in detail. A short introduction regarding the 
technique that is used in the subsequent chapters, mass spectrometry-based proteomics, 
is also enclosed.
Chapter 2 describes a detailed method for identifying protein-protein interactions. Chapter 
3 presents interaction screens for proteins MBD5 and MBD6. The members of the PR-Dub 
complex, which is a chromatin regulatory complex, are identified as interactors. Further 
functional data on MBD5 and MBD6 are presented. In Chapter 4, specific interactors of 
a covalent modification on chromatin are investigated using quantitative proteomics. 
Preliminary experiments as to the functional consequence of the specificity of some of 
the interactors are shown. In Chapter 5, the stability and subunit composition of another 
chromatin regulatory complex, NuRD, are addressed using quantitative and cross-linking 
proteomics. Chapter 6 is a general discussion on the versatility of several chromatin 
regulatory complexes that have primarily been shown to repress gene expression. Various 
technical pitfalls and the necessity of data integration while studying these protein 
complexes are elaborated on. 
Chapter 7 is a general discussion focusing on open questions in relation to the research 
described in the preceding chapters. A short section on mass spectrometry and the 
chromatin field, as well as a discussion about the controversy surrounding some of the 
terminology within the chromatin field, are included.
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Samenvatting
De mens wordt geplaatst in het dierenrijk, binnen het domein Eukaryoten. In eukaryoten 
is het genetische materiaal (het genoom) opgeslagen in een compartiment van de cel dat 
de kern wordt genoemd. Om de informatie die is opgeslagen in het genoom te repliceren 
en interpreteren zijn uiterst geavanceerde mechanismen geëvolueerd. De relatief nieuwe 
tak van wetenschap die Moleculaire Biologie wordt genoemd heeft zich de afgelopen eeuw 
gericht op deze mechanismen, met alsmaar elegantere instrumenten en technieken.
Genetische informatie wordt gebruikt door middel van genexpressie: genen worden tot 
expressie gebracht om functionele eenheden (eiwitten genaamd) te vormen, die zowel 
binnen als buiten de cel een overvloed aan structurele en functionele taken uitvoeren. 
Eiwitten kunnen worden gecategoriseerd gebaseerd op hun functie, structuur en/of locatie. 
Dit proefschrift richt zich op eiwitten die binnen de kern functioneren, waar ze een rol spelen 
in het reguleren van genexpressie via specifieke of aspecifieke interacties met het genoom. 
Eiwitten werken slechts zelden alleen: specifieke en stabiele eiwit-eiwit interacties vormen 
groepen van eiwitten, die worden aangeduid als eiwitcomplexen.
Hoofdstuk 1 van dit proefschrift is een introductie in het eukaryotische genoom, in de vorm 
van chromatine. Componenten en diverse eigenschappen van chromatine worden in detail 
beschreven, evenals verschillende chromatine-interacterende eiwitcomplexen. Ook wordt 
een korte introductie gegeven in een techniek die in de daarop volgende hoofdstukken 
wordt gebruikt; proteomics gebaseerd op massa spectrometrie.
Hoofdstuk 2 beschrijft een gedetailleerde methode voor het identificeren van eiwit-
eiwit interacties. Hoofdstuk 3 introduceert interactiescreenings voor de eiwitten MBD5 
en MBD6. De onderdelen van het PR-Dub complex, wat een chromatine-regulerend 
complex is, worden geïdentificeerd als interactoren. Verdere functionele data wat betreft 
MBD5 en MBD6 worden gepresenteerd. In Hoofdstuk 4 worden specifieke interactoren 
van een covalente modificatie op chromatine onderzocht met behulp van kwantitatieve 
proteomics. Voorlopige resultaten van experimenten naar de functionele consequentie van 
de specificiteit van sommige interactoren worden gepresenteerd. In Hoofdstuk 5 wordt de 
stabiliteit en compositie van een ander chromatine-regulerend complex, NuRD, onderzocht 
met behulp van kwantitatieve en crosslinking proteomics. Hoofdstuk 6 is een algemene 
discussie over de veelzijdigheid van verschillende chromatine-regulerende complexen, 
waarvan hoofdzakelijk is getoond dat ze genexpressie onderdrukken. Er wordt uitgeweid 
over verscheidene technische valkuilen en de noodzaak tot de integratie van data bij het 
bestuderen van deze eiwitcomplexen.
Hoofdstuk 7 is een algemene discussie die zich richt op openstaande vragen met betrekking 
tot het onderzoek dat is beschreven in de voorafgaande hoofdstukken. Een korte sectie over 
massa spectrometrie en het chromatine veld is ook opgenomen, evenals een discussie over 
de controverse rond bepaalde terminologie in het chromatine veld.
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twisted, twisted jokes ;-)).  Annem ve babam - size ansiklopedi setinden aşağısı ithaf edilmezdi 
güzellerim, ama şimdilik bu kadar oldu, idare edin. Baba, sen olmasan kim bana Ankara/Amerika 
haberleri verecek, benimle dünyanın halini tartışacak ve en Malthusçu yorumlarıyla günüme gün 
katacak!.. Ve güzel annem, sen olmasan nasıl taşınacaktı o evler, bu kutular kendilerini toplamaz, 
toplamıyor gene.. Şaka bir yana, ikinize de bütün ilginiz, koşulsuz desteğiniz için; uzun uzun, ince 
ince dinleyip yaptığınız durum analizleri ve önerileriniz için; ve fakat son tahlilde ‘kendi kararını 
kendin ver tabii’ deyip büyümeme izin verdiğiniz için çok çok teşekkür ederim. 
  
  Herkese beni dinlediği için bu kadar teşekkür ettikten sonra ne kadar çok konuşan bir insan 
olduğum gerçeği ortaya çıktı tabii! :-) Anyhow, thank you once again dear colleagues, friends and 
family! Wishing you all the best and also that this won’t be a lasting goodbye…
İrem.
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